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Abstract 
A complex network of cellular, subcellular, and molecular elements is responsible for the 
development of cerebral malaria (CM); the interactions between these elements are still being 
explored to fully understand the aetiology of such a serious syndrome. Almost half of the world’s 
population is at risk of malaria and annually 212 million people are infected, with one to two percent 
of these cases progressing to CM. Plasma microvesicles (MV) are submicron vesicles released from 
all cell types and involved in coagulation, inflammation, and cell-cell communication. Their levels 
are significantly increased in CM patients and in mice with CM, where blocking their release protects 
against brain pathology, indicating a role of MV in neuropathogenesis. 
The microRNA content of circulating plasma MV and of brain tissue during murine cerebral 
and non-cerebral malaria was assessed using microarray and RT-qPCR techniques. Following 
infection, miRNA encapsulated in plasma MV and expressed in the brain tissue were altered in mice 
with CM, coinciding with the onset of the neurological syndrome. Particularly, miR-146a and miR-
193b were found to be significantly dysregulated in plasma MV from CM mice; these miRNA interact 
with mRNA targets to affect the downstream production of proteins involved in apoptosis, cytokine 
regulation and the recruitment of inflammatory cells. Additionally, in the brain of mice with CM, 
miR-19a-3p, 19b-3p, 27a-5p, 142-3p, 223-3p and 540-5p were found to be significantly dysregulated 
compared with the levels detected in non-CM and non-infected mice through detailed microarray 
analysis. This group of significantly dysregulated miRNA specific to the neurological syndrome were 
shown to regulate pathways related to the differentiation of several key players of the innate immune 
response and in malaria resistance, such as pathways controlling TGF-b signalling, endocytosis, 
FoxO signalling and adherens junctions, among others. These data suggest, for the first time, the 
potential of miRNA – either MV-encapsulated or expressed in brain tissue – to play a regulatory role 
in the pathogenesis of experimental CM. 
 Using confocal microscopy, we then investigated the accumulation of various elements of 
CM pathology – specifically, monocytes, platelets, T cells, parasites and ICAM-1-positive cells –
within the cerebral microvasculature of Plasmodium-infected mice, and examined their interactions 
and spatial relationship at the tissue level. All these elements except T cells were found to accumulate 
at branch points of vessels, in association with leaking, haemorrhaging of the vasculature and the 
development of hypoxic regions in the surrounding tissue. These observations were consistent with 
previous observations of blood-brain barrier damage, leading to widespread hypoxia and ultimately 
death.  
We found monocytes to be the most numerous cell type accumulating in the brain of mice at 
the time of CM and therefore targeted them therapeutically. Treatment in vivo with immuno-
modulatory particles (IMP) – known to target Ly6Chi monocytes – combined with artesunate – an 
 xxi 
effective anti-malarial drug – resulted in an 88% protection when administered at the onset of the 
neurological syndrome. In comparison, treatment with artesunate or IMP alone resulted in 56% or 
10% protection, respectively. All successfully treated mice displayed reductions in the clinical signs 
of CM, monocyte numbers and MV numbers, and were immune to reinfection. 
 This thesis presents findings reinforcing the existing hypotheses underpinning the 
pathogenesis of CM. This work also highlights several novel candidates as players in the development 
of the syndrome. We have explored the potential of miRNA as biomarkers of the neurological 
syndrome and their potential to exacerbate CM. We have shown that dysregulated inflammatory cells, 
particularly inflammatory monocytes displaying a Ly6Clo phenotype, play a role in the worsening of 
CM. Furthermore, targeting this cell subset therapeutically presents a novel and effective strategy to 
abrogate late-stage CM, with clear therapeutic potential for patients with CM. 
  
 xxii 
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1 Malaria 
 
1.1 Background 
Malaria is a serious infectious disease that presents a key problem in global health. Malaria, 
together with tuberculosis and HIV/AIDS, make up the “big three” overall accounting for 10% of all 
deaths worldwide annually. Further to this, almost half of the world’s population is at risk of malaria 
infection (WHO, 2016). Around the world, Plasmodium species infect 212 million new people 
annually, an estimated 429,000 of which will die from this infection. 71% of these deaths comprise 
children under five years of age, and 95% of these children are from the African region, where 
millions of people lack access to adequate preventative or therapeutic options. High mortality rates 
exist not only amongst these young children in developing countries but also amongst pregnant 
women in these same areas, immunocompromised people with HIV/AIDS and international travellers 
from non-endemic areas, altogether causing a huge social and economic toll. In 2016, 91 countries 
and areas worldwide were known malaria-endemic regions, though this number is decreasing 
annually (WHO, 2016). 
Malaria is caused by protozoan parasites from the Plasmodium species and is transmitted by 
the bite of infected female Anopheles mosquitoes, to vertebrate hosts such as humans, monkeys, and 
rodents (Schofield and Grau, 2005). In rare cases, malaria can be transmitted from an infected mother 
to the child during pregnancy, or intravenously via blood transfusion or needle sharing. Increased 
rates of transmission occur in temperate locations, enabling a longer lifespan of mosquitoes. These 
locations are favourable to the breeding and survival of the Anopheles mosquito, allowing the parasite 
to have sufficient time to develop inside the mosquito completely. Additionally, within tropical 
countries, mosquitoes have been found to preferentially bite humans instead of other animals (Gallup 
and Sachs, 2001). These reasons both apply to the African vector species, explaining why over 90% 
of the world’s malaria deaths occur in Africa (WHO, 2016). 
Climate affects transmission through the impact on mosquito numbers and survival. Apart 
from temperature, this also includes rainfall patterns and humidity, and this explains why, in some 
locations, seasonal malaria trends occur, following the patterns of the rainy seasons. Sudden climactic 
shifts that favour transmission allow for the spread of malaria to previously unaffected areas, where 
people have little to no pre-existing immunity, with the potential to cause malaria epidemics in those 
areas (Gallup and Sachs, 2001; Parham and Michael, 2010). Therefore, the recent trends of climate 
change must be of increasing concern regarding the spread of tropical infectious diseases like malaria. 
Alternatively, protective immunity can develop amongst adults over years of prolonged exposure 
within areas of moderate or high rates of transmission. This immunity does not completely protect 
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against malaria infection but does reduce the risk of developing severe disease. Hence young children 
are most at risk and most affected in areas of high transmission. Not only does this immunity not 
confer complete protection, but also this partial immunity is not concomitant – that is, it instead relies 
on regular exposure for long-term protection. Following departure from malaria-endemic countries, 
previously protected individuals lose the partial immunity they have acquired over time, and are at 
risk of severe malaria upon return, similar to travellers with no previous exposure (Sachs and 
Malaney, 2002; Greenwood et al., 2005). 
Currently, five Plasmodium species are known to infect humans: Plasmodium malariae, 
ovale, vivax, falciparum, and knowlesi. P. malariae is often clinically silent, although an immune-
complex-associated glomerulonephropathy can develop after chronic infection. P. ovale usually 
causes a relatively benign infection (Mueller et al., 2007). P. ovale has recently been shown to consist 
of two genetically distinctive subspecies – P. ovale curtisi and P. ovale wallikeri, bring the new total 
of Plasmodium species infecting humans to six (Sutherland et al., 2010). Together, these two species 
- P. malariae and P. ovale – represent only a small percentage of total malaria infections. P. vivax is 
rarely fatal, but commonly causes acute febrile illness, and recurring malaria, especially in Oceania, 
Asia, and South America (Vogel, 2013). However, recently it has become increasingly evident that 
P. vivax is able to cause severe malaria and, in rare cases, cerebral malaria (Naing et al., 2014). For 
example, severe malaria cases have been reported in increasing numbers in Thailand, Brazil, 
Indonesia, Papua New Guinea, and India (Luxemburger et al., 1997; Lomar et al., 2005; Tjitra et al., 
2008; Price et al., 2009), and at similar rates to P. falciparum malaria in all age groups (Naing et al., 
2014). Compared to P. falciparum, P. vivax is able to develop in mosquitoes at a lower temperature, 
are therefore has a wider geographical range (Greenwood et al., 2005). Both P. vivax and P. ovale 
are complicated by a dormant liver stage, termed “hypnozoites” (Markus, 1980). Finally, P. 
falciparum causes most cases of severe malaria and malaria-related deaths (WHO, 2014b; de Koning-
Ward et al., 2016; Wassmer and Grau, 2017). 
Until recently only four species of Plasmodium were believed to be able to infect and cause 
disease in humans. P. knowlesi was originally only thought to be found in macaques in South-East 
Asia. However, reports from as early as 1965 provide evidence of its transmission to humans, though 
this was not recognised until much later (Chin et al., 1965; Collins, 2012). Periodic cases in South-
East Asia have been observed since this time, where it accounts for up to 70% of cases in endemic 
areas (Singh et al., 2004). 
 
 
CHAPTER 1 | Introduction 
 4 
1.2 Plasmodium falciparum malaria 
Severe malaria is caused by P. knowlesi, vivax, and falciparum, but P. falciparum is 
responsible for the majority of cases with neurological symptoms. The P. falciparum parasite has two 
hosts – Anopheles mosquitoes and humans. Within the human host, the Plasmodium life cycle 
consists of two separate phases: the exo-erythrocytic or hepatocytic, and the erythrocytic phases 
(Figure 1.1), as reviewed by Greenwood et al. (Greenwood et al., 2005). 
 
 
Figure 1.1: Life cycle of the malaria parasite. 
Figure adapted from the Centres for Disease Control and Prevention, Division of Parasitic Diseases, 
2017 (Centers for Disease Control and Prevention, 2016) 
 
Young female Anopheles mosquitoes carry Plasmodium sporozoites in their salivary glands, 
ingested while taking a blood meal from an infected human. Approximately 100 sporozoites are 
injected into a new human host via the saliva, during a subsequent blood meal [1] (Delves et al., 
2012). This begins the exoerythrocytic phase [A], during which injected sporozoites infect 
hepatocytes in the liver within minutes of their introduction into the human host [2]. Within the 
hepatocytes, each sporozoite matures and forms tens of thousands of schizonts, which rupture and 
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release merozoites [3] (Miller et al., 2002). Notably, a proportion of infected hepatocytes (during P. 
vivax and P. ovale infections) can host hypnozoites, that remain in the liver until reactivation is 
triggered, leading to clinical symptoms weeks, or even years later [(3)] (Adams and Mueller, 2017). 
The host cells rupture [4], and the merozoites are released into the circulation and infect red blood 
cells (RBC), thus beginning the erythrocytic phase of the life cycle [B] (Miller et al., 1994; Delves et 
al., 2012). The parasite escapes undetected from the liver by taking with it the cell membrane from 
the infected liver cell (Vlachou et al., 2006; Delves et al., 2012). The merozoites undergo asexual 
replication in the RBC [5], with morphological and transcriptional changes occurring as they mature 
through the ring, trophozoite, and schizont stages (Le Roch et al., 2003). 
 The merozoites continue multiplying within the schizont until the host RBC eventually lyses 
[6]. Most of these merozoites escape into the blood stream and release toxins, ready to invade new 
RBC. However, a small percentage of trophozoite-infected RBC mature into male and female 
gametocytes [7], which are asymptomatic to the host but infectious to the mosquito. Thus, the 
infection is transmitted back to the mosquito following a blood meal [8] (Miller et al., 2002), 
beginning the sporogonic cycle [C]. Within the mosquito, the gametocytes, male (microgametocytes) 
and female (macrogametocytes) combine to form zygotes [9] and then elongate and become motile 
(ookinetes) [10], which invade the midgut epithelium of the mosquito and differentiate into oocysts 
[11]. The oocysts grow and, after 10-15 days, rupture [12], releasing sporozoites that migrate to the 
salivary gland, ready to be injected into a new human host to restart the malaria life cycle (Ghosh et 
al., 2000). 
 
1.3 Clinical manifestations of malaria 
The clinical manifestations of malaria vary in severity, due in part to the strain of Plasmodium 
parasite, but are predominantly the result of schizont rupture and destruction of RBC. It should be 
noted that here, only P. falciparum will be discussed, as it most commonly causes the cerebral 
syndrome specifically explored in this project. 
The clinical symptoms of malaria infection usually develop 8 to 12 days after infection. 
Increased parasite numbers within the host lead to correspondingly increased manifestations of signs 
and symptoms. It follows then, that mild and uncomplicated infections with lower parasite numbers 
circulating lead to symptoms such as head and muscle aches, nausea, malaise, sweating, diarrhoea, 
abdominal pain, and cyclical fevers and chills (Weatherall et al., 2002). Complications arising from 
prolonged infection include anaemia and jaundice. While all Plasmodium strains cause malaria 
infections, only P. falciparum, vivax, and knowlesi can cause severe malaria, and this will be 
discussed further in section 2. 
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Several methods can be used to diagnose infection with Plasmodium. The most common and 
widely used method involves Giemsa-stained blood smears, either thin or thick. The thick smear, 
prepared using a drop of blood on a glass slide, allows for detection of the presence of parasite in the 
blood, whereas the thin smears typically utilise a smaller volume but in this case the drop of blood is 
spread out, enabling the differentiation of parasite strains, and the quantification of parasitaemia 
(Warhurst and Williams, 1996). Thick smears are 20-40 times more sensitive than thin smears, as a 
screening method for parasite detection (Moody and Chiodini, 2000). The smears are examined 
microscopically, and detection of early (ring) stages of the parasites within RBC confirms a diagnosis 
of malaria infection. Alternatively, fluorescence microscopy, flow cytometry and other molecular 
detection methods can be used. However, blood smears still represent the simplest, most accessible 
method, and are therefore widely used today, particularly in field hospitals (Weatherall et al., 2002). 
 
1.4 Distribution and socioeconomic impact of malaria 
In 2015, 91 countries and areas worldwide were known to be malaria-endemic regions (WHO, 
2016), including countries in Africa, South-East Asia, South America, and parts of the Middle East 
and Oceania (Figure 1.2a). Currently, an estimated 3.4 billion people are at risk of malaria. This risk 
can be defined as low risk (<1 reported case/1000 population), or high risk (>1 case/1000 population). 
Of the 3.4 billion people at risk, 2.3 billion were at low risk, 93% of whom were living in geographic 
regions other than the African region. The other 1.1 billion at high risk were living mostly in the 
Africa (63%) and South-East Asia (22%) regions (WHO, 2016). An estimated 212 million episodes 
of malaria occurred in 2015, 90% of which were recorded in the African region, with the South-East 
Asian region accounting for another 7%. There were also an estimated 429,000 malaria deaths, of 
which 92% in the African region, and 71% globally were children under five years old (WHO, 2016). 
 
 
Figure 1.2a: Countries with ongoing transmission of malaria in 2013 (WHO, 2014a) 
2 | WORLD MALARIA REPORT 2014
The World malaria report 2014 summarizes the status of global efforts 
to control and eliminate malaria. The report is produced every year by the 
WHO Global Malaria Programme, with the help of WHO regional and country 
oﬃces, ministries of health in endemic countries, and a broad range of other 
partners. Data for this year’s report were assembled from 97 countries and 
territories with ongoing malaria transmission, and an additional six countries 
that are working to prevent reintroduction. 
This section outlines the public health burden posed by malaria, the 
strategies that can be used to reduce that burden, and the goals, targets 
and indicators that have been set for 2015. The report then reviews global 
progress towards the goals and targets in relation to funding (Section 2), 
intervention coverage (Sections 3–7), and malaria cases and deaths 
(Section 8). The review is followed by Regional profiles that summarize 
trends in each WHO region. Country profiles are provided both for countries 
with ongoing malaria tra smission and for those r cently achieving zer  local 
cases. Finally, annexes provide sources of data, details of the methodology 
used in the analysis, and tables containing country and regional data.
1.1 The public health challenge posed by 
malaria
Malaria transmission occurs in all six WHO regions. Globally, an 
estimated 3.3 billion people in 97 countries and territories are at risk of being 
infected with malaria and developing disease (Figure 1.1), and 1.2 billion are 
at high risk (>1 in 1000 chance of getting malaria in a year). According to 
the latest estimates, 198 million cases of malaria occurred globally in 2013 
(uncertainty range 124–283 millio ) and the disease led to 584 000 deaths 
(uncertainty range 367 000–755 000), representing a decrease in malaria 
case incidence and mortality rates of 30% and 47% since 2000, respectively. 
The burden is heaviest in the WHO African Region, where an estimated 90% 
of all malaria deaths occur, and in children aged under 5 years, who account 
for 78% of all deaths.
DATA WERE ASSEMBLED FROM 
97 COUNTRIES AND TERRITORIES 
WITH ONGOING MALARIA 
TRANSMISSION, AND AN 
ADDITIONAL SIX COUNTRIES 
WORKING TO PREVENT 
REINTRODUCTION.
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Figure 1.1 Countries with ongoing transmission of malaria, 2013
Source: National malaria control programme reports
Confirmed malaria cases per 1000 population
No ongoing malaria transmission
Not applicable
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10–50
1–10
>100
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Figure 1.2b: Percentage of population living on under US$2 per day, 1995-2013 (WHO, 2014a) 
 
Malaria is of serious concern, not only due to its high morbidity and mortality rates but also 
because of its huge socioeconomic impact. Malaria incidence does vary from country to country; 
however, it tends to occur most frequently in poverty-stricken countries (Figure 1.2b). This is due to 
the combination of poor health care quality and access, and the low quality of housing and living 
conditions that can typically exist in developing countries (Sachs and Malaney, 2002). The rate of 
transmission in a particular area has a great impact on which people are most at risk in that area. In 
areas where malaria transmission is high – for example in Africa, those most at risk are the 
immunonaïve and the immunodeficient, including infants, young children, pregnant women, and 
people who are immunocompromised due to pre-existing HIV or tuberculosis infections (Miller et 
al., 1994; Greenwood et al., 2005; Schofield and Grau, 2005; WHO, 2011; WHO, 2016). However, 
in areas of low malaria transmission, individuals of an older age are instead at high risk (Schofield 
and Grau, 2005; WHO, 2011; WHO, 2016). 
The devastating impact that malaria has is internationally recognised. Global agencies such 
as the World Health Organisation (WHO), the United Nations Children’s Fund, and the World Bank 
have implemented various strategies to decrease the burden of malaria. These organisations had set 
targets for 2015, one of which was to reduce the malaria burden by at least 50%. Unfortunately, this 
goal was not achieved due to lack of required funding – instead, reaching a 37% reduction. New 
targets for 2030 have been set, including reducing global malaria incidence and mortality rates by 
40%; eliminating malaria from at least ten new countries in which malaria was transmitted in 2015; 
and preventing the resurgence of malaria in all countries that are currently malaria-free. These 
measures will only be achieved if universal access to and utilisation of preventative measures can be 
achieved and sustained, as well as universal access to case management in the public and private 
sectors and the community, the acceleration of the development of surveillance systems, and finally, 
the financial contributions to malaria-endemic countries increased substantially. 
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Malaria exacts a heavy burden on the poorest and most vulnerable 
communities. It primarily aﬀects low- and lower-middle income countries 
(Figure 1.2). Within endemic countries, the poorest and most marginalized 
communities are the most severely aﬀected, having the highest risks 
associated with malaria, and the least access to eﬀective services for 
prevention, diagnosis and treatment. Thus, malaria control and ultimately 
its elimination is inextricably linked with health system strengthening, 
infrastructure development and poverty reduction.
Malaria is caused by five species of the parasite belonging to the 
genus Plasmodium. Four of these – P. falciparum, P. vivax, P. malariae and 
P. ovale – are human malaria species, which are spread from one person 
to another by female mosquitoes of the genus Anopheles. There are about 
400 diﬀerent species of Anopheles mosquitoes, but only 30 of these are 
vectors of major importance. In recent years human cases of malaria have 
also been recorded due to P. knowlesi – a species that causes malaria among 
monkeys, and occurs in certain forested areas of South-East Asia.
P. falciparum and P. vivax malaria pose the greatest public health 
challenge. P. falciparum is most prevalent on the African continent, and is 
responsible for most deaths from malaria. P. vivax has a wider geographic 
distribution than P. falciparum because it can develop in the Anopheles 
mosquito vector at lower temperatures, and can survive at higher altitudes 
and in cooler climates. It also has a dormant liver stage (known as a 
hypnozoite) that enables it to survive for long periods as a potential reservoir 
of infection. The hypnozoites can activate months later to cause a relapse. 
Although P. vivax can occur throughout Africa, the risk of infection with this 
species is quite low, because of the absence in many African populations of 
the Duﬀy gene, which produces a protein necessary for P. vivax to invade red 
blood cells. In many areas outside Africa, infections due to P. vivax are more 
common than those due to P. falciparum.
Figure 1.2 Percentage of population living on under US$ 2 per day, 1995–2013
Source: National malaria control programme reports
Percentage of population living 
on under US$ 2 per day
>75%
35–75%
15–35%
<15%
No data
Not applicable
Percentage of population living 
under US$ 2 per day
Not applicable
No data
<15%
15–35%
35–75%
>75%
Percentage of population living under $2/day
Not applicable No data <15% 15-35% 35-75% >75%
Source: World Bank 2014 World Development Indicators: Poverty rates at international poverty lines. 
Available at: http://wdi.worldbank.org/table/2.8, accessed 24 November 2014. Survey years range 
from 1995 to 2013, with about 60% of countries with data from 2010 or earlier.
AN ESTIMATED 3.3 BILLION 
PEOPLE ARE AT RISK OF BEING 
INFECTED WITH MALARIA AND 
DEVELOPING DISEASE, AND 
1.2 BILLION ARE AT HIGH RISK.
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2 Cerebral malaria 
 
2.1 Severe malaria 
Severe malaria is a multisystem syndrome caused by P. falciparum, vivax, and knowlesi, that 
encompasses symptoms such as generalised convulsions, metabolic acidosis leading to respiratory 
distress, cerebral malaria (CM), and severe malarial anaemia due to the destruction of RBC (WHO, 
2016). Other symptoms include severe headaches, hypoglycaemia, splenomegaly and hepatomegaly 
(enlargement of the spleen and liver), pulmonary oedema, cerebral ischaemia, and blackwater fever 
(consisting of haemoglobinuria with renal failure) (Schofield and Grau, 2005). Severe malaria 
typically manifest 6-14 days after infection, and complications may progress to coma and death if left 
untreated. In young children, the elderly, and women, particularly pregnant women and those in areas 
of low transmission, are amongst those at the greatest risk of contracting severe malaria (WHO, 
2014b). Notably, CM occurs more often in children aged 3-6 years old, whereas severe malarial 
anaemia occurs in children younger than two (Kai and Roberts, 2008; Schumacher and Spinelli, 
2012). Those with a greater risk of mortality upon presenting with severe illness are 
immunocompromised individuals or those who have experienced a delay in treatment (Kain, 1998; 
Olliaro, 2008; Hanson et al., 2010). 
 
2.2 Cerebral malaria: clinical syndrome 
Severe malaria commonly manifests itself as severe anaemia or CM. CM is a diffuse 
encephalopathy that is characterised by asexual forms of Plasmodium in the blood, as well as 
unarousable coma and unconsciousness, often leading to death, or neurological sequelae in survivors 
(Bangirana et al., 2016). CM is a multisystem disease that results in a progressive deterioration of the 
host’s health. CM is almost exclusively caused by P. falciparum infection; however, a few cases have 
been reported of CM caused by P. vivax infection have been in young children (Ozen et al., 2006; 
Singh et al., 2011; Tanwar et al., 2011). Approximately one percent of individuals with malaria 
infection develop CM; however, the reason for this is currently unknown. The particular susceptibility 
of some individuals over others has been explored, and it has been found that overall patterns of 
disease depend markedly on the endemic region and age group the patient belongs to, the species of 
parasite they are infected with, the pre-existing levels of innate and acquired immunity of the host, 
and the timing and efficacy of treatment if any (Figure 1.3) (Miller et al., 2002; Schofield and Grau, 
2005). 
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Figure 1.3: Factors influencing the clinical outcome of malarial infection in an African child 
and the resulting range of outcomes (Miller et al., 2002) 
 
2.3 Signs and symptoms of cerebral malaria 
P. falciparum, which is largely responsible for CM, is able to infect multiple organs via the 
circulation, and this blood-stage of the infection is responsible for most CM signs and symptoms, 
although these signs and symptoms vary between children and adults suffering CM. African children 
with CM typically present with fevers, severe weight loss, vomiting, and sometimes coughing, as 
well as respiratory distress, dehydration, and convulsions. Neurologically, they exhibit seizures, 
brainstem signs, and a deep but potentially reversible coma. Brainstem signs occur due to increased 
intracranial pressure (Idro et al., 2007), and these include changes in pupil size and reaction, and 
disorders of conjugate gaze and eye movements, as well as abnormalities in respiratory patterns, 
posture, reflexes and tone (Idro et al., 2005; Pasvol, 2005). Metabolic concerns are also relevant to 
the paediatric CM syndrome, including hypoglycaemia, hyponatraemia, splenomegaly, impaired 
renal function, metabolic acidosis associated with hyperlactataemia, and, in some cases, jaundice 
(Idro et al., 2005; Pasvol, 2005; WHO, 2011; Wu, 2011; WHO, 2016). Notably, there are few data 
on the pattern of clinical disease in children outside of the African region (Nanda et al., 2011). 
In contrast, adults with CM present with a different set of symptoms and signs (Table 1.1). 
Adult CM patients usually present with malaise, headaches, joint pain, severe weight loss, fever, and 
delirium – leading to prolonged coma and death if untreated (Idro et al., 2005; Pasvol, 2005). 
Recovery from coma is far slower, in comparison with the paediatric syndrome. In the adult 
syndrome, some patients suffer from multi-organ complications, including shock, adult respiratory 
distress syndrome, pulmonary oedema, jaundice, anaemia, and Kussmaul’s breathing, combined with 
acute renal failure and severe lactic acidosis. Seizures, bacterial con-infections, and neurological 
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sequelae occur more often in children than adults; conversely, jaundice, renal failure, bleeding or 
clotting disturbances, and multiple organ failure are much more common complications in the adult 
syndrome compared with children (Newton et al., 2000; Idro et al., 2005). 
Concerning both adult and paediatric CM, individuals presenting with severe intracranial 
pressure (ICP) during malarial infection tend to develop neurological sequelae (5-30% of paediatric 
CM cases, and 1% of adult CM cases). These sequelae include ataxia (43%), hemiparesis (39%), 
cognitive, memory and language impairments (39%), and cortical blindness (30%) (WHO, 2014b). 
The cause of these neurological sequelae is not known but possibly multi-factorial, though recovery 
tends to occur within the first six months (Idro et al., 2007; Idro et al., 2010). 
Post-mortem specimens display supporting evidence of the signs and symptoms of CM, 
including an accumulation of host cells (parasitised RBC, leucocytes, and platelets) leading to 
blockage of brain microvessels, alterations of blood-brain barrier (BBB) integrity, brain oedema, 
micro-haemorrhages, and necrosis of surrounding tissues (Grau et al., 2003; Idro et al., 2005; van der 
Heyde et al., 2006; Dorovini-Zis et al., 2011; Ponsford et al., 2012; Palmiere et al., 2014). Indeed, a 
key histological difference between adult and paediatric CM is the ratio of cells accumulating in the 
brain microvasculature – adult CM features a predominant parasitised RBC (pRBC) accumulation, 
whereas the paediatric syndrome demonstrates accumulation of pRBC and various white blood cell 
subtypes, including monocytes and T cells (Hawkes et al., 2013). 
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Table 1.1: Clinical features and outcomes of CM in African children and South-East Asian 
adults (Idro et al., 2005; Hawkes et al., 2013) 
Clinical features African Children Adults 
Illness duration Short: 1-2 days Longer: 5-7 days 
Seizures* 
>80% have history of seizures, 60% have seizures 
in hospital; status epilepticus common; recurrent 
seizures: focal motor (>50%), generalised tonic-
clonic (34%), subtle/electrographic (15%), partial 
with secondary generalisation (14%) 
Occurs in up to 20%, mostly generalised 
tonic-clonic seizures; status epilepticus is 
rare 
Other signs Pallor, respiratory distress, dehydration, rarely jaundice (2%) 
Kussmaul’s breathing, spontaneous 
bleeding, shock, jaundice (40–70%) 
Neurological signs 
Brainstem signs (>30%) – associated 
with raised ICP, raised cerebrospinal fluid 
pressure; retinal abnormalities (> 60%); brain 
swelling on CT scan (40%) 
Patients typically have symmetrical upper-
motor-neuron signs; brainstem signs and 
retinal abnormalities are less common 
Major 
complications & 
involvement of 
other organs  
Severe anaemia in 20–50%, of whom 30%  
require a blood transfusion; severe metabolic 
acidosis, hyperlactaemia, hyponatraemia (>50%), 
hypoglycaemia (30%), changes in potassium, 
renal failure, and pulmonary oedema (rare) 
Multisystem and organ dysfunction 
(circulatory, hepatic, pulmonary, 
coagulation & renal); pulmonary oedema, 
haemoglobinuria, hypoglycaemia (8%), 
lactic acidosis, & renal failure reported 
Coma Develops rapidly often after a seizure (34%) 
Develops gradually following drowsiness, 
disorientation, delirium, and agitation over 
2–3 days or follows a generalised seizure 
(40%) 
Outcome   
Recovery of 
consciousness Rapid, within 1-2 days Slower, 2-4 days 
Neurological 
sequelae 
Occurs in 11%. Common sequelae are 
hemiparesis (4.4%), quadriparesis (3.5%), ataxia 
(2.5%), visual (2.3%), speech (2.1%) and hearing 
(1.9%) impairments, behavioural difficulties 
(1.3%), epilepsy 
Few, occurs in <5%. Common sequelae are 
isolated cranial nerve palsies, mononeuritis 
multiplex, polyneuropathy, extrapyramidal 
tremor, and other cerebellar signs 
Mortality 18.6% (up to 75% of deaths occur within 24  hours of admission) 30% (~50% occur within 24 hours) 
*Measured using the Glasgow and the Blantyre coma scores (latter adapts Glasgow coma score to children 
that cannot talk yet, developed by M. Molyneux and T. Taylor in Blantyre, Malawi (Chimalizeni et al., 2010) 
 
2.4 Pathogenic elements of cerebral malaria 
The fine pathophysiological mechanisms underlying the neurological syndrome of CM have 
been examined extensively; however, the aetiology is still unclear. It has been linked to many factors, 
including increased parasitaemia or cytokine circulation, or vascular accumulation of red and white 
blood cells; however, none of these factors is a prerequisite of CM, nor are they unique to the 
neurological syndrome (Molyneux, 1990; Clark and Rockett, 1994; de Souza and Riley, 2002; Hunt 
and Grau, 2003; Taylor et al., 2004; Sowunmi et al., 2011; Ponsford et al., 2012; Cunnington et al., 
2013). Several hypotheses have been proposed regarding the specific pathogenic mechanisms by 
which the CM occurs, and a combination of these is now accepted as the closest understanding we 
have at present (Berendt et al., 1994; Clark and Rockett, 1994; Grau and de Kossodo, 1994). 
 
2.4.1 Intravascular elements 
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2.4.1.1 Parasite molecules 
Upon invasion of erythrocytes by Plasmodium, host cell contents and membrane are actively 
remodelled: the cytoskeleton is modified and parasite-derived proteins are inserted in the erythrocyte 
membrane (Maier et al., 2009). During infection, various parasite molecules are produced, that can 
regulate pathogenic processes related to the immune response (Schofield and Grau, 2005). P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) forms “knob-like” protrusions on the surface 
of RBC, synthesised during blood-stage infection. PfEMP1 is an important virulence factor, acting 
as an antigen and adhesion protein during infection, enabling parasite binding to a variety of cell 
receptors (discussed in section 2.4.1.7) (Ho and White, 1999). PfEMP1 is encoded by a family of var 
genes, which leads to significant phenotypic changes and increased antigenic variation over time, 
facilitating the parasite’s evasion of host defence mechanisms (Moxon et al., 2011).  
Glycosylphosphatidylinositol (GPI) is a P. falciparum-derived glycolipid and pathogen-
associated molecular pattern (PAMP) released during schizont rupture that, once recognised by the 
host immune system, stimulates the release of cytokines, contributing to systemic pro-inflammatory 
responses (Schofield and Hackett, 1993). GPI release also stimulates increased nitric oxide (NO) 
production and increased expression of intercellular adhesion molecule 1 (ICAM-1), among other 
host endothelial cell adhesion molecules (Schofield et al., 1996; Tachado et al., 1996). Haemozoin is 
a malaria pigment produced via the digestion of haemoglobin by the parasite. Its formation is essential 
for maintaining erythrocyte structure during parasite replication, and thus parasite survival. 
Haemozoin mediates various inflammatory activities (Shio et al., 2010), and haemozoin-containing 
monocytes were increased in fatal severe malaria cases in adults (Phu et al., 1995), and children with 
CM (Dorovini-Zis et al., 2011), compared with survivors. 
 
2.4.1.2 Red blood cells 
pRBC have been shown to accumulate in brain microvessels, causing mechanical blockage 
that leads to pathology (Dondorp et al., 2008), and this is significantly more common in CM than in 
other forms of severe malaria (Pongponratn et al., 1991). Sequestration is present as a major feature 
observed in post-mortem studies of brains from CM patients. Arterioles, post capillary venules, and 
capillaries appear to be engorged with dense packing of pRBC and non-parasitised RBC, and this is 
thought to occur to remove them from circulation to avoid destruction by the spleen (Miller et al., 
2002; Schofield and Grau, 2005; van der Heyde et al., 2006). pRBC also lose flexibility, and this can 
further worsen the pathogenesis of CM. Non-infected RBC, as well as pRBC (but to a lesser extent), 
can change their shape to flow through vessels. However, this ability is impaired during P. falciparum 
infection, leading to significant changes in capillary flow rate, and the plugging of capillary lumens 
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already obstructed with sequestered pRBC (Dondorp et al., 2000; Glenister et al., 2002; Coltel et al., 
2004; van der Heyde et al., 2006; Maier et al., 2009). The ability of pRBC to deform decreases as the 
parasite matures within the cell, by changing the surface to volume ratio of the cell (Newton and 
Warrell, 1998). 
Sequestration results from adhesion of parasite-derived molecules on pRBC to receptors on 
host cells (Rowe et al., 2009). Binding interactions between pRBC and host cells can be divided into 
three main categories (Figure 1.4): 
1. Cytoadherence: interaction with endothelial cells 
2. Rosetting: interaction with non-infected RBC 
3. Clumping: interaction with other pRBC via platelet bridges 
 
Cytoadherence is the adhesion of pRBC to receptors on endothelial cells, including various 
adhesion molecules to be discussed later, all of which have been demonstrated as present on 
endothelial cells in the brain during CM (Berendt et al., 1994; Turner, 1997). This cytoadherence 
leads to pRBC sequestration in the microvasculature of various organs and tissues, including the brain 
and lungs. Cytoadherence can occur in all malarial infections (Medana and Turner, 2007). 
Conversely, rosetting and clumping are specifically associated with severe pathological 
outcomes of malaria (Rowe et al., 2009). RBC aggregation and rosetting may contribute to an increase 
in viscosity of the blood, as well as the presence of parasites. Sequestered cells adhere to the RBC 
that squeeze past. Agglutination of pRBC and aggregation of RBC to pRBC may be a result of higher 
plasma fibrinogen levels. The phenomenon of rosetting is not common in peripheral blood as mature 
forms of pRBC are few due to sequestration. pRBC are also able to bind platelets and form clumps 
in vitro, with platelets acting as bridges between individual pRBC (Figure 1.5) (Pain et al., 2001), via 
CD36-mediated binding. Analysis of the presence of rosetting and clumping shows that they are in 
direct correlation with, and therefore indicative of, the severity of CM (Dondorp et al., 2000). 
As previously stated, all of these binding interactions have been associated with and identified 
in severe malaria, in humans (Rowe et al., 1995; Pain et al., 2001) and in mice (El-Assaad et al., 
2013). As pRBC sequestration occurs in almost all cases of P. falciparum infection, including non-
cerebral cases (Clark and Rockett, 1994; Hunt and Grau, 2003), we can conclude that although 
sequestration is clearly necessary for the development of CM, it is not exclusively responsible, and 
other factors must be involved in initiating or maintaining the process leading to coma (Turner, 1997). 
Additionally, pRBC and indeed parasitaemia are not always indicative of high mortality, as patients 
with high parasitaemia can remain asymptomatic and vice versa (van der Heyde et al., 2006). 
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Figure 1.4: Adhesion of P. falciparum-infected erythrocytes to human cells. 
a) Schematic representation of the adhesion properties of pRBC to different host cells. Giemsa-
stained light microscopy images show b) cytoadherence of pRBC to endothelial cells, c) rosettes 
forming between RBC and pRBC within P. falciparum culture in vitro, and d) platelet-mediated 
clumps of pRBC formed after in vitro co-incubation (Rowe et al., 2009). 
 
2.4.1.3 Platelets 
Platelets have been long-established contributors to neurovascular lesions in CM and, in fact, 
a strong correlation has been observed between platelet accumulation and disease severity (Hunt and 
Grau, 2003). In CM patients, platelets accumulate in brain microvessels and contribute to BBB 
disruption (Grau et al., 2003). Moreover, their adhesion to endothelial cells is TNF-mediated, and 
reliant on the interactions between lymphocyte function-associated antigen 1 (LFA-1) and ICAM-1 
(Lou et al., 1997). Grau et al. found electron microscopic evidence of platelets in the lumen of brain 
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venules, between sequestered monocytes and pRBC (Grau et al., 1993). Further to this, platelets have 
been found to sequester in brain and lung microvessels during CM but not non-cerebral malaria (Grau 
et al., 1993; Lou et al., 2001; Grau et al., 2003). Conversely, platelet-expressed LFA-1 was targeted 
by a monoclonal antibody in vivo during experimental CM, and late administration successfully 
abrogated platelet sequestration and, subsequently, CM (Grau et al., 1991). Finally, confirming the 
crucial role of platelets in CM pathogenesis, experimental induction of thrombocytopenia (an 
abnormally low level of platelets) protects against the development of CM, and the associated 
mortality (Grau et al., 1993; Cox and McConkey, 2010). 
Platelets have also been shown to have a protective effect during CM. The low parasitaemia 
present early in infection stimulates local platelet activation which has been shown to have a 
protective effect, by binding to pRBC and killing P. falciparum (Polack et al., 1997; McMorran et 
al., 2009). Later in infection, systemic platelet activation occurs due to increased parasitaemia, 
contributing to sequestration and vascular damage. In Malawian patients dying of CM, accumulated 
platelets were regularly found to colocalise with malaria pigments on the endothelial cell surface, 
suggesting their close interaction with endothelial cells and pRBC during CM development (Grau et 
al., 2003). In fact, platelets have been shown to act as a bridge between EC and pRBC by directly 
binding to tumour necrosis factor (TNF)-activated endothelial cells, via platelet CD41 and endothelial 
CD40 (Figure 1.5) (Wassmer et al., 2004). Platelets are also able to bind to endothelial cells indirectly, 
by binding to von Willebrand Factor (vWF) multimers on the surface of endothelial cells (Bridges et 
al., 2010). Following platelet activation and adhesion, they then bind pRBC directly via CD36 
(Wassmer et al., 2004), forming a bridge between endothelial cells and pRBC – something that would 
not have been possible without the constitutively-expressed CD36 provided here by platelets. 
Platelets have also been shown to mediate the clumping of pRBC in vitro (Pain et al., 2001) and in 
patients in Kenya (Pain et al., 2001), and Malawi (Wassmer et al., 2008). 
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Figure 1.5: Summary of the in vitro and ex vivo findings on platelet interactions with pRBC in 
CM and their relevance in vivo (Wassmer et al., 2011a). 
 
2.4.1.4 T cells 
Experimental CM has been shown to be a T cell-dependent syndrome, involving both CD4+ 
(Grau et al., 1986; Amante et al., 2007; Amante et al., 2010), and CD8+ T cells (Yanez et al., 1996; 
Belnoue et al., 2002; Coltel et al., 2004; Hunt et al., 2010). In fact, depletion of CD4+ T cells, or 
administration of cyclosporin A to Plasmodium berghei ANKA (PbA)-infected mice (a well-
established and widely verified experimental model of CM, to be discussed further in section 2.5) 
prevented acute mortality, likely due to the correspondingly decreased production of TNF (Grau and 
Craig, 2012). Similarly, the vital role of CD8+ T cells has been confirmed through depletion studies, 
on D6 post infection (p.i.), protecting against CM, as well as adoptive transfer studies, whereby CD8+ 
T cells from infected mice were transferred to CM-resistant mice, triggering CM in these mice (Lau 
et al., 2011). These CD8+ T cells have also been shown to launch a parasite-expressed antigen-specific 
response during experimental CM (Lundie et al., 2008). Therefore, even though there is only a small 
increase in total brain CD4+ and CD8+ T cells following infection, these cells are critical to CM 
development (Belnoue et al., 2002; Renia et al., 2006). 
histamine release factor [12] and the release of Weibel-Palade
body contents occurs very early on in experimental human
infections [13].
Both mechanisms may contribute to PRBC sequestration in
vivo, either independently or in concert with each other, and
explain the peripheral pattern of platel t accumulation
observed in children who died of CM (Fig. 1a). These findings
offer promise that a CD36 blocking agent might eventually
prove valuable in the treatment of CM.
Clumping
Platelets have also been shown to mediate the clumping of
PRBC in vitro [14] (Fig. 1b), a phenomenon that was associated
with severe malaria in patients from Kenya [14], Thailand
[15], Malawi [16] and Mozambique [17]. onversely, a study
in Mali found an association with high parasitaemia, but not
severe disease [18]. The molecular mechanisms underlying
the interactions of PRBC with platelets are not fully under-
stood; however, three platelet receptors for clumping have
been identified to date: CD36, a class B scavenger receptor
ubiquitously expressed on a variety of cell types including
adipocytes, monocytes, macrophages, platelets, hepatocytes,
vascular endothelial cells and intestinal enterocytes [14]; the
globular C1q receptor (gC1qR/HABP1/p32), expressed on
diverse cell types, including endothelial cells, platelets and
dendritic cells [19]; and P-selectin, stor d n granular struc-
tures of vascular endothelial cells (Weibel-Palade bodies) and
platelets (a-granules) [16]. While the formation of clumps has
been reported in vitro and ex vivo, it s probable that this
phenomenon would contribute significantly to the vascular
obstruction observed in CM, should it occur in vivo. In the
study conducted n Malawi, plasma and PRBC from children
suffering from CM were co-incubated and the clumping
phenomenon quantified. Because of the thrombocytopenic
state of the patients, clumping int n ity was weak; however
when platelet counts were adjusted to a physiological value,
clumping increased dramatically. This suggests that throm-
bocytopenia, by reducing platelet clumping, could represent
a protective mechanism during CM [16]. An alternative
hypothesis would be that observed thrombocytopenia might,
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Interestingly, depletion studies had differing levels of success in protecting against CM, 
depending on the mouse strain used, the T cell subset depleted, and the timing of depletion during the 
infection course. Early depletion (D0 or 3 p.i.) of CD4+ but not CD8+ T cells protected against CM 
in CBA mice (Grau et al., 1991). Early depletion of either CD4+ or CD8+ T cells in C57BL/6 mice 
did not affect CM development; however late depletion (D5 or 6 p.i.) of both individually did protect 
against CM (Yanez et al., 1996; Yanez et al., 1999). Finally, late depletion of CD4+ T cells in 
129/Sv/ev x C57BL/6 mixed background mice did not protect against CM development, though early 
CD4+ and late CD8+ T cell depletion were successful. Therefore, depending on the mouse strain, 
CD4+ T cells can play a role exclusively in the induction phase, or in the effector phase of CM as 
well. CD8+ T cells appear to play a role in the effector phase only. 
T regulatory cells (Tregs) have also been investigated during CM. CD4+ CD25+ Tregs have 
been shown to suppress CD4+ T cell function and inhibit development of PbA-specific Th1 responses 
involved in experimental CM pathogenesis (Nie et al., 2007; Keswani et al., 2016). In addition to 
this, in vivo expansion of Tregs has been shown to prevent experimental CM (Haque et al., 2010). 
Finally, depletion of Tregs protects against CM, leading to decreased parasitaemia and CD8+ T cell 
accumulation in the brain (Amante et al., 2007). 
T cell co-stimulation occurs through the binding of molecules such as CD40 ligand (CD40L) 
on T cells, to CD40 and other molecules on antigen presenting cells, as well as adhesion molecules 
such as LFA-1 and ICAM-1 (Sharpe, 1995; Frauwirth and Thompson, 2002). T cells appear to 
accumulate in the brain in a chemokine-dependent manner, particularly CCR5 (Belnoue et al., 2002). 
 
2.4.1.5 Monocytes and macrophages 
Monocytes are active participants in the host immune response and, although they comprise 
3-8% of total circulating cells in a physiological state, this is increased during inflammatory 
conditions (Yang et al., 2014). Monocyte adhesion in the cerebral microvasculature D5-7 p.i. is 
commonly associated with fatal murine CM (Jerusalem et al., 1983; Polder et al., 1991). This focal 
accumulation of monocytes, enhanced by TNF-induced overexpression of adhesion molecules such 
as ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) on the endothelium, may lead to the 
predominance of lesions in the central nervous system (CNS) (Figure 1.6), and has been identified in 
both human (Pongponratn et al., 1991; Porta et al., 1993; Grau et al., 2003; Hochman et al., 2015) 
and mouse CM (Grau et al., 1987). Indeed, CM is the only syndrome in which intravascular 
monocytes accumulating in the brain acquire features of tissue macrophages without migrating into 
the tissue (Figure 1.6) (Grau et al., 1987; Medana et al., 1997a). Furthermore, the intravascular and 
perivascular presence of monocytes and macrophages has been linked to increased production of 
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inflammatory mediators, endothelial activation, vascular impairment, and cerebral oedema (Brown 
et al., 2001; Nacer et al., 2014).  
Monocytes, as well as gd T cells, represent a major source of cytokines and chemokines in 
CM pathogenesis (Stanisic et al., 2014). Macrophages are essential for the clearance of pRBC, as 
observed in humans (McGilvray et al., 2000) and in mouse models of infection (Couper et al., 2007; 
Grau and Wassmer, 2017), and can phagocytose pRBC infected with as early as the ring stages of the 
parasite (Dorovini-Zis et al., 2011; Olivier et al., 2014). Further to this, inflammatory monocyte 
depletion – either clodronate- or CCR2 antibody-mediated, early in PbA-infected mice reduces 
pathology, reinforcing the pathological involvement that these cells have during infection (Pai et al., 
2014; Schumak et al., 2015). Specifically, depleting pro-inflammatory Ly6high monocytes using an 
anti-CCR2 mAb decreases interferon gamma (IFN-g) levels, as well as IFN-g+ CD8+ T effector cells 
in the brain (Schumak et al., 2015). 
 
 
Figure 1.6: Monocytes, macrophages, and microglia in mouse (A-B) and human (C-F) CM. 
a) intravascular accumulation of macrophages at the time of murine CM, compared with b) mice 
protected from CM by anti-TNF treatment (Grau et al., 1987). c) and e) typical low levels of CD68 
in controls, with 1 perivascular macrophage (arrow), compared with d) and f) CM patients with 
enhanced macrophage/microglial responses to haemorrhages (arrows and arrow heads). Scale bars: 
C-D = 25 µm, E-F = 100 µm (Medana and Turner, 2006). 
 
2.4.1.6 Cytokines and chemokines 
Within RBC, Plasmodium releases malarial toxins, stimulating the release of pro- and anti-
inflammatory cytokines (Miller et al., 1994; Idro et al., 2005; van der Heyde et al., 2006). The 
pathogenesis of CM is likely to depend – to some extent at least – on the balance between these 
(Combes et al., 2010), and their release can account for most of the signs and symptoms exhibited by 
an infected individual. 
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2.4.1.6.1 Pro-inflammatory cytokines (Th1-type) 
Toxins produced by P. falciparum bind to pattern recognition receptors (PRR) of the innate 
immune system, which, having been stimulated, in turn, trigger the activation of monocytes, and a 
cascade of cytokines (van der Heyde et al., 2006; Van den Steen et al., 2008). The most common pro-
inflammatory cytokines detected during CM are TNF, IFN-g, lymphotoxin-a (LT-a), interleukin 
(IL)-1, and IL-6 (Ringwald et al., 1991; van der Heyde et al., 2006). 
TNF is a vital element in the pathogenesis of experimental CM (Grau et al., 1989; Clark and 
Rockett, 1994). TNF is present at high levels in the serum at the time of CM, as part of the immune 
response in reaction to circulating parasite (Grau et al., 1986). Equally, an infusion of TNF induces a 
CM-like syndrome, whereas blocking it in vivo can prevent CM (Grau et al., 1987; Kwiatkowski et 
al., 1990). However, monotherapy directed against TNF has been unsuccessful at treating active CM 
(van Hensbroek et al., 1996). Furthermore, an association of plasma TNF levels with severe malaria 
patients has been identified (Grau et al., 1989; Kwiatkowski et al., 1990), but this was not specific to 
CM (Molyneux et al., 1991; Shaffer et al., 1991). Therefore, TNF cannot be the only element 
responsible for the symptoms unique to CM. 
High levels of IFN-g have also been detected in CM patients (Ringwald et al., 1991; van der 
Heyde et al., 2006). As with TNF, neutralising IFN-g protected against experimental CM and, 
conversely, IFN-g-/- (Yanez et al., 1996) and IFN-gR-/- mice (Amani et al., 2000) were resistant to 
CM. Natural killer and gd T cells have been identified in vitro as potential sources of IFN-g during 
infection (Hensmann and Kwiatkowski, 2001). Finally, there is a fine balance between protection and 
pathology elicited by IFN-g production, where early release is protective rather than deleterious 
(Mitchell et al., 2005). 
LT-a (previously called TNF-b) is produced by activated T lymphocytes and, like TNF and 
IFN-g, has been proposed to have a key role in triggering neuropathology (Engwerda et al., 2002). 
Though not confirmed in human CM, there have been animal experiments with the knockout of the 
LT-a gene where protection against CM occurred (Engwerda et al., 2002; Hunt and Grau, 2003; 
Combes et al., 2007). LT also upregulates TNF expression and shares at least one of the TNF 
receptors (Hunt and Grau, 2003). Through this binding to TNF-Receptor 2, LT-a likely upregulates 
ICAM-1 on brain microvascular endothelial cells (Lucas et al., 1997). 
Cytokines such as TNF and IL-1, or neuroactive mediators such as nitric oxide (NO) can be 
toxic to the CNS when overproduced; however, their temporary nature may explain the reversible 
symptoms of coma in CM (Kwiatkowski et al., 1990; Adams et al., 2002). NO, produced by NO 
synthases, is thought to be a key effector for TNF in malaria pathogenesis. The physiological role of 
NO in host defence is killing intracellular organisms, and maintaining vascular status, and it also 
CHAPTER 1 | Introduction 
 20 
plays a role in neurotransmission (Idro et al., 2005). Pro-inflammatory cytokines are thought to play 
a role in generating NO in response to malarial infection, as it is known to be toxic to asexual blood 
stages of P. falciparum (Kremsner et al., 1993). Pro-inflammatory cytokines are thought to generate 
NO by upregulating inducible NO synthase in brain endothelial cells (Clark and Cowden, 2003). 
However, the role of NO is still controversial, as higher systemic levels have been measured in 
uncomplicated malaria patients in contrast to CM patients (Clark et al., 1992; Clark and Cowden, 
2003; Gouado et al., 2009). Further studies have identified an association between low NO 
bioavailability, brain microcirculatory complications, and CM pathogenesis (Gramaglia et al., 2006; 
Cabrales et al., 2011; Carvalho et al., 2014). Associations found between disease and NO activity 
have not been consistent, with results varying with age, geographical location, and the endemic nature 
or not, of the disease in that area (Coltel et al., 2004; Idro et al., 2005). 
Finally, IL-1 and IL-6, like TNF, are secreted by innate immune cells upon recognition of 
PAMP or host-derived danger-associated molecular patterns by PRR. Specifically, GPI stimulates 
the release of TNF and IL-1 by macrophages (Schofield and Hackett, 1993), as well as inducing NO 
production (Tachado et al., 1996), chemokines from human monocytes, or murine macrophages 
(Olivier et al., 2014), and human monocyte-derived dendritic cells (Bujila et al., 2016). Both IL-1 
and IL-6 are increased in African children with CM (Prakash et al., 2006). However, high levels of 
inflammatory cytokines are detected in non-lethal cases of malaria (van der Heyde et al., 2006). This 
suggests that these cytokines are necessary but not sufficient for the development of CM. 
 
2.4.1.6.2 Anti-inflammatory (Th2-type) 
The host also plays a protective role in murine CM by releasing anti-inflammatory cytokines. 
Adults with CM had lower levels of IL-10 than those with non-cerebral severe malaria (Day et al., 
1999) whereas, in paediatric CM, IL-10 was increased (Prakash et al., 2006). IL-10 administration 
confers partial protection against CM induced by PbA infection. Conversely, following infection with 
a resistant strain, this led to a significant increase in CM (Kossodo et al., 1997). Further to this, in 
vitro stimulation with malaria antigens of peripheral blood mononuclear cells from CM patients lead 
to production of IL-10, IFN-g, and TNF, with the latter inhibited following further addition of IL-10 
(Ho et al., 1998). Further to this, IL-10 inhibits the production of chemokines and other cytokines, 
including macrophage colony-stimulating factor, IL-1, IL-6, and TNF (Moore et al., 2001). 
TGF-b has been proposed as an important immunoregulatory molecule determining the 
balance between immune and immunopathological reactions in murine malaria (Omer and Riley, 
1998). TGF-b is significantly elevated in the blood and cerebrospinal fluid (CSF) of CM patients 
(Brown et al., 2000; Prakash et al., 2006), and in human CM post-mortem brain tissue from Malawian 
children with CM or other severe neuropathologies, such as meningitis (Brown et al., 1999). 
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2.4.1.6.3 Chemokines 
Chemokines (chemotactic cytokines) recruit lymphocytes and monocytes to the site of 
pathogen accumulation, and thus promote CM pathogenesis. For example, initial IFN-g responses 
induce chemokines such as CXCL9 and CXCL10, which in turn acts to recruit T cells and natural 
killer cells to the site of infection via the CXCR3 receptor (Liehl et al., 2014; Miller et al., 2014). 
Additionally, CXCL8, CXCL4 and CXCL10 are elevated during P. falciparum infection (Hermsen 
et al., 2003; Wilson et al., 2011), and CXCL10 has been studied extensively as a marker of CM 
severity (Kwiatkowski et al., 1990; Wilson et al., 2011). Activated endothelial cells have been shown 
to secrete CCL2 (monocytes), CCL20 (Th17 cells, B cells and dendritic cells), CXCL1 (neutrophils), 
CXCL2 (monocytes and macrophages), CXCL9 (T and NK cells) and CXCL10 (T and NK cells) 
during Plasmodium infection (Viebig et al., 2005; Tripathi et al., 2006; Chakravorty et al., 2007; 
Tripathi et al., 2009; Dunst et al., 2017). 
 
2.4.1.7 Endothelial cells and adhesion molecules 
Endothelial cells are specially adapted, in the brain, to prevent the flow of molecules either 
between or across cells, via highly organised tight junctions between cells, low rates of fluid-phase 
pinocytosis, and specific transporters and efflux mechanisms allowing only essential molecules to 
gain access while others are returned to the circulation (Adams et al., 2002). These junctional proteins 
regulate permeability in a tightly regulated manner, interacting with the cell’s actin cytoskeleton via 
cytoplasmic proteins such as zonula occludens (ZO) 1-3 (Huber et al., 2001). Following activation of 
endothelial cells, the integrity or permeability of these junctions can be altered (Adams et al., 2002). 
Murine CM is characterised by extensive endothelial cell activation in the brain 
microvasculature (Hunt et al., 2006; Hempel et al., 2014; Dunst et al., 2017) as indicated by ICAM-
1 and VCAM-1 upregulation, as well as morphological changes such as swelling of the endothelium 
and focal endothelial cell damage and necrosis (Jerusalem et al., 1983; Grau et al., 1991; Polder et 
al., 1991; Turner, 1997). There are two major categories of endothelial “damage”: firstly, breakdown 
of BBB function with involvement of host effector cells and pRBC (Faille et al., 2009a; Jambou et 
al., 2010), resulting in leakage from cerebral vessels and increased brain oedema (Medana and Turner, 
2007). This process includes alterations to junctional proteins, for example zonular occludens 1 (ZO-
1), a tight junction protein found at the surface between endothelial cells. The second type of 
endothelial damage is the apoptosis of endothelial cells, which is increased in patients with 
neurological complications and, in combination with platelets or microvesicles, contributes to 
vascular damage (Wassmer et al., 2006; Pankoui Mfonkeu et al., 2010; Nantakomol et al., 2011). The 
endothelial changes in CM vary based on activation from contact with pRBC or leucocytes, invariably 
leading to a cascade of inflammatory responses, including cytokine induction (Combes et al., 2010). 
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The over-vigorous immune response that can be stimulated following infection with a virulent 
parasite strain could predispose those individuals to severe malaria and CM (Adams et al., 2002). 
vWF has been demonstrated to increase during CM, and in critical in the early stages of P. falciparum 
cytoadherence to endothelial cells (Hollestelle et al., 2006; Lopez, 2010). Vascular endothelial growth 
factor levels are also modified during severe malaria, due to the angiogenic dysregulation that occurs 
(Furuta et al., 2010). Finally, endothelial cell activation leads to expression of many adhesion 
molecules, including ICAM-1, VCAM-1, CD36, thrombospondin (TSP/THBS), chondroitin sulfate 
A (CSA), and E-selectin. Many of these adhesion molecules also act as endothelial receptors for 
leucocytes during inflammatory responses and immune surveillance (Adams et al., 2002). For 
example, ICAM-1 binds to the leucocyte adhesion molecule 1 (LFA-1), and this adhesion, as well as 
additional signalling and changes in junctional permeability could allow leucocytes to enter the brain 
during inflammation; however, the latter does not occur during CM (Perry et al., 1997; Hickey, 2001). 
 
2.4.1.8 Blood-brain barrier 
Any theory about the development of the CM syndrome must involve either the transfer of 
active mediators from the blood into the brain tissue, or a parenchymal response to signals coming 
from inside blood vessels, making the blood-brain barrier (BBB) a crucial interface in this syndrome 
(Adams, 2002). 
The blood brain barrier (BBB) is highly specialised structural and functional interface 
between the intravascular space and the CNS. It is composed of endothelial cells, basement 
membrane, pericytes, and astrocyte foot processes, and is set up to tightly limit and polarise molecular 
and cellular trafficking into the brain (Figure 1.7) (Medana and Turner, 2006). The high mortality 
associated with CM is thought to be related to the ability of the infection to disturb the integrity of 
the BBB. Histological, immunohistochemical, and ultrastructural studies of post-mortem brain tissue 
from fatal cases of human CM and in the mouse model have revealed structural changes at the BBB 
(Adams et al., 2002). Examples of these include evidence of endothelial cell activation, upregulation 
of ICAM-1 and E-selectin, and other constitutively expressed adhesion molecules, and induction of 
soluble mediators from other CNS cells (Turner et al., 1994; Medana and Turner, 2006). The process 
by which the parasite is thought to adhere to the BBB is through P. falciparum erythrocyte membrane 
protein-1 (PfEMP-1). This protein mediates pRBC adhesion to ICAM-1 and other cell receptors 
including TSP, CSA, P-selectin, and endothelial protein C receptor (Rowe et al., 2009; Turner et al., 
2013). This binding increases junctional permeability of the BBB and suppresses dendritic cell and 
macrophage activation (Adams et al., 2002; Schofield and Grau, 2005; Medana and Turner, 2006; 
Faille et al., 2009b). The adhesion of pRBC and endothelial cells triggers the release of soluble 
products such as cytokines and parasite toxins, which could, in turn, trigger further changes in host 
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cells. For example, TNF and LT have been shown to induce changes in the BBB structure (Hunt and 
Grau, 2003). Furthermore, decreased blood flow, resulting from vascular accumulation of adherent 
cells and leading to hypoxia, may activate or damage cerebral endothelial cells and perivascular cells 
(Dondorp et al., 2008; Beare et al., 2009; Cabrales et al., 2010; Desruisseaux et al., 2010). 
In the murine model (discussed more in section 2.5), there are two distinct phases of BBB 
changes: firstly there is a mild localised breakdown three days after infection, and then, seven days 
after infection, more extensive disruption occurs, leading to plasma leakage into the perivascular 
space, activation and alteration of the distribution of astrocytes and glial cells, as well as the changes 
previously mentioned such as upregulation of endothelial adhesion molecules, accumulation of 
sequestered cells, increase in BBB permeability, cytokine stimulation leading to activated 
inflammatory processes disturbing neuronal function and leading ultimately, to death (Medana et al., 
1996; Medana et al., 2000). 
 
 
Figure 1.7: The blood-brain barrier in malaria. 
A schematic representation of the structures forming the BBB, the events occurring during malaria 
and some of the possible mechanisms that may influence the function of the BBB during CM (Medana 
and Turner, 2006). 
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2.4.2 Surrounding brain parenchyma 
 
2.4.2.1 Hypoxia 
Oxygen is a requirement for normal function of mammalian cells, in order to maintain 
homeostasis, and providing the basis for aerobic metabolism. Transcriptional changes can occur 
quickly, to reduce hypoxia-associated tissue damage, for example the rapid upregulation of the 
transcription factor hypoxia-inducible factor (HIF)-1a in response to hypoxic conditions (Sharp and 
Bernaudin, 2004). Impaired cerebral microcirculation has previously been shown to be caused by 
vascular occlusion due to sequestered pRBC, platelets, and leucocytes, among other factors. Cerebral 
hypoperfusion is one consequence of this microcirculatory blockage, and failure to adapt to hypoxia 
resulting in irreversible tissue damage and a clear association with poor clinical outcomes for patients 
(Dondorp et al., 2008; Beare et al., 2009). In the mouse model, increased intracranial pressure and 
correspondingly decreased cerebral blood flow have been identified (Penet et al., 2005), leading to 
cerebral ischaemia (Rae et al., 2004) and potentially hypoxia (Polder et al., 1991; Cabrales et al., 
2013). Reversing this therapeutically, for example using erythropoietin, which is a hypoxia-
responsive hormone, decreases cerebral disease and improves survival (Kaiser et al., 2006; Wiese et 
al., 2008). Hempel et al. demonstrated the presence of multifocal areas of cerebral hypoxia in 
experimental CM, detecting widespread low-grade intercellular and intracellular hypoxia, as well as 
specifically in neuronal and glial foci (Hempel et al., 2011). 
 
2.4.2.2 Glial cells and neuronal changes 
Activation of glial cells, particularly astrocytes and microglia, has been suggested as a 
hallmark of CM pathogenesis (Medana et al., 1997a; Medana et al., 2002). Following PbA infection, 
glial cells – particularly astrocytes and microglia, have been shown to become more numerous, 
become activated and change their morphology (Medana et al., 1997a). During CM, alterations in 
BBB function incite changes in the distribution and properties of astrocytes and microglia, both key 
non-neuronal elements in the brain parenchyma (Medana et al., 1997a). 
Microglia have been shown to become activated within 48-72 hours post PbA infection and, 
later in the infection course, take on an amoeboid appearance, which is representative of an 
immunologically activated state (Medana et al., 1997a), and subsequently express TNF (Medana et 
al., 1997b). TGF-b and IL-6 (as have already been discussed in section 2.4.1.6) have been shown to 
affect the morphology and activation of glial cells in the brain during CM and, in fact, anti-IL-6 and 
to some degree anti TGF-b treatments demonstrated success in protecting against the development of 
the neurological syndrome and inhibiting parasitaemia development (Sarkar et al., 2017). 
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Furthermore, microglia have been shown to phagocytose pRBC in CM only, compared with non-CM 
and non-infected mice (Shrivastava et al., 2017). 
Astrocytes are essential components of the BBB, and function to modulate synaptic 
transmission and maintain ionic balance within the brain, and to control metabolic processes and 
microvascular behaviour (Combes et al., 2012). They have been studied in great detail in CM, due to 
their role in biochemically supporting endothelial cells and thus, BBB function. Astrocytes, as well 
as microglia, can become dysfunctional in response to pRBC sequestration and parasite molecules 
(Deininger et al., 2002), and in support of this, axonal and astrocytic injury markers are found 
increased in CSF samples from CM patients (Medana et al., 2007). Oxidative stress and neuronal 
injury have also been demonstrated in the vicinity of vessel haemorrhaging (Medana et al., 2001). 
Furthermore, many inflammatory mediators are produced by astrocytes during CM, including 
CXCL10 (Sawada et al., 1989; Bakmiwewa et al., 2016). Early in the development of CM, astrocytes 
proliferate in response to hypoxic conditions and cytokines such as IFN-g and LT-a (Bakmiwewa et 
al., 2016), and clusters of astrocytes are more frequently observed by electron microscopy in mice 
with CM (Ampawong et al., 2014). Later in the syndrome, however, a focal loss of astrocytes is 
observed (Medana et al., 1996), leading to impaired BBB integrity and increased oedema. A typical 
feature of CM pathology is enlarged perivascular spaces. Aquaporin 4, a water channel protein, is 
highly expressed in astrocytes and its upregulation in astrocyte foot processes leads to increased 
oedema in the brains of mice with CM and, to a lesser extent, in non-CM mice with severe malaria 
(Ampawong et al., 2011; Promeneur et al., 2013). 
 
2.5 Modelling cerebral malaria 
Studying CM pathogenesis in humans is only recently beginning to be implemented, through 
studies utilising controlled human malaria infections (Spring et al., 2014). Post-mortem studies are 
another alternative, however limited information is provided by such studies as only the endpoint of 
the disease can plainly be analysed. Therefore in vivo approaches, such as use of animal models and 
in vitro techniques modelling the human BBB, provide a useful tool in further understanding the 
disease. Weksler et al. developed one of the first immortalised human cerebral microvascular 
endothelial cell lines – the hCMEC/D3, a stable in vitro culture that retains many of the morphological 
and functional characteristics of brain endothelial cells (Weksler et al., 2005), and therefore used as 
a model of the human BBB during CM (Jambou et al., 2010). 
Experimental models in vivo have also been widely used to study the syndrome; however, the 
main challenge facing researchers using animal models is to replicate the features of the disease as 
accurately as possible. Models exist in various primates, and rodents such as hamsters, rats, and mice. 
Primates are naturally affected by malaria but not much is known about the outcome of the disease 
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in this situation. Rhesus monkeys are typically infected with P. knowlesi, P. coatneyi, or P. fragile 
for experimental study. Monkeys develop acute symptoms a week p.i. show cerebral vascular 
congestion, pRBC sequestration in the brain, rosette formation, and increased levels of ICAM-1, 
TNF, and IFN-g similar to human CM (de Souza and Riley, 2002). Therefore, as the pathological 
changes so closely resemble human CM, and as malaria infections occur naturally in primates, this 
model is useful for comparison and study (Lou et al., 2001). However, some limitations exist with 
this model: determining the time of CM onset is difficult, and the incidence of this syndrome is low 
and somewhat unpredictable in the monkeys. In addition, there are ethical considerations, significant 
financial expenditure, and lack of genetically modified primates (Combes et al., 2005b). 
Hamsters and rats have also been used as experimental models, but infrequently. The majority 
of rodent experiments involve mice infected with PbA, which reproduces over 25 pathophysiological, 
biochemical, clinical, histopathological, and immunological features of human CM (Lou et al., 2001; 
Hunt and Grau, 2003; Combes et al., 2005b; Hunt et al., 2010; Riley et al., 2010; Craig et al., 2012). 
For example, the same behavioural changes, histopathological features and expression of molecules 
in the brain and retina, and changes to BBB function can be seen in paediatric, adult, and murine CM 
(Hunt and Grau, 2003). The rodent and human parasites also share defined malaria antigens. 
Moreover, mice are quicker and more simply bred, and many different strains and genetic 
modifications are known to be susceptible or not to CM. A higher incidence of the disease occurs in 
mice, and the disease tends to follow a more easily predictable infection course (de Souza and Riley, 
2002). This model, compared with that of monkeys, is more easily managed and widely available. 
Known CM susceptible mice include CBA, C57BL/6, and DBA/1 mice, and these mice 
reproducibly die between days 7 and 10 following PbA infection (clinical scores of 3-4). Known 
resistant mice include BALB/C and ABCA-1-/- DBA/1 mice, and these mice reproducibly die during 
the third week after infection, but do not develop CM, but instead are affected by severe anaemia and 
hyperparasitaemia (clinical score £ 2) (Figure 1.8, Table 1.2) (Lou et al., 2001; Combes et al., 2005a). 
 
Table 1.2: Scoring system used to evaluate the typical clinical signs observed in CM 
Clinical 
Evaluation Score Observation 
0 No discernible clinical signs 
1 Hunched poster, slightly ruffled fur 
2 Very ruffled fur, incipient motor impairment 
3 Very ruffled fur, severe motor impairment such as ataxia, hemiplegia and paraplegia, convulsions, fitting 
4 Very little movement, cold to the touch (coma state) 
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Figure 1.8: Experimental mouse model of PbA infection in CM-susceptible and CM-resistant 
mice 
 
Despite the large amount of insight the murine models provide into the disease, some 
disadvantages do exist. There are obvious anatomical and physiological differences between mice 
and humans, and this may impact experimental findings (Lou et al., 2001). Obviously, primates are 
a closer approximation of this, but, as detailed above, there are a number of other issues with that 
model. In the murine model, pRBC cytoadherence does not occur for all parasites, the syndrome 
cannot be reversed, and some parasitological differences exist between murine and human parasites 
(Amante et al., 2010; Franke-Fayard et al., 2010; Strangward et al., 2017). In addition, P. falciparum 
does not infect mice, limiting the comparisons with humans (Combes et al., 2005b). However, even 
considering these disadvantages, the murine model remains a valuable tool in discovering more 
insight into the pathogenesis of CM. 
 
2.6 Techniques used to study cerebral malaria 
The best way to study the various elements of CM pathogenesis and their interactions is to 
examine them in real time during infection – using magnetic resonance imaging (MRI), retinal 
imaging, or biological fluid examination in human patients, or depletion studies, directed therapies, 
adoptive transfer, or microscopy or flow cytometry-based approaches in experimental models of CM.  
Retinal imaging, examination of plasma or CSF, and MRI are all used to examine CM 
pathophysiology in patients, and in experimental CM and recently, some of these methods have been 
shown to be critical in establishing an accurate diagnosis of CM. Severe malaria is commonly 
misdiagnosed due to the non-specific nature of the signs and symptoms presented, and the possibility 
of comorbidities. A further challenge is the prevalence of asymptomatic parasitaemia (up to 70%) in 
areas with high transmission (Smith et al., 1993; Beare et al., 2006). Malarial retinopathy particularly, 
has been used to distinguish severe pathology. The components of malarial retinopathy are retinal 
whitening, vessel changes, retinal haemorrhages, and papilledema (swelling of the optic nerve), with 
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the first two unique to malaria (Beare et al., 2006). The advantages of malarial retinopathy as a 
diagnostic tool for severe malaria include the accessibility of the retina for non-invasive assessment, 
and the reflection in the retina of vascular changes in the brain during CM (MacCormick et al., 2014). 
Examination of plasma or CSF has also been implemented to rule out comorbidities or 
diseases presenting with similar symptoms, e.g. a lumbar puncture in coma patients may serve to rule 
out bacterial meningitis. Furthermore, plasma and CSF samples have been shown to indicate subtle 
but quantifiable changes consistent with impaired BBB function in CM (Brown et al., 2001). 
Increased TNF and angiopoietin-1 have been identified as biomarkers to distinguish uncomplicated 
malaria or comatose non-malaria patients from CM patients with or without retinopathy (Molyneux 
et al., 1993; Conroy et al., 2010). The levels of tau and S-100B proteins were also assessed in the 
CSF, and tau protein levels were found to be inversely correlated with the level of consciousness of 
CM patients, and increased levels of S-100B correlated with an increased risk of repeated seizures 
(Medana et al., 2007). This method of diagnosis can be performed more easily in areas where 
resources are limited, compared with indirect ophthalmology to detect retinopathy (Conroy et al., 
2010). 
MRI enables the detection and tracking of BBB disruption, oedema development, and brain 
swelling in murine and human CM (Penet et al., 2005; Penet et al., 2007; Hoffmann et al., 2017; 
Mohanty et al., 2017). MRI, compared with other techniques, can detect cortical changes including 
atrophy in the brain, to understand how seizures and increased ICP contribute to the development of 
neurological sequelae (Kampondeni et al., 2013). MRI has enabled us to further differentiate between 
adult and paediatric CM, with cerebral swelling minimal in adults, compared with increased brain 
swelling and coma or death in children, where it is a particularly useful tool to study retinopathy-
negative cases (Maude et al., 2014; Postels et al., 2014). 
Depletion studies and adoptive transfer experiments have been widely used to ascertain 
whether specific cell types, vesicles, or soluble products contribute to disease progression in CM, and 
their role during infection. Interestingly, specifically depleting certain cytokines or cells during PbA 
infection prevents CM, however this success is dependent on the timing of depletion and, to some 
degree, the mouse strain used, as detailed in section 2.4 (Chang et al., 2001; van der Heyde et al., 
2005; Schumak et al., 2015). Directed therapies, similarly to depletion studies, can be used to target 
individual cell types or groups. Though most treatment options for CM are directed at the parasite, 
immune-targeting therapies provide a new avenue to address the syndrome (Zumla et al., 2016). 
Adoptive transfer has been utilised in the opposite manner, to see whether introducing particular cell 
types or cytokines can induce disease in healthy mice or worsen disease progression in infected mice. 
In this technique, cells can be harvested from donor mice and sorted out of a heterogeneous population 
of cells based on specific light scattering and fluorescent characteristics of each cell using 
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fluorescence-activated cell sorting (FACS). These sorted cells, and a variety of molecules can then 
be reinjected into recipient mice, and the effects monitored (El-Assaad et al., 2014). 
Fluorescence microscopy-based approaches have been used to study circulating and tissue-
resident cells in the brain and other tissues for many years; however, recently, new and improved 
optical imaging techniques, such as 2-photon microscopy, and clearing methods have allowed tissue 
sections of increasing size to be examined, up to whole tissues or whole organisms, through ex vivo 
or intravital imaging (Becker et al., 2012; Pai et al., 2014; Susaki et al., 2015). As the technology 
continues to improve, so too will the speed and resolution at which this imaging can take place. 
Finally, multi-colour flow cytometry allows us to specifically label many different cell types 
and identify changes in number and surface markers in response to infection, with increased 
sensitivity and complexity compared with confocal microscopy (Basiji et al., 2007). The number of 
markers able to be tested in one panel is continually increasing, with 18 markers being the current 
demonstrated maximum (Ornatsky et al., 2010). More recently, CyToF technology (mass cytometry) 
has emerged, where antibodies are labelled with heavy metal ion tags instead of fluorochromes, 
enabling many more markers to be assessed simultaneously in a single sample, without significant 
spectral overlap between channels. Up to 30 unique markers have been assessed at one time, with up 
to 60 distinguishable labels theoretically possible (Ornatsky et al., 2010). However, the practical flow 
rate is considerably lower than in traditional flow cytometry (Fluidigm, 2017). 
 
2.7 Current treatments and preventative measures of cerebral malaria 
 
2.7.1 Anti-malarial drugs 
Upon admission, most patients are given supportive therapy to improve their survival chances 
and allow the therapeutic drugs time to work. Shock, hypoglycaemia, hypoxia, and severe metabolic 
acidosis are managed by saline, fluid and glucose resuscitation and by whole blood transfusions (Idro 
et al., 2005). Antibiotics can be administered prophylactically, to avoid possible secondary infections. 
Adults presenting with pulmonary oedema or renal failure can be treated with ventilation and renal 
dialysis, respectively (Greenwood et al., 2005). 
Antimalarial drugs also exist to treat uncomplicated falciparum malaria (Table 1.3). The 
cinchona alkaloid group, including chloroquine, takes effect during the later stages of parasite 
development (Idro et al., 2005). Cinchona alkaloids can be administered intravenously or 
intramuscularly, but are no longer useful in treating most cases of malaria, due to the development of 
resistance (Conway, 2007). Sulfadoxine-pyrimethamine (SP) has been introduced to replace 
chloroquine, however resistance to this drug has also developed in most countries (WHO, 2016). 
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To avoid resistance developing and overcome the emergence of resistant parasites, combination 
drug therapies are now being utilised as first-line treatment for P. falciparum infections. This involves 
using multiple drugs with different modes of action and therapeutic targets but with similar half-lives 
(WHO, 2016). Artemisinin-based combination treatments (ACTs) have been effective in Africa and 
Asia. Artemisinins are active at early and late stages of parasite development (Idro et al., 2005) and 
ACTs represent the most effective treatment currently available, with recovery from malarial 
infection usually occurring within three days. ACTs are easier to administer than cinchona alkaloid 
derivatives and have fewer side effects (Idro et al., 2005). However, they cost up to ten times that of 
single drug therapies such as chloroquine (WHO, 2016). This increased cost, combined with the 
shortage of Artemisia annua (the plant source of artemisinin) has prompted production of synthetic 
versions of artemisinins (Greenwood et al., 2005). There is also increasing resistance to artemisinin 
in South-East Asia. Evidence of P. falciparum parasites with reduced in vivo susceptibility to 
artemisinin derivatives has emerged in western Cambodia (Noedl et al., 2008; Dondorp et al., 2009). 
However, prompt administration of ACTs for uncomplicated malaria patients resulted in a 99% 
reduced mortality in children ages 1-23 months, and by 97% in children aged 24-59 months (WHO, 
2016). Parenteral artesunate or another artemisinin derivative is the recommended treatment for 
severe malaria, particularly CM, combined with early hospitalisation and critical care (Kyu and 
Fernández, 2009; Sinclair et al., 2012). Finally, a new class of antimalarial drugs – spiroindolones – 
has emerged, successfully inhibiting protein synthesis in the parasite (Rottmann et al., 2010). 
 
Table 1.3: Current antimalarial drugs and combination treatments (WHO, 2015; WHO, 2016) 
Monotherapies (previously or currently used) 
Quinine 
Effective and widely used in acute cases of severe P. falciparum. Widespread 
resistance, but still used in areas with chloroquine resistance, and post-exposure 
treatment of individuals returning from malaria-endemic regions. 
Chloroquine 
Was the most widely used anti-malarial, prior to the spread of resistance, due its 
effectiveness, safety of use, and cheap cost. Still widely used in most sub-Saharan 
countries. 
Amodiaquine Similar in structure and mechanism of action to chloroquine; used in cases of chloroquine resistance. 
Pyrimethamine Used in the treatment of uncomplicated malaria, and in cases of chloroquine resistance. Not effective alone. 
Doxycycline Very prevalent anti-malarial due to its relative effectiveness and cheapness; used in areas where chloroquine resistance exists. 
Mefloquine Chemically similar to quinine; used for prevention of resistant strains of P. falciparum only, in acute therapy. Can also be used prophylactically. 
Artemisinin and 
derivatives 
Rapid action used effectively alone or in combination with other anti-malarial 
drugs. Derivatives include artemether, artesunate, dihydroartemisinin, and 
arteether, all with similar modes of action. Artesunate is the most commonly used 
of all artemisinin-type drugs. 
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Non-artemisinin combinations 
Quinine & SP Used effectively in Europe and parts of Asia. Long treatment course, cost, and side effects make combination inappropriate for the African market. 
Quinine &  
doxycycline 
Similar to quinine & SP, mainly used where SP resistance is a problem (e.g. 
Thailand). 
SP & chloroquine Current policy used in some African countries but is ineffective where resistance to both drugs is high. 
SP & amodiaquine Substantially more effective than SP and chloroquine in areas where amodiaquine resistance is low. 
Artemisinin-based combination treatments (ACTs) 
Artemther-
lumefantrine 
Currently the only internationally licensed co-formulated ACT. Available in Asia 
and Africa. 
Artesunate & 
amodiaquine 
Currently co-packaged. Adopted as policy by some African counties. Effective 
where amodiaquine resistance is low. 
Dihydroartemisinin-
piperaquine 
Co-formulated drug that has been used widely in Asia and is presently being 
assessed in a new formulation for licensing. 
Artesunate & 
mefloquine 
Mainstay of antimalarial drug policy in much of South-East Asia. Regarded as too 
expensive for the African market. 
Artesunate & SP 
 
Treatment used in some Asian countries (e.g., Afghanistan). Ineffective where SP 
has failed. 
Dihydroartemisinin-
napthoquine-
trimethoprim  
New formulation used in China and Vietnam. Early reports are encouraging 
 
2.7.2 Vector control 
Vector control has been one of the main efforts targeted at malaria eradication. Many 
approaches have been implemented, including the use of dichloro-diphenyl-trichloroethane (DDT) as 
an insecticide for indoor residual use, insecticide treated bed nets, draining of breeding sites and the 
use of lavivorous fish to control mosquitoes at the larval stages (Sachs and Malaney, 2002; WHO, 
2011; WHO, 2016). Sterile insect technique is emerging as a potential mosquito control method. This 
involves transgenic, or genetically modified mosquitoes that have been made malaria-resistant. This 
involves introducing a gene into the mosquito that functions to impair the development of the parasite 
within its gut (Marrelli et al., 2007; Corby-Harris et al., 2010). In experimental malaria, promising 
fitness comparison results have been observed, providing potential implications for the control of 
mosquito vectors. Alternatively, new genetic techniques have been used to instead impair the ability 
of the mosquito to transmit the parasite, without affecting the mosquitoes otherwise – transgenic 
mosquitoes express antiparasitic genes introduced in their midgut epithelium, or bacterial species 
introduced into their flora that serve the same purpose (Ito et al., 2002; Riehle et al., 2007). 
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2.7.3 Malaria vaccines 
Currently, a completely effective vaccine does not exist, because of the complexity of parasite 
biology. Target antigens need to serve a function critical to the parasite, and be associated with 
naturally acquired immunity or be protective in animal models (Greenwood et al., 2005). So far, most 
efforts have been directed at the development of pre-erythrocytic stage vaccines designed to prevent 
the invasion of hepatocytes by sporozoites or to destroy infected hepatocytes. Currently, a single 
candidate vaccine has completed stage 3 clinical trials, and was approved for pilot trials in a few 
select countries by the European Medicines Authority (Committee for Medicinal Products for Human 
Use (CHMP), 2015). Another 22 projects are in phase 1 or phase 2 clinical trials, tackling the pre-
erythrocytic, blood-stage and sexual-stage of the parasite, as well as testing the viability or irradiated 
sporozoites as an inactivated vaccine (WHO, 2016; WHO, 2017). RTSS/AS02A is the most advanced 
pre-erythrocytic vaccine, and is a hybrid consisting of a circumsporozoite protein of P. falciparum 
expressed with hepatitis-B surface antigen in yeast. This vaccine is given with the complex adjuvant, 
AS02, and has provided substantial, short-lived protection in volunteers exposed experimentally or 
naturally to bites from infected mosquitoes. This vaccine reduced clinical incidence of malaria by 
39% overall, and specifically severe malaria by 31.5% (Greenwood et al., 2005). 
Another type of vaccine that has the potential to help control the spread of malaria is a 
recombinant set of vaccines called transmission-blocking vaccines. These vaccines work by 
preventing the development of malarial parasites within the mosquito vector, and thus eliminating 
the cascade of secondary infections in humans. As a crucial stage of the Plasmodium life cycle is the 
evolution of the parasite in the midgut of the Anopheles mosquito, targeting midgut antigens that 
serve as ligands for the parasite offers a potential solution in the control of this disease (Mathias et 
al., 2012). For example, the highly conserved, midgut-specific, anopheline alanyl aminopeptidase N 
(AnAPN1) is a putative ligand for P. falciparum and vivax ookinetes invasion and can be purified 
from an Escherichia coli vector. AnAPN1 is able to trigger the generation of functional malaria 
parasite transmission-blocking antibodies, and adsorbs completely to incomplete Freund’s adjuvant, 
a safe adjuvant that enhances the immune response of the recipient. The current research suggests 
that this vaccine could be suitable to progress to phase 1 clinical trials (Mathias et al., 2012). 
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3 Microparticles/Microvesicles 
 
3.1 Introduction 
Microparticles, now called microvesicles (MV), are submicron elements that originate from a 
loss of phospholipid asymmetry associated with the remodelling of the cytoskeleton and the increase 
in cytosolic calcium (Zwaal and Schroit, 1997). They are cellular-derived vesicles, and range from 
0.2 – 1 µm in size (Combes et al., 2010), and are also described in the literature as microparticles, 
ectosomes, exovesicles and shed vesicles (Doeuvre et al., 2009; Burger et al., 2013). All cell types 
have the capacity to vesiculate (produce MV) under normal physiological conditions, upon cellular 
activation, and during apoptosis (Coltel et al., 2006). MV released from platelets, endothelial cells, 
RBC, and monocytes have been studied extensively in comparison to other cell types. Wolf first 
observed them in 1967, where he referred to them as “platelet dust.” They were described as 
fragments derived from platelets in human plasma, and were thought to be a residue or by-product of 
platelet activation, hence the name platelet dust (Wolf, 1967). 
 
3.2 Microvesicles and other extracellular vesicles 
Due to inconsistent nomenclature use, MV have been confused with other extracellular 
vesicles in the past, particularly exosomes and apoptotic bodies (Table 1.4), however their size, 
contents, mechanism of formation, and membrane composition are extremely heterogeneous 
(Schindler et al., 2014). While MV, as described in more detail in sections 3.3-7, are in the 200-1000 
nm size range, exosomes are smaller, ranging from 40-200 nm, and apoptotic bodies are larger, 
though the strict separation of these vesicle types by size particularly, has not been established 
concretely (Witwer et al., 2013; Colombo et al., 2014). In addition, these three types of vesicles are 
formed via very different pathways, from different cellular compartments. MV are plasma membrane-
derived and, as previously stated, form under normal physiological (section 3.6) and pathological 
conditions (Section 3.7). Apoptotic bodies, like MV, are plasma membrane-derived, however they 
form specifically in apoptosis-mediated conditions. Conversely, exosomes are formed within the cell, 
in early endosomes and multi-vesicular bodies (MVB), and are released through a process called 
exocytosis, where the MVB fuses with the plasma membrane. Exosomes contain, as well as proteins 
and RNA from their cell of origin, a common set of evolutionarily-conserved protein molecules and 
double-stranded (ds) DNA (Thakur et al., 2014; Maguire, 2016), and are usually characterised by 
their surface markers, including LAMP1, CD63, and TSG101 (Mathivanan et al., 2010). MV and 
exosomes are isolated via differential centrifugation protocols, but both play important immuno-
modulatory roles (Théry et al., 2002). 
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Table 1.4: Characteristics of various types of extracellular vesicles. Adapted from Burger et al. 
(2013), Schindler et al. (2014) and Witwer et al. (2013) 
Characteristic Exosomes Microvesicles Apoptotic bodies 
Size 40-200 nm 200-1000 nm >1000 nm 
Mechanism of 
formation 
Fusion of multivesicular 
bodies with plasma 
membrane 
Outward blebbing of 
plasma membrane 
Cell shrinkage and 
apoptosis 
Appearance Homogenous Heterogeneous Heterogeneous 
Centrifugation 
isolation speed 100,000 g 10,000 g 1,200 g 
Detection 
Electron microscopy and 
Western blotting 
(characterisation with 
exosome-enriched 
markers) 
Flow cytometry, 
capture-based assays, 
and electron microscopy 
Flow cytometry and 
electron microscopy 
Characteristic 
features 
LAMP1, CD63, and 
TSG101 
PS detection by 
Annexin-V and presence 
of cell-specific surface 
markers 
PS detection by 
Annexin-V, DNA, and 
permeable membrane 
Composition Protein, dsDNA, RNA, microRNA 
Protein, RNA, 
microRNA 
Cell organelles, protein, 
DNA, RNA, microRNA 
Membrane 
properties 
Rich in lipid rafts and 
impermeable 
Externalised PS, rich in 
lipid rafts, impermeable 
Externalised PS and 
permeable 
 
3.3 Vesiculation 
MV are produced via the process of vesiculation, which occurs when numerous enzymes, 
proteins, and cellular components coordinate to ultimately disrupt the plasma membrane and result 
in blebbing (Freyssinet, 2003). The translipid bilayer distribution of the plasma membrane is under 
the control of three enzymes. The first of these is an inward-directed pump or a “flippase”, specific 
for PS and PE, called aminophospholipid translocase. The second is an outward-directed pump 
referred to as “floppase”; and the third is a lipid scramblase, responsible for promoting random 
movement of phospholipids in both directions across the bilayer (Figure 1.9) (Freyssinet, 2003; Hugel 
et al., 2005). Flippase and floppase are adenosine 5’-triphosphate (ATP)-dependent (Piccin et al., 
2007). The increase in cytosolic calcium, as described above, occurs during cell activation and 
apoptosis, and stimulates the random movement of phospholipids across cell membranes though the 
action of scramblase, a membrane enzyme, while inhibiting the flippase enzyme (Zwaal and Schroit, 
1997; Martinez et al., 2005; Piccin et al., 2007). Other enzymes involved in this process are gelsolin, 
which contributes to actin reorganisation, and calpain, which cleaves cytoskeletal filaments, 
facilitating MV shedding (Piccin et al., 2007). 
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Figure 1.9: Transporter-controlled exchange of phospholipids between both lipid leaflets of the 
cell membrane (Zwaal et al., 2005) 
 
In the resting state, as calcium levels are low, scramblase is inactive, and ATP-dependent 
flippase and floppase are responsible for maintaining phospholipid asymmetry (PS and PE still on 
the inside of the membrane). When cells are subjected to procoagulant, pro-inflammatory, or 
apoptogenic stimulation, a spontaneous collapse of their membrane asymmetry typically occurs. As 
calcium is released by the endoplasmic reticulum, scramblase is activated, and flippase and floppase 
are inactivated, and phospholipid asymmetry begins to be compromised. Following cellular 
activation, cytoskeletal disruption occurs, structural proteins are distorted, phospholipids are 
reorganised and, through the “flip-flop” mechanism, PS migrates from the inner to the outer leaflet. 
Finally, MV are released, completing the vesiculation process (Figure 1.10) (Zwaal and Schroit, 
1997; Piccin et al., 2007; Latham et al., 2013; Hankins et al., 2015). 
 
Figure 1.10: Blebbing and shedding of membrane microvesicles during cell activation (Doeuvre 
et al., 2009) 
CHAPTER 1 | Introduction 
 36 
All through this process, calcium acts as an agonist triggering cell activation. Calcium levels 
rise in response to cell activation, and this in turn stimulates the activation of calpain, and gelsolin. 
Calpain cleaves cytoskeletal filaments, facilitating MV shedding, and activating apoptosis. Gelsolin 
disturbs actin filaments in platelets, also contributing to the reorganisation of the membrane, and thus, 
MV formation (Zwaal and Schroit, 1997; Piccin et al., 2007). 
The ATP-binding cassette (ABC) transporters are members of one of the largest families of 
proteins. These transporters require ATP to overcome the substrate concentration gradient to transport 
substrate through the membrane. The ATP-binding cassette transporter A-1 (ABCA-1) is a prototype 
of ABC family subclass with a function to transport lipids and other metabolites across plasma 
membrane (Hamon et al., 2000). ABCA-1 has been repeatedly implicated in processes that are likely 
to be affected by dynamic distribution of lipid species across the membrane bilayer. ABCA-1 
functions at the plasma membrane as a floppase of PS with the net result of increasing the amount of 
this lipid in the outer leaflet, hence suggesting that ABCA-1 activation promotes the release of MV 
from the plasma membrane, as demonstrated in mice deficient in the ABCA1 gene (Hamon et al., 
2000; Combes et al., 2005a). 
 
3.4 Microvesicle structure and composition 
MV are known to vary in size, density, and composition depending on their cell of origin 
(Combes et al., 1999; Jimenez et al., 2003). The protein, lipid, and nucleic acid composition of MV 
varies depending on the environment of the cell of origin. Much of the structure of MV has been 
elucidated from electron microscopic studies. MV are known to be comprised of cytoplasmic 
molecules, cytoskeletal components, enzymes, cofactors, and various surface antigens unique to the 
cells from which they originate as well as the mechanisms by which they are formed (Zwaal and 
Schroit, 1997; Coltel et al., 2006; Piccin et al., 2007). 
Each MV has a bilayer membrane asymmetrically distributed with positively and negatively 
charged phospholipids. Phosphatidylcholine (PC) and sphingomyelin (SM) – both positively charged 
phospholipids – are located on the outer leaflet of the membrane, whereas phosphatidylserine (PS) 
and phosphatidyl-ethanolamine (PE) – negatively charged phospholipids – are located on the inner 
leaflet of the membrane (Hugel et al., 2005). PS exposure has been described in detail in relation to 
MV biogenesis, however it makes up only a small fraction of MV membrane composition. 
Lipidomics analysis revealed that, while PC, SM, and PE are the predominant phospholipids 
distributed in the membrane of MV – comprising 59%, 20.6%, and 9.4% of the total phospholipid 
content, respectively; comparatively, PS and other phospholipids each make up around 5% of MV 
membrane lipid distribution (Weerheim et al., 2002). In general, the lipid composition of MV is very 
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similar to the cell of origin, however PS and glycerophosphoserine are enriched in MV (Kreimer et 
al., 2015). 
Analysis of the proteomic, lipidomic, and nucleic acid content of MV provides a strong basis 
for future studies to understand MV biology and pathophysiology (Weerheim et al., 2002; Yoon et 
al., 2014; Tiberti et al., 2016). Transcriptomic analysis profiling mRNA and miRNA content of MV 
has been carried out extensively and will be discussed further in section 4.4.1. MV proteome analysis 
is carried out using gel electrophoresis, liquid chromatography, and mass spectrometry, and these 
results can aid the identification of different proteins found in MV. Using these techniques, the protein 
composition of MV derived from circulating cells has been examined in detail, including those of 
plasma, platelet, endothelial, and monocyte origin (Banfi et al., 2005; Garcia et al., 2005; Jin et al., 
2005; Smalley et al., 2007; Bernimoulin et al., 2009; Bosman et al., 2012), between which significant 
proteomic variances have been observed (Antwi-Baffour et al., 2016). In disease states, MV derived 
from injured organs likely contain valuable markers for determining the site, type, and extent of 
disease pathology. However, the basic protein characteristics of plasma MV are still being explored. 
Smalley et al. demonstrated the expression of 21 additional proteins involved in cell processes 
such as apoptosis, immune responses, and coagulation, in plasma-derived MV compared with platelet 
MV (Smalley et al., 2007). Jin et al. found that MV displayed distinct protein features compared to 
whole plasma samples (Jin et al., 2005). Garcia et al. found that MV displayed many proteins intrinsic 
to and well characterised on platelets, for example P-selectin (Garcia et al., 2005). Proteomic analysis 
of MV from pRBC revealed the enrichment of several host and parasite proteins related to host cell 
invasion (Mantel et al., 2013). Furthermore, the plasma MV proteome is affected by experimental 
CM, and specific changes may relate to pathogenic mechanisms of the syndrome (Tiberti et al., 2016). 
Originally, proteins such as tetraspanins (e.g. CD63 and CD81) and heat shock proteins (e.g. HSP70 
and 90) were thought to be unique to exosomes, but further work has characterised them in a range 
of extracellular vesicles, including MV (Lee et al., 2011). Further to this, various integrins, selectins, 
and metalloproteinases have also been characterised in MV (Choi et al., 2007; Barteneva et al., 2013; 
Choi et al., 2013). 
 
3.5 Detection of microvesicles 
In the past few decades, research aimed at MV has expanded considerably, though only 
recently have standardised isolation and analysis techniques been established, as well as the minimal 
set of biochemical, biophysical, and functional standards to attribute any specific biological cargo or 
functions to EVs (Hill et al., 2013; Witwer et al., 2013; Lötvall et al., 2014). Various methods of MV 
detection include flow cytometry (Gelderman and Simak, 2008; van der Heyde et al., 2011), antibody-
capture ELISA assays (Osumi et al., 2001), electron or confocal microscopy (Latham et al., 2015), 
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functional coagulation assays (Van Der Meijden et al., 2012), mass spectrometry (Kreimer et al., 
2015), and high-performance liquid chromatography (Weerheim et al., 2002). It is generally agreed 
that a number of methods are required in order to best characterise MV, due to their heterogeneity in 
size, function, refractive index, cellular origin, and content, and to distinguish them from other 
extracellular vesicles. 
Of these, flow cytometry is most commonly used, as it is a versatile technique allowing for 
the quantitation and detection of size, density, composition, and various surface markers, allowing 
for an understanding of MV as well as establishing their cells of origin. Flow cytometry is a high-
throughput method allowing for the analysis of large samples sizes in a short amount of time and has 
therefore been considered the gold standard for MV detection and analysis. However, the technique 
has also received some criticism, as reviewed by (Lacroix et al., 2010). For example, the difficulty in 
separating particles of small size such as MV from electronic noise on the machines. Some of these 
issues are being addressed in new generations of flow cytometers with simultaneous quantitation and 
imaging capabilities, and through alternatives to fluorescence detection in tagging methods (Latham 
et al., 2015). 
MV are first distinguished from smaller cells such as pRBC or platelets, or cellular debris, by 
size. However, there can be some overlap in size, therefore fluorescent staining is additionally 
required. PS is an obvious target for MV, as many express this ligand on their surface, as discussed 
in section 3.4. Annexin V or lactadherin have been used to detect MV, as they selectively target 
negatively charged phospholipids such as PS (Dachary-Prigent et al., 1993; Piccin et al., 2007; Fu et 
al., 2010; Latham et al., 2015). MV are purified from platelet-free plasma (PFP) samples (Pankoui 
Mfonkeu et al., 2010), or can be detected in culture supernatant (Wen et al., 2014). They are then 
incubated with annexin V, allowing flow cytometric analysis or enzyme-linked immunosorbent 
assays (ELISA) to detect the annexin V, and thus positive MV. However, this method has some 
shortcomings. Annexin V not only binds to MV, but also negatively charged phospholipids on cell 
fragments, which impacts on the accuracy of analysis of MV populations. In addition to this, it has 
recently been found that not all MV populations are annexin V-positive (Jimenez et al., 2003; Piccin 
et al., 2007; Connor et al., 2010; Latham et al., 2015). 
Another method of MV detection involves labelling with antibodies. As MV express specific 
antigens on their surface both when in a resting state, or when the cell is undergoing apoptosis, these 
can be targeted. Antibodies can specifically target surface markers indicative of particular cellular 
origins of MV or activation state, and this has been reviewed extensively by Gelderman et al. 
(Gelderman and Simak, 2008). Briefly, endothelial-derived MV (EMV) markers include CD34, 
CD51, and E- and P-selectin; platelet-derived MV (PMV) markers include CD31, CD41, CD61, and 
CD63; and markers for other types of MV include CD11b for monocytes, CD3 for lymphocytes, and 
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glycophorin A for RBC (Piccin et al., 2007). Therefore, antibodies raised against these markers will 
detect these specific types of MV. 
More recently, research has begun investigating alternatives to flow cytometry, and one such 
example is nanoparticle tracking analysis (NTA). As with flow cytometry, NTA is a high-throughput 
laser-based method for particle analysis, in which light is used to illuminate the movement of particles 
within a suspension in order to gain information about particle size, with the sensitivity to detect 
particles down to 10 nm in diameter. This movement is recorded by video and analysed afterwards 
with high precision and accuracy and is gaining momentum within the field as an alternative detection 
method (Dragovic et al., 2011; Soo et al., 2012). 
In order to gain more morphological insight into MV, microscopy analysis has been used 
extensively, with electron rather than confocal microscopy analysis commonly used, due to the 
limited resolution of current confocal methods. Electron microscopy, however, does have the 
necessary resolution to provide quantitative and morphological information about MV. In fact, a 
study by Arraud et al. examined plasma extracellular vesicles and found that, compared with electron 
microscopy, flow cytometric analysis quantitates as little as one percent of the total vesicles, whereas 
electron microscopy has the capability to detect vesicles below the limit of detection of current flow 
cytometers (Arraud et al., 2014). Couper et al. found that, compared with non-infected MV, which 
were heterogeneous in size when analysed by electron microscopy, MV induced by PbA infection 
were homogenous in size, the majority falling in the size range of 150-250 nm (Figure 1.11) (Couper 
et al., 2010). 
 
 
Figure 1.11: Scanning electron micrographs of microvesicles prepared from the plasma of non-
infected mice (non-infected MV) and from PbA-infected mice (day 7) (Couper et al., 2010). 
 
 
PbA-infected      Non-infected 
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3.6 Role of microvesicles in non-infectious disease-related conditions 
Low levels of MV can be detected in the circulation of healthy individuals, mostly of platelet 
origin, but also RBC, leucocyte and endothelial cell-derived (Piccin et al., 2007). It is known that MV 
are not simply inert elements, but instead are instead active vectors capable of stimulating a number 
of biological processes, including activation of coagulation, modulation of vascular function and 
induction of inflammatory processes (van der Heyde et al., 2006; Piccin et al., 2007; Wassmer et al., 
2011a). The aminophospholipids present on the surface of MV provide binding sites for various 
clotting factors, including IXa, VIII, Va, prothrombinase and tenase. This allows them to play an 
active role in cell-cell interactions, propagation of signals, angiogenesis, inflammation, coagulation, 
and vascular function (Combes et al., 2010). In general, low levels of MV under normal physiological 
conditions play a very important and positive role in homeostasis throughout the body. 
In addition to the aminophospholipids, MV have other elements that play a role in their 
coagulating and physiological properties, thus contributing to haemostasis and triggering clot 
formation (Hrachovinova et al., 2003). EMV express ultra large vWF multimers, which stimulate 
platelet aggregation (Piccin et al., 2007) and PMV express P-selectin (Freyssinet, 2003). The 
expression of PS by MV is thought to contribute to the phagocytosis of apoptotic cells. The interaction 
of the PS receptor on macrophages and the PS expressed on MV has been examined, and thought to 
assist in the clearance of apoptotic cells (Piccin et al., 2007). EMP have been shown to play both anti- 
and proangiogenic properties depending on their levels in the circulation (Todorova et al., 2017). At 
low levels, they appeared to be proangiogenic, promoting endothelial survival and capillary formation 
in vitro; however, at higher levels, these same EMP instead played an inhibitory role in the angiogenic 
process (Taraboletti et al., 2002; Deregibus et al., 2007). 
 
3.7 Role of microvesicles in pathological conditions 
The pathogenic role that MV play in several diseases has been explored in detail in the past 
few decades. While MV play a role in maintaining homeostasis at normal physiological levels, as 
stated above, imbalances in numbers of circulating MV, have been shown to be associated with 
pathological conditions (Combes et al., 2010), playing both beneficial and detrimental roles. 
Specifically, in individuals suffering from particular pathologies, MV levels differ from the baseline 
concentration found in their healthy counterparts, either showing a significant increase or decrease. 
This change indicates their potential involvement in disease development, progression, or resolution 
in a wide range of infectious, autoimmune, cardiovascular, and inflammatory diseases, as well as a 
variety of cancers (Schindler et al., 2014). 
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Circulating MV numbers are decreased in several conditions, including systemic lupus 
erythematosus, Scott’s syndrome, and Burkitt’s leukaemia. Specifically, circulating MMV are 
decreased in active neuropsychiatric SLE (Crookston et al., 2013). Scott’s syndrome is a severe 
bleeding disorder in which microvesiculation is impaired (due to impaired phospholipid scramblase 
activity and thus, reduced PS exposure), leading to a reduction in the procoagulant effect of platelets 
and a decrease in the release of procoagulant vesicles (Toti et al., 1996; Zwaal et al., 2004). 
Conversely, increased MV numbers have been detected in, and implicated in the development 
of many conditions, particularly those involving inflammation, coagulation, and altered vascular 
function (Xiong et al., 2012; Ohno et al., 2013; McGinn et al., 2016). Increased MV numbers have 
been demonstrated in a range of cancers, including in brain, breast, colorectal, lung and prostate 
cancers (Muralidharan-Chari et al., 2010; Thaler et al., 2012). Increased MV have also been 
implicated in several inflammatory pathologies, including atherosclerosis, diabetes mellitus, Crohn’s 
disease, and rheumatoid arthritis (Knijff-Dutmer et al., 2002; Leonetti et al., 2013; Alexandru et al., 
2016). In contrast to the findings discussed above, some studies have also indicated increased MV 
numbers in SLE (Dignat-George et al., 2004; Mobarrez et al., 2016). Indeed, PMV are known to be 
pro-thrombotic, and are increased in several cardiovascular pathologies, where they also function to 
activate endothelial cells (Zwaal and Schroit, 1997). EMV have been described as markers of 
endothelial dysfunction in multiple sclerosis, hypertension, and diabetes (Nomura et al., 2002; 
Combes et al., 2004; Horstman et al., 2004; Muralidharan-Chari et al., 2010; Alexandru et al., 2016; 
Zinger et al., 2016). Raised levels of MV have been identified in other neuropathologies, such as 
Alzheimer’s disease and, in the case of our study, cerebral malaria (further detailed in section 3.7.1) 
(Combes et al., 2005a; Xue et al., 2012). 
 
3.7.1 Microvesicles in cerebral malaria 
Increased numbers of circulating MV are associated with several pathological conditions, 
including CM. MV are increased in both malaria patients and infected mice specifically with CM 
(Combes et al., 2004; Combes et al., 2005a; Nantakomol et al., 2008; Pankoui Mfonkeu et al., 2010; 
Wassmer et al., 2011b). TNF acts as an agonist in this process, circulating in high titres in severe 
malaria patients (Grau et al., 1989), and triggering a substantial increase in EMV displaying a 
pathogenic phenotype, by expressing coagulation and cell adhesion molecules (Combes et al., 1999; 
Combes et al., 2004; Wassmer et al., 2011b; Sahu et al., 2013). These EMV levels are increased in 
CM patients during the acute CM phase, compared to non-infected subjects and severe malarial 
anaemia patients (Combes et al., 2004). EMV levels were also shown to correlate with plasma TNF 
levels, suggesting that TNF could have a significant effect on vesiculation in vivo, similar to what 
was previously demonstrated in vitro (Combes et al., 1999; Wassmer et al., 2011b). 
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In CM patients, PMV are the most abundant and their levels are significantly correlated with 
coma depth, thrombocytopenia, and disease severity (Piguet et al., 2002; van der Heyde et al., 2005; 
van der Heyde et al., 2006; Pankoui Mfonkeu et al., 2010). MV numbers were increased in CM 
patients, compared to trauma patients or those severely ill due to sepsis (Nantakomol et al., 2011). In 
vitro studies have also shown that PMV can transfer antigens to the pRBC membrane following 
adhesion, modifying their phenotype and dramatically increasing pRBC cytoadherence to endothelial 
cells, potentially leading to CM pathology (Faille et al., 2009b). These studies suggest a pathogenic 
role of MV in human CM. 
Studies using the murine model of CM have provided more evidence for this pathogenic role. 
Plasma MV are increased in mice with CM, and specifically at the onset of neurological signs (El-
Assaad et al., 2014). Further to this, adoptively transferring MV from mice with CM into healthy or 
infected recipient mice resulted in the arrest of MV in the vessels of infected mice only (El-Assaad 
et al., 2014). Conversely, mice with the ABCA-1 gene deficient do not up-regulate MV numbers and 
are 100% resistant to CM (Combes et al., 2005a). Pharmacologically inactivating the ABCA1 gene 
with pantethine had the same effect (Penet et al., 2008), and increased survival was observed in mice 
treated with anti-CD41 or 61 monoclonal antibodies (van der Heyde et al., 2005). MV from infected 
but not naïve mice induce potent activation of macrophages as measured by CD40 up-regulation and 
TNF production. However, similar levels of immunogenic MV were produced in WT and in TNF-/-, 
IFN-g-/-, IL-12-/-, and RAG-1-/- PbA-infected mice, but were not produced in mice injected with LPS 
(Couper et al., 2010). From this, they concluded that inflammation is not required for MV production 
during malaria infection and that, instead, pRBC-derived MV induce systemic inflammation during 
malaria infection, indicating their role in severe disease and in generating adaptive immune responses. 
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4 MicroRNA 
 
4.1 Background 
microRNA (miRNA) are small, single-stranded, and highly conserved non-coding RNAs that 
regulate the translation of mRNA and protein. miRNA are found in plants, animals, and even some 
viruses, and control more than 30% of protein-coding genes, through post-transcriptional regulation 
of targeted gene expression and RNA silencing (Bartel, 2004). Particularly, in humans, ~2600 
miRNA may be encoded, controlling around 60% of protein-coding genes (Griffiths-Jones et al., 
2006; Friedman et al., 2009). This number is slightly lower in mice, with ~1900 mature miRNA 
identified. While the majority of miRNA are intracellularly located, some miRNA have been 
identified circulating in various biological fluids and cell culture media, termed extracellular miRNA 
(Turchinovich et al., 2013). 
 
4.2 MicroRNA biogenesis 
miRNA biogenesis has been reviewed a number of times (Bartel, 2004; Treiber et al., 2012) 
(Figure 1.12). To summarise, miRNA genes are transcribed in the nucleus by RNA polymerase II 
(Pol II), to form primary miRNA transcripts (pri-miRNA), which contain 1-6 miRNA precursors, can 
be several thousand nucleotides in length, and are polyadenylated with multiple adenosines (a poly(A) 
tail). This transcript is spliced by the Drosha or Pasha enzyme to form precursor miRNA (pre-
miRNA, ~70 nt). The pre-miRNA moves to the cytosol mediated by Exportin-5 and incorporated as 
single-stranded RNA sequences into the RNA-induced silencing complex (RISC), which contains the 
Dicer enzyme, and the Argonaute (Ago) protein family. pre-miRNA are then cleaved by Dicer to 
form mature effective miRNA (~22 nt), bound to Ago proteins within the RISC, and directed toward 
their target mRNA to be regulated. Mature miRNA are able to pair with mRNA perfectly or 
imperfectly, either inhibiting mRNA, or leading to their degradation, affecting downstream protein 
synthesis (Treiber et al., 2012). There is quite a lot of redundancy in miRNA targeting, whereby 
multiple miRNA can regulate the expression of a single mRNA or, conversely, one miRNA can target 
multiple mRNA, and subsequently affect several families of genes (Baltimore et al., 2008). 
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Figure 1.12: MicroRNA biogenesis (Winter et al., 2009) 
 
4.3 Detection of microRNA 
A number of methods are available to study miRNA interactions, biogenesis, expression, and 
function, including microarrays, quantitative real-time PCR, in situ hybridisation, and RNA 
sequencing (Thomson et al., 2007; Reid et al., 2011; Pritchard et al., 2012). These techniques can be 
applied to various sample types, as miRNA are found in blood, plasma, and serum, as well as other 
biological fluids such as urine, saliva, and other sample types such as tissues, model organisms, and 
host extracellular vesicles including exosomes and MV. miRNA profiling then forms the basis for 
further downstream target identification and analysis (Weber et al., 2010; Reid et al., 2011). 
 
4.4 MicroRNA in pathology 
miRNA are known to play key regulatory roles in numerous biological processes, including 
cell proliferation, development, differentiation, and apoptosis (Bushati and Cohen, 2007; Liang et al., 
2013), but have been shown to be dysregulated in a range of diseases caused by viruses, bacteria, and 
parasites (Ding and Voinnet, 2007; Hakimi and Cannella, 2011; Eulalio et al., 2012). miRNA have 
also been shown to play a critical role in regulating the cellular and molecular networks controlling 
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the inflammatory process within a range acute and chronic inflammatory pathologies, including 
multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, inflammatory bowel 
disease, sepsis, and various types of cancer, during which their levels are altered (Fulci et al., 2010; 
O'Connell et al., 2012; Hessvik et al., 2013; Fourie et al., 2014; Tacke et al., 2014; Alexandru et al., 
2016; Poon et al., 2017; Yang et al., 2017a). Indeed, there is a strong correlation between loss of 
enhanced expression of miRNA, and cancer (Hunter et al., 2008).  
This range of disease areas into which miRNA research has expanded, has demonstrated the 
usefulness in profiling miRNA as biomarkers of severity; aiding diagnosis and prognosis (Reid et al., 
2011). miRNA are generally well-suited as disease biomarkers, due to their stability in biofluids and 
widespread presence across biological sample types. Particularly, their presence in biological fluids 
such as blood, saliva, and urine allow them to be sampled relatively non-invasively (Pritchard et al., 
2012; Xu et al., 2013). Therefore, miRNA have been targeted for therapeutic purposes, either using 
anti-miRNA to inhibit or reduce their expression, or miRNA mimics to verify and enhance their 
function, both for downstream effects in gene regulation (Hoss et al., 2015; Krützfeldt, 2016; 
Rupaimoole and Slack, 2017). 
Few studies exist the examine the role of miRNA in malaria, however these have been reviewed 
in Chapter II, and this has been explored further in Chapter IV. Fewer still explore miRNA within 
extracellular vesicles during malaria – to the best of our knowledge there are currently only three 
studies, one of which explores MV specifically, instead of exosomes, and none examine cerebral 
malaria specifically, yielding the purpose of the study detailed in Chapter III. 
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4.4.1 MicroRNA in microvesicles 
Previously, it was not known whether MV contained miRNA, but in the study by Hunter et 
al. in 2008, miRNA expression was identified and defined in circulating plasma MV (Hunter et al., 
2008). This was also found by Yuan et al. in 2009, where MV were engineered to express green 
fluorescent protein (GFP) and transfer of GFP and a subset of miRNA was observed in vitro (Yuan 
et al., 2009). Collino et al. found evidence of MV released from human bone marrow-derived 
mesenchymal stem cells and liver resident stem cells shuttling functional mRNA that were also found 
to contain selected miRNA. Further to this, those MV with highly expressed miRNA were transferred 
to target cells, allowing for the possibility that the biological effect of stem cells may, in part, depend 
on MV-shuttled miRNA (Collino et al., 2010). Furthermore, this miRNA transfer has been shown to 
be enhanced by increased TNF levels (Alexy et al., 2014). The miRNA content of MV has been 
implicated in several diseases, including lung cancer, pulmonary tuberculosis, pneumonia, 
Parkinson’s and Alzheimer’s diseases, atherosclerosis, and other cardiovascular pathologies 
(Hulsmans et al., 2011; Diehl et al., 2012; Jaiswal et al., 2012; Burgos et al., 2014; Lin et al., 2016), 
as well as effecting systemic change circulating in biological fluids such as plasma and CSF 
(Moldovan et al., 2013; Patz et al., 2013; Quackenbush et al., 2014; Tietje et al., 2014; Laffont et al., 
2016). Analysing the miRNA and mRNA content of MV may hold clues to further understand their 
role in pathologies such as malaria. 
The role of miRNA within MV and exosomes during malaria infection is just beginning to be 
explored. Particular miRNA, including miR-16, 17, 332, 451 and 497, are increased in exosomes 
from pRBC (Mantel et al., 2016; Wang et al., 2017; Yang et al., 2017b), and function to impact 
angiogenesis in mice, while also inhibiting tumour growth (Yang et al., 2017b). Furthermore, 
exosomes have been shown to contain host erythrocyte-derived miRNA-Argonaute 2 complexes, 
capable of modulating barrier function during malaria infection (Mantel et al., 2016). MV numbers 
are increased in pregnant women with placental malaria, in which total as well as specifically 
trophoblast-derived MV have been shown to play an immunopathogenic role (Moro et al., 2016).
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5 Hypotheses and aims of thesis 
 
The events leading to the development and manifestation of the CM syndrome are complex 
and involve intricate interactions between the parasite, endothelium, soluble mediators, adhesion 
molecules, circulating host cells, and the surrounding parenchyma. However, despite thorough 
investigation into these various elements and their interactions, the fine pathophysiological 
mechanisms of CM are still incompletely understood. 
Using the in vivo model of CM, we aimed to study the gap in knowledge regarding the 
neurological lesion, specifically studying the role of MV and miRNA in the development of CM 
(reviewed in Chapter II), examining the interactions between elements of pathology in the brain, and 
testing a novel treatment for the neurological syndrome. We hypothesise that miRNA, MV, and 
monocytes are all integral elements that, through their interactions, play active roles in CM 
pathogenesis. 
 
The primary research aims of this thesis were: 
• In chapter III, to examine in detail the abundance of miRNA carried within plasma MV in 
experimental CM, non-CM, and non-infected mice. Furthermore, to compare the abundance of 
specific miRNA of interest in MV to those circulating in MV-free plasma, and brain tissue, in 
order to understand more about the role of MV in the pathogenesis of CM. 
• In chapter IV, to characterise further the role of miRNA within brain tissue in experimental CM, 
non-CM, and non-infected mice. 
• In chapter V, to examine, using microscopy and three-dimensional reconstruction, the vascular 
lesion in order to investigate the spatial distribution and relationship between circulating immune 
cells and the corresponding vasculature in normal and disease states. 
• In chapter VI, to evaluate the efficacy of immuno-modulatory particles (IMP), alone and as an 
adjunct therapy (together with known anti-malarial compounds), to prevent or treat experimental 
CM. Furthermore, to study the effect of IMP on cellular and subcellular changes during CM. 
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Abstract 
 
Malaria is a mosquito-borne infectious disease caused by parasitic protozoa of the genus Plasmodium. 
It remains a major problem affecting humans today, especially children. However, the pathogenesis 
of malaria, especially severe malaria, remains incompletely understood, hindering our ability to treat 
this disease. Of recent interest is the role that small, non-coding RNAs play in the progression, 
pathogenesis of, and resistance to, malaria. Independent studies have now revealed the presence of 
microRNA (miRNA) in the malaria parasite, vector, and host, though these studies are relatively few. 
Here, we review these studies, focusing on the roles specific miRNA have in the disease, and how 
they may be harnessed for therapeutic purposes. 
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Introduction 
 
Malaria is a mosquito-borne infectious disease transmitted by the bite of Plasmodium-infected 
female Anopheles mosquitoes, to vertebrate hosts (Schofield, 2005; Xue, 2008). Malaria remains a 
major problem affecting humans today, with approximately half of the world’s population at risk 
(WHO, 2013). Each year, Plasmodium falciparum (Pf) infects over 200 million people worldwide, and 
is responsible for an estimated 660,000 deaths, mostly of children under five years old. 80% of these 
deaths occur in sub-Saharan Africa. 
The clinical manifestations of malaria are primarily due to schizont rupture, leading to 
destruction of erythrocytes (RBC), and vary in severity, which depends on host age, immune status, 
and strain of the parasite. Severe malaria is a multi-system disease caused almost exclusively by 
untreated Pf infection. Cerebral malaria (CM) and anaemia are the two most common manifestations 
of severe malaria. CM is a syndrome characterised by unarousable coma and neurological sequelae. 
The fine pathophysiological mechanisms underlying this neurological syndrome are not fully 
understood, although several hypotheses have been put forward: (i) the “mechanical” hypothesis, 
involving cell sequestration, the deformity of RBC and aggregation (Berendt, 1994; Schofield, 2005; 
van der Heyde, 2006), (ii) the “immunological” hypothesis, attributing the development of infection to 
the stimulation of production and release of pro-inflammatory and anti-inflammatory cytokines (Clark, 
1994; Idro, 2005; van der Heyde, 2006), and (iii) a combination of these (Grau, 1994; Combes, 2010), 
being the most likely hypothesis, since each alone cannot fully explain all manifestations and clinical 
signs of CM (Combes, 2006). 
Recently, emerging research has focused on microRNA (miRNA) to understand more about 
their roles in normal and pathophysiological conditions. miRNA are a type of single-stranded, non-
coding RNA approximately 22 nucleotides in length, that function as post-transcriptional regulators of 
targeted gene expression in eukaryotes, thus regulating the translation of mRNAs and proteins. It is 
now known that miRNA play crucial regulatory roles in numerous biological processes, including 
apoptosis, cell proliferation, metabolism, development, and differentiation (Bushati, 2007; Liang, 
2013). miRNA are also known to be involved in a broad range of infectious diseases and inflammatory 
pathologies. Recently, our understanding of the cellular and molecular networks that regulate 
inflammation has improved considerably, including the critical role miRNA play in managing features 
of the inflammatory process, often associated with a range of pathologies, including chronic 
inflammation, autoimmunity, and cancer (O'Connell, 2012). The dysregulation of miRNA in viral, 
bacterial, and parasitic diseases has been studied extensively (Ding, 2007; Hakimi, 2011; Eulalio, 
2012), though few studies exist examining the role of miRNA in malaria specifically. In this review, 
we address the ways in which parasite, vector, and host miRNA have been implicated in the 
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pathogenesis of, or protective immunity against, malaria and the dynamic interactions between these 
three components in malaria transmission. As depicted in Figure 2.1, miRNA are present in each of 
the parasite, vector, and host, but a significant sharing of material exists between these entities, and 
this active sharing process of miRNA has a great impact on the transmission and pathogenesis of, or 
protective immunity against, malaria. 
 
miRNA in host-parasite interactions 
 
Significant material exchange occurs between the host cell and Pf during the intraerythrocytic 
developmental cycle (Deitsch, 2001). Xue et al. detected the presence of human miRNA within the 
parasite; however, interestingly, they found no parasite-specific miRNA (Xue, 2008), consistent with 
previous reports by Rathjen et al. (Rathjen, 2006). Of the 132 short RNA found by Xue et al., 54 were 
rRNAs and tRNAs from human blood and Plasmodium, 18 were degraded fragments of human blood 
and Plasmodium mRNA, 26 were human miRNA, and 24 did not match the human or Plasmodium 
genome. Notably, among the miRNA found in uninfected normal RBC, human miR-451 was 
significantly enriched in parasitised RBC (pRBC) (Xue et al., 2008). 
LaMonte et al. investigated how human miRNA are translocated into the parasite, since Pf lacks 
orthologs of Dicer/Ago (Hall, 2005; Baum, 2009), involved in the conventional mode of RNA 
interference, which occurs as follows: RNA interference (RNAi) is initiated by the enzyme Dicer, 
which cleaves dsRNA into shorter molecules that dissociate into ssRNA. One strand is degraded, and 
the other is incorporated into the RNA-induced silencing complex. If this strand pairs with a 
complementary sequence of mRNA, it is degraded by Ago. RNAi is important in defending cells 
against parasitic nucleotide sequences. Using Illumina deep sequencing, 5’ RACE PCR, and 
ribonuclease protection assays, LaMonte et al. confirmed that human miRNA transferred into the 
parasite formed chimeric fusions with Pf mRNA via impaired ribosomal loading, resulting in 
translational inhibition, eventually impairing parasite biology and survival (La Monte et al., 2012). It 
is not yet known what determines the specific enrichment of particular miRNA or their incorporation 
into specific parasite mRNAs. 
Interestingly, La Monte et al. explored the protective immunity and resistance to Plasmodium 
conferred to RBC by human miRNA and the variant haemoglobin allele (HbS), that causes sickle cell 
disease (La Monte, 2012). In malaria-endemic regions, sickle cell disease occurs at relatively high 
frequencies (Livingstone, 1971; Nagel, 1989), and mutations as part of this disease often provide 
protection against the malaria parasite (Aidoo, 2002). This enhanced resistance is thought to be due, at 
least partly, to more rapid phagocytosis of pRBC by monocytes (Ayi, 2004), suggesting that the 
parasite is more rapidly cleared by the immune system. 
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The presence of ~100 human miRNA was detected within the parasites, using multiplex real-
time PCR, and, in pRBC, found similar enrichment in miR-451 as well as miR-223 and miR-19b (Xue, 
2008; La Monte, 2012) confirming and expanding previous data (Xue, 2008). Elevated levels of 
specific human miRNA were found in RBC with heterozygous  (HbAS) and homozygous sickle cell 
haemoglobin (HbSS), when compared to normal RBC (HbAA), implying a functional role of these 
miRNA (La Monte, 2012). Specifically, miR-16 was present in abundant levels in HbAA RBC, and 
miR-181a had no effect upon parasitaemia, whereas transfection with miR-451, miR-223 or let-7i led 
to a markedly reduced percentage of pRBC in vitro. Combined transfection with miR-451 and miR-
223 reduced the infection rate by 46%, with a similar effect seen for additional combination with let-
7i. Increased parasite growth was observed in HbAS and HbSS pRBC due to the inhibition of host 
miRNA, specifically miR-451. HbAA pRBC showed almost no inhibition of miR-451, and no change 
in parasite growth. The expression of miR-451 was also examined in Plasmodium berghei-infected 
mouse RBC by Xue et al. (Xue, 2008), and found to also be independent of erythrocytic stage and 
parasitaemia, as shown in human erythrocytes by LaMonte et al. (La Monte, 2012). Potential gene 
targets for these miRNA include PKA-R (cAMP-dependent protein kinase) or are implicated in red 
cell remodeling. Therefore, miRNA-451 contributes significantly to malaria resistance, by the role 
played in the differentiation and/or maturation of primary RBCs. 
 Together, these data confirm that human miRNA regulate protozoan gene expression via cross-
species chimeric transcripts, and raise the question of how erythrocyte miRNA modify parasite 
mRNAs. Examining further these seemingly independent mechanisms of parasite resistance will 
provide fresh insights into the complex relationship between the host genome and threatening microbial 
pathogens. In addition to this, further identification of targets genes will shed light on the biological 
roles of these miRNA of interest. However, what can currently be concluded is that the unidirectional 
exchange of miRNA from host to parasite protects the host by negatively affecting parasite survival. 
 
miRNA in vector-parasite interactions 
 
miRNA in Anopheles gambiae mosquitoes play physiological and protective roles during 
Plasmodium infection. In the life cycle and transmission of the malaria parasite, the passage 
Plasmodium takes across the Anopheles midgut constitutes the major bottleneck. Recently, research 
has focused on the role of miRNA in regulating the Anopheles defence reaction. Studying interactions 
between the parasite and insect vector provides an opportunity to identify methods to disrupt or reduce 
pathogen transmission. 
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Using a combination of shotgun cloning and bioinformatic analysis, Anopheles mosquito 
miRNA were analysed, specifically their homology with other species and their localisation within the 
mosquito (Winter, 2007). 152 clones were found that could be potential miRNA, however only 
eighteen met all the criteria to be bona fide miRNA. These eighteen miRNA found in A. gambiae 
mosquitoes, included three unique to the strain. Twelve were expressed ubiquitously across the body, 
independent of gender, while the other six exhibited an expression pattern restricted to the digestive 
system, including the three mosquito-specific miRNA. Interestingly, the expression of four specific 
miRNA, again including the three unique miRNA, was affected by the presence of Plasmodium. 
Knocking down Dicer1 and Ago1 mRNAs via gene silencing techniques led to increased susceptibility 
of the mosquitoes to Plasmodium infection (Winter, 2007; Campbell, 2008; Mead, 2012), therefore 
providing evidence for miRNA-mediated post-transcriptional regulation of the genes involved in 
defence reactions, as mosquito genes of the silencing pathway would affect parasite development in 
the midgut. 
Xu et al. too examined the expression profile of miRNA in A. gambiae mosquitoes, and found 
200 putative miRNA precursors expressed. Of these precursors, 78 encoded mature miRNA conserved 
in at least one other animal species (Xu, 2008). In the Asian malaria mosquito, A. stephensi, 23 
conserved, and four new miRNA sequences were identified. The expression profile of eight of these 
miRNA, including four miRNA unique to this mosquito strain, revealed distinct patterns from early 
embryo to adult stages in the mosquito development. For example, given the expression profile, miR-
x-2 was likely involved in female reproduction, and consistent expression of miR-14 suggests its likely 
importance across all mosquito life stages (Mead, 2008). 
During blood feeding, Plasmodium induces several host effector molecules in the mosquito. 
Blood feeding and parasitised blood feeding revealed regulation of 13 and 16 mosquito miRNA, 
respectively, for example miR-124, 305, and 309, which are known to target multiple genes in immune 
pathways. miRNA controlling metabolic, redox homeostasis and protein processing pathways were 
down-regulated upon parasitised blood feeding. Another set of miRNA showed significant expression 
changes between 42 h and 5 days post infection (p.i., coinciding with the late phase of midgut invasion 
by the parasite and initiation of sporozoites release from the oocytes, respectively), indicating a parasite 
stage-specific role of host miRNA (Jain, 2014). Biryukova et al., too, showed a shift in miRNA 
expression following blood feeding and parasitised blood feeding. They found 4 miRNA with a 
significant expression shift after blood feeding: miR-7, miR-92a, miR-317, and miR-N3; and 6 after 
parasitised blood feeding, including miR-317, and miR-2940 (Biryukova, 2014). Therefore, miRNAs 
that affect the development and maturation of the parasite within the mosquito are targeted, following 
a blood meal, indicating some mechanisms of survival and propagation of the parasite. 
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Understanding miRNA functions contributes to a better understanding of mosquito 
reproduction, longevity, and mosquito-pathogen interactions that might provide a revolutionary way 
to hinder malaria transmission. Further research will enhance this understanding, especially in terms 
of functional miRNA exchange between the parasite and vector, as well as the little explored topic of 
miRNA exchange between the vector and the target host. 
 
Mammalian host miRNA 
 
Evidence is accumulating that miRNA are critically implicated in the outcome of diseases, but 
little information is available regarding their mechanism of action in these cases. To date, Glinksy et 
al. are the only study to publish research regarding miRNA in human patients. Using PBMCs from 
malaria patients, they showed, using microarray analysis, that chloroquine therapy reversed the 
disease-associated phenotypes of nuclear import and inflammasome pathways (Glinsky, 2008). Their 
analysis showed that miRNA and mRNAs controlling the Karyopherin Alpha 1 (KPNA1), and NLR 
family pyrin domains containing 1 and 3 (NLRP1 and NLRP3) genes (inflammasome-related genes) 
showed changed levels of expression following chloroquine therapy: decreased expression of KPNA1 
and NLRP1 during infection was reversed after chloroquine, and their expression was elevated by 66% 
and 13%, respectively. In addition, infection-induced increased expression of NLRP3 was reduced by 
57% after chloroquine. 
miRNA have been shown as key components, in the liver and elsewhere, in the immune 
response following malaria infection, with many miRNA known to control cell growth and 
proliferation, stress responses, and metabolism, as well as gene expression and susceptibility to 
infection (Bala, 2009; Chen, 2009; Lu, 2009; Wang, 2009; Kerr, 2010). The liver is a known anti-
malaria effector organ, as the site of the pre-erythrocytic development of Plasmodium (Haussinger, 
2004; Crispe, 2009), where Kupffer cells and extrathymic lymphocytes are generated following 
infection to carry out important protective immune functions, such as phagocytosis of pRBC (Krucken, 
2009). 
Delić et al. examined miRNA expression in the liver of malarial-infected mice and found a 
hepatic miRNA signature in female C57BL/6 mice infected with self-healing P. chabaudi (Delic, 
2011). These mice displayed peak parasitaemia of approximately 50% on day 8 p.i. and in 80% of 
cases these infections were self-healing. Among those mice that survived the initial infection, 100% 
survived subsequent challenges eight weeks later, with a peak parasitaemia of 1.5%. Liver miRNA 
profiles were analysed using miRXplore microarrays and quantitative RT-PCR (RT-qPCR). The liver 
was found to respond to primary infections with an upregulation of three miRNA and a downregulation 
of sixteen other miRNA, some of which had known roles in apoptosis and cancer. Among them, the 
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high expression of miR-1274a in the liver was confirmed by RT-qPCR. Surprisingly, a similar pattern 
of miRNA expression was found in immune mice, i.e. mice that survived the first infection, and also 
upon re-infection of these mice, suggesting that the modulations of expression of these miRNA are 
specific to the infection status irrespective of their levels. Interestingly, no changes in expression were 
detected of those miRNA currently known to be critically involved in adaptive immune responses, 
such as antibody formation, development, B cell maturation, and the formation of memory B cells, 
CD4+ T cells, and CD8+ T cells. Thus, the development of protective immunity against blood stages 
of P. chabaudi is associated with a reprogramming of the expression of distinct miRNA species yet to 
be identified in the mouse liver. 
In another study, Al-Quraishy et al. tested testosterone-induced susceptibility to blood-stage 
malaria of P. chabaudi and measured the coinciding changes in miRNA expression of the anti-malaria 
effector sites, the spleen and liver (Al-Quraishy, 2012). Female C57BL/6 mice were treated with 
vehicle or testosterone for 3 weeks and, 12 weeks later, were challenged with P. chabaudi. miRNA 
expression was examined during testosterone treatment, after 12 weeks of testosterone withdrawal, and 
following this, during infections at peak parasitaemia. Changes could be observed in miRNA 
expression during testosterone treatment and after its cessation. For example, a specific upregulation 
during testosterone withdrawal was observed only in the spleen for miR-200a, and only in the liver for 
miR-142-5p and miR-342-3p. The latter two miRNA have been shown to be upregulated in cancer 
cells (Van der Auwera, 2010), leucocytes (Schaefer, 2011), in antigen-induced differentiation of T cells 
(Wu, 2007), and in B cell activation in leukemia (Ronchetti, 2008; Li and Wucherpfennig, 2011), and 
the target genes of miR-342-3p are involved in different processes such as cell proliferation (Van der 
Auwera, 2010). These results imply an influx of cells expressing these two miRNA into the liver. Upon 
infection, however, these changes in miRNA expression were not maintained. Various changes were 
observed, notably a downregulated expression of most miRNA species by more than 2-fold in the 
spleen and liver. The same response to P. chabaudi malaria was observed in miRNA expressions in 
these two organs in testosterone-pretreated mice and vehicle-treated control mice. This change in 
expression suggests that testosterone-induced susceptibility to P. chabaudi does not affect miRNA 
expression and, therefore, gene expression. This susceptibility was shown to be irreversible, i.e. mice 
pre-treated with testosterone remained susceptible to infection after 12 weeks of withdrawal. This 
response to infection following testosterone treatment and subsequent withdrawal was also observed 
by Delic et al. (Delic, 2010) This study went on to confirm that the testosterone-induced upregulation 
of specific miRNAs coincided with an at least 2-fold downregulation of some of their known gene 
targets. Altogether, the reprogramming of miRNA expression in the spleen and liver is essential for 
the development of protective immunity against blood-stage malaria, and that the responsiveness of 
this reprogrammed expression is not affected by testosterone-induced susceptibility. 
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 Hentzschel et al. studied the role of miRNA in protection against liver stages of Plasmodium 
infection. Here, they examined the role specifically of miR-155 in mice infected with genetically 
attenuated parasites (GAP). Previously, it had been shown that GAP arrested in the liver, induce sterile 
immunity, but only after several administrations. It was found that GAP-injected mice displayed a 
broad activation of IFN-g-associated pathways and a significant increase in miR-155 within 
macrophages in the liver (Hentzschel, 2014). This upregulation enhanced the protective capacity of 
GAP substantially, highlighting the crucial role of mammalian miRNAs in Plasmodium liver infection. 
The presence of miRNA was also associated with pathogenesis and the development of the 
neurological syndrome in the murine model of CM. When animals are infected with Plasmodium 
berghei ANKA (PbA), they develop a neurological syndrome where the brain is the main targeted 
organ. El Assaad et al. examined the expression of a selection of miRNA, known to be associated with 
inflammation and infection, by RT-qPCR in the brain and the heart during malaria infection with PbA, 
and compared it to a non-encephalitogenic strain Plasmodium berghei K173 (PbK)-infected CBA 
mice, as well as uninfected mice (El-Assaad, 2011). Significant changes were found in the expression 
of let7i, miR-27a, and miR-150 in the brain tissue of PbA-infected mice compared to uninfected mice 
at the time of the neurological syndrome. In contrast, no changes in these miRNA were detected in the 
heart, an organ with no known pathology, during CM (El-Assaad, 2011). Distinct expression profiles 
were observed in the brains of PbA- and PbK-infected and uninfected mice. This difference in 
expression could not be attributed to parasite load, as mice showed comparable levels of parasitaemia. 
Using the miRBase database, predicted gene targets of the three miRNA showing significant changes 
in CM regulate pathways involved in inflammation, innate pathogen recognition, apoptosis, and 
immune functions (Bullen, 2003; Chen, 2007; O'Hara, 2010). Both strains of parasite induced an 
increase in the expression of let-7i and miR-150 compared with the level in uninfected mice, with PbA 
inducing a greater response. The let-7 family has previously been shown to control cellular 
proliferation and innate immune responses (Chen, 2007; O'Hara, 2010), and miR-150 was highly 
expressed in monocytes and has been implicated in cell proliferation, development, and differentiation. 
This change in expression is crucial, as an accumulation of monocytes in the cerebral microvasculature 
has been associated with fatal murine CM (Grau, 2003). The sequestration of monocytes within the 
cerebral microvessels of PbK-infected mice can still be observed, albeit at a lower level than in PbA-
infected mice, and this is consistent with the changes in miRNA expression observed. Of the six 
selected miRNA, miR-27a expression was significantly increased in PbA-infected mice only, 
suggesting that it may have a more specific role in CM. miR-27a has been shown to induce apoptosis, 
disrupt mitochondrial membrane potential, increase sensitivity to TNF (Chlabra, 2009), and control the 
regulation of T cell proliferation and the NF-KB signalling pathway during inflammation (Tourneur, 
2010). Thus, overexpression of these three miRNA during PbA infection in mice may be critical for 
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triggering the neurological syndrome. Since these altered expression levels coincided with increased 
apoptosis, and levels of circulating inflammatory cytokines in the brain, demonstrated by Lackner et 
al. (Lackner, 2007), the regulation of potential targets of these miRNA appears crucial. 
Not only does malarial infection modulate particular sets of miRNA, but also the host genetic 
background may play a role in determining a miRNA profile associated with CM. In these studies, the 
potential link between alterations in miRNA expression and malaria pathogenesis was explored and 
these alterations could be reversed following treatment, though evidence of this is only provided in the 
case of non-cerebral malaria. 
 
 
 Figure 2.1: Dynamic interactions between the parasite, vector, and host in malarial infections. 
Cross-species interactions and regulation affects the transmission and pathogenesis of, and/or 
resistance to malaria infections. (A) Human miRNA (e.g. miR-19b, -223, and -451)2,21 and (C) 
mosquito miRNA (e.g. miR-34, -989, -1174, and -1175)26 affect malaria parasite biology and 
survival. (B) Parasite miRNA (e.g. miR-124, -305, and -309)31 regulate metabolic pathways in 
Anopheles mosquitoes. (D) Host miRNA (e.g. let-7i, miR-27a, -150,51 -1274a42) regulate host gene 
expression. 
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Conclusions 
 
The study of miRNA and their importance during malaria infection is at its beginning but is 
showing promise since miRNA have been shown to play roles in the resistance to and protective 
immune response against malarial infection, and in the pathogenesis of the infection in some cases. 
These roles are not strictly limited to host miRNA acting within the host either as evidence of 
interspecies miRNA transcripts impairing the normal function of Plasmodium in order to confer 
resistance to the host were demonstrated. miRNA translocation is a dynamic process between parasite, 
host, and vector, allowing for the protective or pathogenic interactions between these elements of 
malarial transmission. Certain areas, such as the role of miRNA in the interaction between vector and 
host, have not yet been explored, and more data is needed to support the conclusions regarding the 
direct role miRNA play in host defence against Pf. Indeed, despite the role miRNA play in infection, 
whether pathogenic or protective, the mechanisms of action are still incompletely understood. This is 
partly due to the redundancy in the control of gene expression, where individual miRNA control 
numerous mRNAs, resulting in innumerable changes in gene expression. Therefore, to attribute one 
feature of the disease to a single miRNA is practically impossible. While some functional studies have 
been performed, linking miRNAs with target genes involved in malaria infection or pathogenesis, more 
research is needed in this area. In addition, unravelling the details of miRNA mechanism of action 
during infection may give us more hints to understand malarial pathogenesis, serve as biomarkers for 
disease progression and, most importantly, be useful for developing therapeutic uses for miRNA or 
their inhibitors in patients with severe malaria. 
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Abstract 
 
Cerebral malaria (CM) is a fatal complication of Plasmodium infection, mostly affecting children 
under the age of five in the sub-Saharan African region. CM pathogenesis remains incompletely 
understood, although inflammatory cells aggregating in the cerebral blood vessels, and the 
microvesicles (MV) that they release in the circulation, have been implicated. Plasma MV numbers 
increase in CM patients and in the murine model, where blocking their release, genetically or 
pharmacologically, protects against brain pathology, suggesting a role of MV in CM 
neuropathogenesis. In this work we define, for the first time, the microRNA (miRNA) cargo of MV 
during experimental CM with the overarching hypothesis that this characterisation could help 
understand CM pathogenesis. The change in abundance of miRNA was studied following infection 
of CBA mice with Plasmodium berghei ANKA (causing experimental CM), and Plasmodium yoelii 
17XNL, which causes severe malaria without cerebral complications, termed non-CM (NCM). 
miRNA expression was analysed using microarrays to compare MV from healthy and CM mice, 
yielding several miRNA of interest. The differential expression profiles of these selected miRNA 
(miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analysed in 
mouse MV, MV-free plasma, and brain tissue by quantitative reverse transcription PCR (RT-qPCR). 
Two miRNA – miR-146a and miR-193b – were confirmed as differentially abundant in MV from 
CM mice, compared with NCM and NI mice. These miRNA have been shown to play various roles 
in inflammation, and their dysregulation during CM may be critical for triggering the neurological 
syndrome via regulation of their potential downstream targets. Our data suggests that, in the mouse 
model at least, miRNA may have a regulatory role in the pathogenesis of severe malaria. 
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Introduction 
 
Malaria is a devastating infectious disease transmitted to vertebrate hosts by the bite of 
Plasmodium-infected female Anopheles mosquitoes (Schofield and Grau, 2005; Xue et al., 2008). 
Malaria remains a substantial problem affecting humans today, with approximately half of the world’s 
population at risk. Every year, around 200 million people are infected by Plasmodium falciparum alone 
worldwide (WHO, 2016). Severe malaria is most commonly caused by infection with P. falciparum 
(Singh et al., 2004), and cerebral malaria (CM) is the most severe manifestation of malaria infection. 
CM is a syndrome characterised by unarousable coma and unconsciousness, often leading to death, or 
the occurrence of neurological sequelae in survivors (Bangirana et al., 2016). Approximately 1% of 
individuals with malaria infection develop CM; however, the reason for this is currently unknown. The 
pathology of this syndrome is still incompletely understood, as the existing hypotheses cannot fully 
explain all manifestations and clinical signs of CM (Storm and Craig, 2014; Sahu et al., 2015). Other 
manifestations of severe malaria can result in severe anaemia and respiratory distress, termed here non-
cerebral severe malaria (NCM) (WHO, 2012). Current treatment options for CM – that is, anti-malarial 
medications combined with immediate intensive care – have an 80-85% success rate. However, this is 
not the case in many parts of Africa, where there is increasing levels of drug resistance (Lu et al., 2017) 
and, in some cases, insufficient access to adequate hospital care (Sahu et al., 2015). In fact, despite 
successful prevention, persisting neurological sequelae and long-term impairments are present in 25% 
of paediatric CM cases (Idro et al., 2010). Therefore, further research into the pathology, progression, 
and treatment is essential in the prevention and elimination of malaria. 
Of recent interest is the role that microvesicles (MV) play in the pathogenesis of CM both as 
markers of severity and effectors. Plasma MV are submicron vesicles (diameters of 200-1000 nm) 
released from most cell types in the microvasculature, including those involved in the pathogenesis of 
CM, such as platelets, erythrocytes, endothelial cells, and leucocytes (Coltel et al., 2004). They form 
through the budding of the plasma membrane and take with them cytoplasmic proteins, lipids, and 
nucleic acids, as well as surface antigens from the cell of origin. Consequently, they are present in the 
circulation and can bind to target cells, propagating biological signals and participating in cell-cell 
communication (Hugel et al., 2005). While circulating MV play a role in maintaining homoeostasis at 
normal physiological levels (van der Heyde et al., 2006; Piccin et al., 2007), imbalances in their 
numbers have been shown to be associated with pathophysiological conditions (Combes et al., 2010; 
Wassmer et al., 2011). During CM, higher levels of MV correlate with the presence of neurological 
symptoms, increased disease severity, and coma depth in human patients (Combes et al., 2004; Pankoui 
Mfonkeu et al., 2010; Nantakomol et al., 2011) and the murine model (Combes et al., 2005; Combes 
et al., 2010; El-Assaad et al., 2014a; El-Assaad et al., 2014b), while in NCM infections, the same 
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significant increase is not observed (Combes et al., 2005; El-Assaad et al., 2014b). In addition, blocking 
the production of MV, genetically (Combes et al., 2005) or pharmacologically (Penet et al., 2008), is 
associated with protection against the development of experimental CM. In mice, MV accumulate 
within the brain microvessels of infected but not healthy recipient mice, following adoptive transfer 
(El-Assaad et al., 2014b). Analysis of MV, protein, lipid, and nucleic acid content provides a strong 
basis for studies to understand their biology and pathophysiology (Weerheim et al., 2002; Yoon et al., 
2014; Tiberti et al., 2016). In disease states, MV derived from the injured organ likely contain valuable 
biomarkers, including miRNA, for determining the site, type, and extent of disease pathology 
(Muralidharan-Chari et al., 2010; Fleissner et al., 2012). 
miRNA are small, single-stranded non-coding RNA that control more than 30% of protein-
coding genes, through post-transcriptional regulation of targeted gene expression and RNA silencing 
(Bartel, 2004). miRNA are known to play key regulatory roles in numerous biological processes, 
including cell proliferation, development, differentiation, and apoptosis (Bushati and Cohen, 2007; 
Liang et al., 2013). miRNA were first characterised within circulating plasma vesicles by Hunter et 
al. in 2008 (Hunter et al., 2008) and Yuan et al. in 2009 (Yuan et al., 2009). Further to this, miRNA 
contained within MV were shown to be transferred to target cells through the circulation, suggesting 
that the biological effect of cells may, at least partially, depend on MV-shuttled miRNA (Collino et 
al., 2010). 
miRNA have been shown to be dysregulated in a range of diseases caused by viruses, bacteria, 
and parasites (Ding and Voinnet, 2007; Hakimi and Cannella, 2011; Eulalio et al., 2012). Specifically, 
in malaria infections within mammalian hosts, several studies have explored miRNA changes before 
and after Plasmodium infection in different tissues, including liver and brain (Delic et al., 2011; El-
Assaad et al., 2011; Chamnanchanunt et al., 2015; Barker et al., 2017), and within circulating 
extracellular vesicles – both MV and exosomes (Mantel et al., 2016; Moro et al., 2016; Yang et al., 
2017). Studies using the murine model have investigated the effect of Plasmodium infection on miRNA 
signatures within these tissues and plasma, and found that miR-16 and miR-451 decrease in abundance, 
while miR-27a and miR-150 increase in response to infection, and that blocking some of these miRNA 
confers protection to those mice. In contrast, miR-451 is increased in extracellular vesicles from 
infected red blood cells (Mantel et al., 2016). These changes in miRNA abundance are reversed 
following anti-malarial treatment (Delic et al., 2010; Al-Quraishy et al., 2012; Cohen et al., 2015; Dkhil 
et al., 2017). These studies suggest that miRNA could be involved in the protective immune response 
or resistance against malarial infection, as well as in CM pathogenesis, depending on their downstream 
targets and abundance during infection. In addition, there is evidence of the impact that interactions 
between parasite, host, and vector can have on miRNA abundance during malarial transmission (Mead 
and Tu, 2008; Xue et al., 2008; La Monte et al., 2012; Jain et al., 2014). 
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Despite these studies, an unbiased high-throughput characterisation of miRNA abundance in 
MV during CM has not yet been carried out. Our study examines the abundance of miRNA carried 
within plasma MV during experimental CM and NCM, as well as in non-infected (NI) mice. MV 
miRNA are then compared to those circulating in MV-free plasma and expressed in brain tissue, 
showing that, following infection, specific changes are observed in the three types of samples. These 
changes provide potential novel avenues of research into further understanding the pathogenesis of 
CM, in order to harness this information for therapeutic purposes. 
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Materials and methods 
 
i. Mice 
7-10-week-old CBA mice were obtained from the Animal Resource Centre (Perth) and housed under 
pathogen-free conditions, as per approved protocols of the University of Sydney Animal Ethics 
Committee (protocol numbers 2015/832 and 2013/5317). For experimental comparisons, three 
biological groups of mice were used: non-infected (NI), CM caused by Plasmodium berghei ANKA 
(PbA) infection, and NCM caused by P. yoelii 17XNL (Py) infection (from the lab of Prof C. 
Engwerda, QIMR Australia). As previously described, CBA mice are susceptible to PbA infection 
and succumb to CM during the neurological phase, between day 6 and day 14 post-infection (p.i.) 
(Rae et al., 2004). Mice infected with Py survived beyond this point and display severe anaemia in 
the third week after infection. 
 
ii. Plasmodium inoculation 
All infections were initiated by intraperitoneal injection of 1 x 106 PbA or Py-parasitised red blood 
cells (pRBC), as previously described (Grau et al., 1986). Parasitaemia was monitored by counting 
pRBC in Diff-Quick-stained (ProSciTech) thin blood smears by light microscopy on day four p.i. and 
every 1-2 days after this throughout the infection. Mice were assessed using a clinical evaluation 
score, and CM diagnosed if mice presented with ruffled fur, severe motor impairment or convulsions, 
and were given a score of 3 or 4 as previously described (Potter et al., 2006). PbA-infected mice were 
sacrificed at the time of CM, and Py-infected mice without any of the signs mentioned above were 
classified as NCM, and sacrificed at the same time, with comparable levels of parasitaemia. 
 
iii. Blood sampling, MV purification, and brain tissue preparation. 
Mice from all biological groups were sacrificed, and blood and brain tissue were collected. Mouse 
venous blood was collected by retro-orbital puncture under anaesthesia in 0.129 mol/L sodium citrate 
(ratio of blood to anticoagulant 4:1). Platelet-free plasma (PFP) was prepared as previously described 
(El-Assaad et al., 2014b). PFP was then centrifuged at 18000g for 45 min and the supernatant 
removed and retained (MV-free plasma), while the pellet was centrifuged for a further 45 min at 
18000g in a solution of PBS and sodium citrate (ratio of PBS to anticoagulant 3:1) to pellet MV. 
100mg of brain tissue from each mouse was placed immediately in RNAzol (Molecular Research 
Centre, Inc.) and homogenised. MV, MV-free plasma, and homogenised brain tissue samples were 
stored at -80°C until RNA extraction was performed. For microarray analysis, MV samples were 
pooled during vesicle purification; all samples for RT-qPCR analysis were taken from individual 
mice and kept separate. 
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iv. RNA extraction 
Total RNA was extracted from pelleted MV, 0.4 mL MV-free plasma, and 100 mg brain tissue using 
the commercially available protocol from Molecular Research Centre Inc. A phase separation step 
using 4-bromoanisole (MRC) was added to optimise RNA preparation from low amounts of starting 
material. All centrifugation steps were performed at 4°C, and precipitation was performed overnight 
at -20°C, with glycogen added to preserve small RNA. The concentration of RNA was determined 
using Nanodrop ND-1000 spectrophotometry (Nanodrop Tech), and the purity was assessed by 
calculation of the ratio of absorbance at 260 and 280 nm, with a cut-off of 1.6 used. RNA 
concentrations of approximately 30-150, 50-300, and 3000-9000 ng/µL were achieved from MV, 
MV-free plasma, and brain tissue respectively. 
 
v. cDNA synthesis and preamplification 
For OpenArray analysis the starting RNA concentration was set at 100 ng; for RT-qPCR analysis, it 
was 10 ng. For both, preamplification was used to increase the amount of cDNA. cDNA synthesis 
and preamplification were performed using commercial rodent kits (Megaplex RT and 
preamplification kits) and rodent MegaplexTM Primer Pools for OpenArray, or custom primer pools 
of the targets of interest described below, for RT-qPCR (ThermoFisher Scientific). 
 
vi. OpenArray analysis 
Pre-amplified samples were loaded onto TaqMan OpenArray MicroRNA Panels to be run on the 
QuantStudio 12K Flex system, as per the manufacturer’s instructions (ThermoFisher Scientific). 754 
rodent miRNA, consisting of validated mature mouse and rat miRNA (Sanger miRBase release v.15), 
were amplified in each sample, with technical replicates, together with internal controls. QuantStudio 
and ExpressionSuite Analysis software (ThermoFisher Scientific), utilising the comparative (DD) CT 
method, were used to quantify relative expression across all miRNA and samples with relative 
quantification values expressed as CM/NI. Global normalisation was performed using the global 
mean CT value of targets common to every sample as the normalisation factor, on a per sample basis 
– the recommended and most robust strategy for normalisation in large scale (>384) miRNA 
expression profiling studies (Mestdagh et al., 2009). To reduce false positive results, CRT (cycle of 
relative threshold) values were filtered to remove values over 30, considered not to be true results. 
Technical replicates with a standard deviation (SD) over 0.5 between CRT values, and an amplification 
score below 1.2 (low quality) were also removed. Lastly, miRNA amplified in less than 50% of 
biological replicates were considered as lowly expressed and excluded from the analysis. Relative 
quantification was calculated using algorithms included in the ExpressionSuite analysis software. 
Statistical calculations were performed using multiple t tests – one per row, with fewer assumptions. 
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vii. Pathway analysis 
Microarray results were analysed with DIANA miRPath version 3 (Vlachos et al., 2015) to combine 
filtering and miRNA matching to mRNA targets in order to provide insight into the potential 
biological effects of miRNA and to predict their role within target pathways. This software uses 
TarBase version 7 (Sethupathy et al., 2006), which houses a manually curated collection of 
experimentally tested miRNA targets. The input dataset was compared to all available biological 
pathways provided by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 
2000), with significantly influenced pathways identified (p<0.05) and a False Discovery Rate of 5%. 
The database was searched with the full names of each murine miRNA as per the ThermoFisher 
Scientific product information and miRBase version 21: mmu-miR-16-1-3p, mmu-miR-21a-3p, 
mmu-miR-146a-5p, mmu-miR-150-5p, mmu-miR-193b-3p, mmu-miR-205-5p, mmu-miR-215-5p, 
mmu-miR-297a-3p, mmu-miR-328-3p, mmu-miR-335-3p, mmu-miR-467a-5p, mmu-miR-486a-5p, 
mmu-miR-685, mmu-miR-1949, and rno-miR-10b-5p. 
 
viii. RT-qPCR analysis 
RT-qPCR analysis was performed using the Taqman gene expression master mix, following 
recommended protocols. The starting RNA concentration was set at 10 ng and each sample was tested 
in duplicate. Taqman small RNA assays for hsa-miR-146a, hsa-miR-150, hsa-miR-205, hsa-miR-
486, hsa-miR-590-5p, mmu-miR-10b, mmu-miR-193b, mmu-miR-215, mmu-miR-467a, rno-miR-
450, U6, U87, snoRNA-135, and snoRNA-202 were used, with the latter four chosen from the 
prescribed control assay panel used in the microarray analysis. RT-qPCR data normalisation was 
performed with the last four miRNA listed as controls. Replicates for which the SD was >0.5 were 
removed. Statistical calculations were performed using a non-parametric Kruskal-Wallis test, and a 
two-stage post hoc test to correct for multiple comparisons by controlling the False Discovery Rate 
for significant results. Results were considered significant, if P < 0.05. All results were analysed using 
GraphPad Prism version 5.02 (GraphPad Software) 
 
ix. Sample size calculation 
A sample size calculation was performed using GraphPad Statmate software v2.0. As this formula 
required a known SD, we used the OpenArray results to inform the calculation of a sample size 
necessary for subsequent RT-qPCR verification. A significance level (alpha) of 0.05 (two-tailed) and 
a 90% power were chosen as the parameters for this calculation in order to increase the stringency, 
and decrease the chance of false-positive findings for this verification analysis. It was found that a 
sample size of 5 in each group was sufficient to detect a significant difference between means of ≥ 
5.93.  
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Results 
 
Experimental design. 
To examine the abundance of the miRNA cargo of MV released during CM, compared with NI 
conditions, we used the OpenArray system (ThermoFisher Scientific). The targets of interest found 
in the initial screening process were verified using qPCR analysis: examining MV, MV-free plasma, 
and brain tissue from NI, NCM and CM mice. miRNA of interest were evaluated in relation to CM 
pathogenesis using target prediction and pathway analyses. A graphical representation of the 
experimental design used is shown in Figure 3.1. 
 
 
Figure 3.1: Experimental design. Graphical summary of the experimental design applied in the 
present study. PFP = platelet-free plasma; MV = microvesicle; NI = non-infected; CM = cerebral 
malaria. Images were obtained from Pixabay.com and ChemDraw (PerkinElmer).  
CHAPTER 3 | Microvesicle microRNA in cerebral malaria 
 102 
Distinct profile of miRNA within MV in CM compared with NI mice, using array analysis. 
The abundance of miRNA contained in MV purified from PFP obtained from NI and CM CBA mice 
were compared using OpenArray® analysis. For microarray analyses, three groups of NI mice and 
four groups of CM mice were used, with five samples pooled per group. A distinct abundance profile 
was observed in the MV from CM compared with NI mice. Within each biological group, 
approximately 60% of miRNA were detected in all replicates within a biological group, and 408 and 
361 miRNA were detected in >50% of NI (blue, vertical stripes) and CM replicates (red, vertical 
stripes), respectively, and were therefore studied further. 431 miRNA were quantified in at least one 
biological group (dark grey) and 348 miRNA were common to both biological groups (differential, 
light grey), while 60 and 23 miRNA were detected only in NI (blue) or CM MV (red), respectively 
(Figure 3.2A). 
 
Differentially abundant miRNA play potential roles in malaria infection and inflammation. 
miRNA that were present in >50% of replicates within both NI and CM groups were further analysed 
to identify significant miRNA of interest (differential miRNA from Figure 3.2A, n = 348). A cut-off 
of ± 2-fold was used to compare the relative expression of these miRNA between the groups, 
measured as a ratio of CM/NI. Figure 3.2B displays the results in a volcano plot, where miRNA 
common to both biological groups were plotted according to their fold change, and the significance 
of that association. Four miRNA, shown in green, showed significantly decreased abundance in CM 
conditions, and 11 miRNA (red) were significantly increased compared with NI conditions. These 
miRNA of interest were further investigated and shown to have diverse roles defined in the literature, 
and using DIANA miRPath software. 19 pathways were significantly regulated by the chosen miRNA 
of interest, as detailed in Supplementary Table 3.1, and include those relating to Prion diseases (P = 
2.2e-20, 7 genes controlled by 5 miRNA in pathway), regulation of actin cytoskeleton (P = 0.02, 41 
genes by 8 miRNA), gap junctions (P = 0.04, 14 genes by 5 miRNA), Chagas disease (P = 0.04, 21 
genes by 6 miRNA), and toxoplasmosis (P = 0.04, 22 genes by 8 miRNA). Interestingly, these 
miRNA strongly regulate other neurological conditions, pathways related to MV formation, or other 
parasitic diseases, further highlighting their potential importance in CM. Of the 15 miRNA identified 
by OpenArray analysis as significantly differentially abundant, eight were chosen according to their 
postulated roles in CM for verification by RT-qPCR. 
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Figure 3.2: Detectable miRNA profiles in MV from NI compared with CM CBA mice. A The 
number of miRNA quantified in one or more biological group, and in >50% or 100% of replicates in 
each biological group are shown. miRNA present in >50% of replicates are further separated into 
groups of those common to both biological groups (further examined in Figure 3.1B) and those 
expressed in one biological group only. B The volcano plot displays miRNA present in both 
biological groups; for each miRNA, the fold change (log2FC) and the significance (-log10P-value) are 
reported. P-values were obtained with a student’s t-test, with fewer assumptions. Horizontal threshold 
line: P = 0.05, a higher value indicates greater significance; vertical threshold lines: fold change= -2 
(left) and 2 (right). Highlighted in red are miRNA that are significantly increased in abundance in 
CM conditions, and in green, decreased. 
 
Choice of reference miRNA candidates for RT-qPCR normalisation. 
RT-qPCR results often depend on the quality of the endogenous control genes chosen, with some 
controls valid for some types of samples and some for others. The ideal endogenous control should 
demonstrate gene expression that is constant and highly abundant across tissues and cell types, and 
across changing biological conditions or treatments. Seven internal controls were included by default 
in the OpenArray analysis: ath-miR-159a, dme-miR-7, sno-RNA-135, sno-RNA-202, U6, U87, and 
Y1 – and the variations in miRNA abundance were evaluated using global normalisation, which 
considered all miRNA, including these internal controls. To verify the miRNA of interest, four 
control miRNA (U6, Y1, sno-RNA-135, and sno-RNA-202 – the murine miRNA from the original 
control panel from the OpenArray) were tested for their robustness of normalisation, and their 
expression across all biological groups and sample types. To determine the best normalisation 
strategy to be applied to RT-qPCR results, the four candidate controls were investigated on the 
OpenArray results. In particular, the global normalisation strategy was compared to U6, and to two 
different combinations – one including U6 and one not (Figure 3.3), as the validity of U6 as a control 
has previously been debated (Benz et al., 2013). Candidate control miRNA were deemed suitable if 
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they were detected in over 70% of samples, and if the CRT values fell within the range of 18-28, as 
per previous rigorous testing (Roberts et al., 2014; Eriksen et al., 2016), and all four fulfilled these 
requirements (Figure 3.3A). The number and type of miRNA found to be significant with the four 
different normalisation strategies were then compared (Figure 3.3B-D), and increasing numbers of 
significant miRNA were observed using fewer candidate control miRNA (Figure 3.3B). As 
previously stated, 15 miRNA were found to be significantly differentially abundant using global 
normalisation – the preferred method for this dataset. Notably, 12, 11 and seven of these miRNA 
remained significant when normalising with all four candidate controls, three of the four controls, 
and U6 alone, respectively (Figure 3.3C, 3D). Importantly, of the eight miRNA from this list of 15 
that were chosen for further validation by RT-qPCR, 7, 6 and 4 were also found to be significant 
when normalising with the respectively listed groups above (Figure 3.3C). Additionally, no statistical 
significance was observed in the variation in abundance of the selected control miRNA across all 
samples (data not shown). Therefore, all four controls were chosen to normalise RT-qPCR results, as 
this strategy was found to be the most similar to global normalisation. 
 
 
Figure 3.3: Assessing normalisation strategies for miRNA relative quantification. Four candidate 
controls were used to normalise OpenArray results in two different combinations - one including U6 
and one not, as well as U6 alone; and compared to the global normalisation used for OpenArray 
analysis. A Each candidate control was assessed individually in terms of percentage detection and 
mean CRT of candidate controls across all samples and biological groups tested using the OpenArray 
system, These candidate controls were also assessed across the four normalisation strategies in terms 
of B number of significant miRNA, and further to this C significant miRNA from global 
normalisation that were also significant with other normalisation strategies, and, of those significant 
and common miRNA, how many from the list of those chosen for further validation by RT-qPCR. D 
Venn Diagram shows the overlap between statistically significant miRNA as determined by all 
normalisation methods. 
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Significantly changed abundance of miR-146a and miR-193b in MV following PbA infection. 
Eight miRNA, chosen among the differentially abundant by OpenArray analysis, were analysed for 
verification by RT-qPCR on newly generated samples – i.e. MV, MV-free plasma, and brain tissue 
from NI, NCM, and CM mice. Two additional miRNA – miR-590-5p and miR-450 – were selected 
among those unique to either biological group, for further verification. The additional biological 
groups and sample types were included to achieve a more comprehensive analysis of the changes 
occurring during Plasmodium infection, especially to identify those specific to neurological 
complications, in comparison to non-cerebral infections or non-infected status. For RT-qPCR 
analysis, five mice from each of the three biological groups were used, with each mouse representing 
an individual sample. All selected miRNA were expressed at detectable levels in all samples under 
normal physiological conditions apart from miR-10b, but their expression levels after the inoculation 
of PbA (CM) or Py (NCM) demonstrated altered abundance in 95% of cases. Significant changes 
were found in the abundance of miR-146a, miR-193b, miR-205, miR-215, and miR-467a, as shown 
in Figures 3.4 and 3.5. miR-146a was significantly more abundant in MV and MV-free plasma from 
mice at the time of CM (P = 0.027 and 0.005, respectively), compared with that of NI mice, and in 
MV-free plasma compared with NCM mice (P = 0.012), while no significant differences were 
observed in the brain samples. In MV samples only, miR-193b was less abundant at the time of CM, 
compared with both NI (P = 0.007) and NCM conditions (P = 0.007) (Figure 3.4). The significant 
changes in miRNA abundance in MV reflected the findings of the OpenArray. Specifically, miR-
146a and miR-193b were both significantly dysregulated in the MV from CM mice compared with 
NI – increasing 3.2 or 7.2-fold in the case of miR-146a, or decreasing 2.7 or 7.5-fold (miR-193b) in 
array and RT-qPCR analysis respectively (Table 3.1). miR-467a was significantly less abundant in 
the MV-free plasma from CM mice (P = 0.050) and NCM mice (P = 0.020) compared with NI (Figure 
3.5). Interestingly, different profiles were observed in the brain samples: miR-205, miR-215, and 
miR-467a were significantly increased abundance in the brains of CM mice compared with NI (P = 
0.011, 0.016, and 0.015 respectively), but no change was observed in the brains of NCM mice (Figure 
3.5). Data for miR-10b, miR-590-5p, and miR-450 were not shown, as amplification was not adequate 
across all samples and biological groups. 
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Figure 3.4: Significant changes in relative expression of miR-146a and miR-193b in MV, MV-
free plasma and brain tissue from NI, NCM and CM CBA mice. Dot plots show the expression 
levels of miR-146a and miR-193b measured for MV, MV-free plasma, and brains from NI, NCM, 
and CM conditions, expressed as normalised values as compared to the expression of a panel of 
control miRNA in each case. The horizontal line denotes the mean value, and the error bars denote 
SEM A nonparametric Kruskal-Wallis test was carried out. If the Kruskal-Wallis test was significant, 
post hoc tests – Dunn’s multiple comparisons test – were carried out. The results of these are denoted 
as * = 0.05-0.01, ** = 0.01-0.0001, *** = < 0.0001. 
 
Table 3.1: RT-qPCR results mimic directional changes in abundance of miRNA of interest in 
OpenArray. The list of significantly differentially expressed miRNA in MV from CM mice 
compared with NI from the OpenArray analysis was compared with the results obtained by RT-qPCR 
analysis. p-value: * = 0.05-0.01, ** = 0.01-0.0001, *** = < 0.0001. 
miRNA Significance of fold change in CM vs. NI MV 
OpenArray RT-qPCR 
hsa-miR-146a 3.2** 7.2* 
hsa-miR-150 1.8* 2.7 (ns) 
hsa-miR-205 2.3* -0.5 (ns) 
hsa-miR-486 2.3*** 4.7 (ns) 
mmu-miR-193b -2.7** -7.5* 
mmu-miR-215 2.1* 4.6 (ns) 
mmu-miR-467a -2.0* -5.6 (ns) 
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Figure 3.5: Significant changes in relative expression of chosen miRNA targets in MV-free 
plasma and brain tissue from NI, NCM and CM CBA mice. Dot plots show miRNA expression 
levels measured for MV-free plasma and brains from NI, NCM, and CM conditions, expressed as 
normalised values as compared to the expression of a panel of control miRNA in each case. The 
horizontal line denotes the mean value, and the error bars denote SEM A nonparametric Kruskal-
Wallis test was carried out. If the Kruskal-Wallis test was significant, post hoc tests – Dunn’s multiple 
comparisons test – were carried out. The results of these are denoted as * = 0.05-0.01, ** = 0.01-
0.0001, *** = < 0.0001. 
 
No significant change in the abundance of miR-150, miR-205, miR-215, miR-467a, and miR-
486 in MV following Plasmodium infection. 
Of the eight significantly differentially abundant miRNA tested by RT-qPCR, miR-146a and miR-
193b showed the same significant change in abundance as in the OpenArray (from Figure 3.2B). A 
further four miRNA – miR-150, miR-215, miR-467a, and miR-486 showed the same directional 
change in abundance as in the OpenArray analysis, without reaching significance (Table 3.1 and 
Supplementary Figure 3.1). miR-205 showed a small decrease in abundance in the RT-qPCR 
validation experiments, compared to the significantly increased abundance in the OpenArray 
analysis. For the final miRNA, miR-10b, results were not shown, due to poor RT-qPCR amplification 
across all sample types. For 4 of the 7 miRNA discussed here: miR-150, miR-205, miR-193b, and 
miR-467a, the direction of regulation in CM conditions was the opposite for MV and brain tissue. 
For 5 of the 7 miRNA discussed: the 4 listed above plus miR-146a, the direction of regulation in CM 
conditions was the same for MV and MV-free plasma. In all cases within the brain samples – except 
miR-150 – miRNA abundance increased (significantly or not, in the case of specific miRNA) in CM 
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compared with NI and NCM conditions, with NCM being an intermediate abundance level between 
the other two biological groups. This intermediate abundance in NCM conditions was applicable in 
almost all miRNA tested in MV and MV-free plasma samples as well. 
 
Significantly differentially abundant miRNA regulate genes with identified roles during 
malaria infection. Of the 15 significantly differentially abundant miRNA from the OpenArray 
analysis, eight regulate genes within the KEGG malaria pathway, shown in Figure 3.6, which 
summarises the changes occurring during malaria infection at the gene level, and the impact this has 
on various cell types and molecules produced. This figure has been revised from the original KEGG 
pathway, with genes involved highlighted based on the miRNA of interest and their roles in regulating 
these genes. Within the malaria pathway, a collection of miRNA specifically regulate the groups of 
genes surrounding MV release, regulation of inflammatory cytokines, and cytoadherence of cells to 
the vascular endothelium. To summarise, 7 miRNA: miR-10b, miR-146a, miR-193b, miR-328, miR-
335, miR-467a and miR-486, control 12 genes within the malaria pathway: CD40, CD40 ligand 
(CD40L, CD154), CXCL8 (IL-8), IFN-g, IL12A, Integrin b2 (ITGb2), Transforming Growth Factor 
b2 (TGFb2), Thrombospondin genes (THBS1/TSP1, THBS2/TSP2), Toll-Like Receptors (TLR2, 
TLR4), and TNF. Further to this, many of these miRNA also have roles defined in the literature, 
relating to similar neuro-inflammatory conditions (more detail in Supplementary Table 3.1). 
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Figure 3.6: Malaria KEGG pathway. DIANA mirPath v.3 and Tarbase v.7 were used to compile 
lists of genes controlled by significantly differentially expressed miRNA tested using OpenArray and 
RT-qPCR analysis. Following this, the KEGG pathway for genes known to be involved in malaria 
infection was modified to show the role played by these miRNA. NB: some genes, including LFA1, 
IL8, TGFβ, and TSP are listed in the original KEGG pathway, but have been changed here to 
alternative but equivalent names – ITGB2, CXCL8, TGFβ2, and THBS1 respectively, as these gene 
names reflect those in the lists for the specific miRNA analysed. 
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Discussion 
 
As miRNA research has expanded into numerous disease areas, it has become clear that 
expression levels of certain miRNA are altered in many diseases, including malaria (Hunter et al., 
2008; El-Assaad et al., 2011; O'Connell et al., 2012; Barker et al., 2017). However, despite these 
studies examining miRNA during malaria infection, the mechanism of action of miRNA and whether 
they play a pathogenic or immuno-protective role is still unclear. This study describes for the first 
time, the changes in miRNA content of MV during Plasmodium infection in mice and shows a clear 
dysregulation of miRNA abundance within circulating MV during experimental CM as compared 
with non-infected and non-CM mice. 
In mice, P. berghei infection triggers an intricate series of events that leads to CM, including 
an increased release of extracellular vesicles, released from endothelial cells, platelets, and RBC 
(Combes et al., 2005; El-Assaad et al., 2014b). miRNA have also been implicated in this process by 
actively regulating the immune or inflammatory response. In fact, many studies have shown that 
miRNA constitute a key mechanism by which MV mediate cellular communication. Specifically, 
during malaria infections, miRNA from pRBC MV have been shown to modulate endothelial cell 
permeability, affecting vascular function (Mantel et al., 2016). Furthermore, evidence of changed 
miRNA levels in the brains of mice with CM compared with NCM or NI mice has been reported (El-
Assaad et al., 2011; Barker et al., 2017). Using OpenArray technology as a screening approach, we 
assessed 754 miRNA targets and detected 15 miRNA with significantly dysregulated abundance in 
MV from CM mice in comparison to NI mice. To verify the screened results, and to better understand 
miRNA changes during the severe infection, eight of these targets were selected and their abundance 
measured by RT-qPCR in MV, MV-free plasma, and brain tissue from CM and NI mice. To assess 
the results regarding their specificity to the malarial neurological syndrome, samples from NCM mice 
were also analysed. 
Upon verification, two miRNA were confirmed as significantly dysregulated in CM MV: 
miR-146a and miR-193b. miR-146a was significantly over-abundant in CM MV and MV-free plasma 
compared to NI, but not in brain tissue – although the same trend in abundance shift was observed. 
An increased abundance of miR-146a is triggered by inflammatory factors including IL-1 and TNF 
(Sheedy and O'Neill, 2008), and dysregulates several targets, the majority of which are involved in 
toll-like receptor pathways, triggering a cytokine response, or in the innate immune system (Sheedy 
and O'Neill, 2008; Sonkoly et al., 2008). Within the malaria pathway, miR-146a regulates the CD40L, 
CXCL8, IFN-g, TLR2, TLR4, and ITGb2 genes. Together with miR-155 and miR-21, miR-146a 
operates in a negative feedback loop to specifically calibrate inflammatory responses (Quinn and 
O'Neill, 2011). The role this miRNA plays within inflammatory conditions (Sonkoly et al., 2008) has 
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been researched extensively, including as a biomarker for sepsis (Giza and Vasilescu, 2010) and prion 
infections (Bellingham et al., 2012). Interestingly, in the latter, miR-146a was part of a miRNA 
signature within exosomes from prion-infected neuronal cells. Finally, miR-146a has also been 
implicated in the overactive response to infection, therefore has previously been proposed to have 
potential as a therapeutic target (O'Connell et al., 2012). 
Remarkably, miR-193b was significantly decreased in CM MV as compared not only to NI, 
but also NCM MV. Critically, no similar significant difference was observed in the MV-free plasma 
or brain tissue, though the opposite trend in abundance shift was observed in the latter. miR-193b 
plays a role in the TGFb2 signalling pathway (Zhong et al., 2014), and in monocyte-macrophage 
differentiation (Eigsti et al., 2014). Within the malaria pathway, miR-193b regulates the THBS1, 
THBS2, and TGFb2 genes; and regulates apoptosis by targeting myeloid leukaemia cell 
differentiation protein (Mcl)-1, among others (Braconi et al., 2010). Notably, miR-193b is a 
biomarker in sepsis, where it is decreased in abundance (Wang et al., 2012; Tacke et al., 2014). 
Similarly, decreased abundance has been found in Alzheimer’s disease (Zhang et al., 2014) and 
Amyotrophic lateral sclerosis (Li et al., 2017) and, like miR-146a, has been characterised within 
exosomes during prion infections (Bellingham et al., 2012). In fact, similarly to our study, Saba et al. 
found the opposite trend in accumulation of particular miRNA within the brain tissue compared with 
exosomes (Saba et al., 2008; Bellingham et al., 2012; Saba et al., 2012). 
The specific changes in abundance of miR-146a and miR-193b in MV and MV-free plasma 
that we observed in our study suggest a role for these miRNA in cerebral pathology, as their 
expression levels were altered at the time of CM, and the significant same changes were not observed 
in NCM mice (Lackner et al., 2007). Indeed, these miRNA have previously been implicated as 
biomarkers for various infectious diseases and neurological conditions sharing similarities with CM. 
Moreover, both miR-146a and miR-193b have demonstrated roles in the induction of inflammatory 
cells and apoptosis, as well as cytokine regulation; and these roles could easily translate to the 
pathology and kinetics observed in CM. In support of this, the CM-specific changes in miRNA 
abundance demonstrated coincide with increased levels of circulating inflammatory cytokines and 
apoptosis, as has been previously shown at the time of CM (Grau et al., 1987). 
Interestingly, miR-146a and miR-467a were significantly increased and decreased, 
respectively, in both CM and NCM MV-free plasma compared to NI. Therefore, these miRNA are 
likely to be indicative of a severe malaria infection, rather than specific to neurological complications. 
Different results were obtained from the comparison of miRNA abundance in MV and brain tissue: 
a separate set of miRNA – miR-205, miR-215, and mir-467a – were increased only in the brains of 
CM compared with NI mice, or NCM mice. These data support the observation that particular miRNA 
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may be detectable only in specific samples, suggesting a preferential expression from specific cell 
types (Liang et al., 2007; Weber et al., 2010). 
The differences in abundance profiles observed in the three different sample types analysed 
provide further evidence that miRNA appear to be selectively expressed in the circulation, whether 
in the MV-free plasma itself, or expressed on the surface of or packaged within circulating MV. 
Specifically, the directional change in abundance of our miRNA of interest in MV-free plasma in CM 
conditions more closely reflected the changes within MV, compared with the opposite changes within 
brain tissue. This contrasts with findings by Burgos et al., where the serum or CSF of Alzheimer’s or 
Parkinson’s disease patients contained significantly deregulated miRNA similar to those in brain 
tissue, although the two biological fluids demonstrated very little overlap in significantly 
dysregulated miRNA between them (Burgos et al., 2014). In examining further, the brain, all but one 
miRNA (miR-150) showed increased abundance in the brains of CM mice, as compared with their 
NI counterparts; interestingly their NCM counterparts demonstrated intermediate levels of 
expression, further demonstrating the difference in the degree of in severity between the two 
infections.  
In line with previous studies comparing plasma or serum, and MV, MV-free plasma samples 
showed a more variable expression pattern for these 7 miRNA (Zhao et al., 2016). With the MV 
portion of the MV-free plasma removed, remaining miRNA are likely to be stable circulating 
extracellular miRNA secreted from cells, or present in other types of vesicles not tested in our analysis 
– such as exosomes, as both of these sources have previously been identified in other diseases or 
conditions (Chen et al., 2012; Creemers et al., 2012; Mantel et al., 2013; Alexander et al., 2015; 
Mantel et al., 2016). Previous studies have identified miRNA present in a range of fluids and 
biological specimens or tissue types. Among these profiles, some highly abundant miRNA were 
common to multiple sample types, while others were enriched only in particular conditions (Weber 
et al., 2010), and we observed the same phenomenon. The difference in abundance of particular 
miRNA in particular sample types here indicates the variety of the roles played by certain miRNA in 
specific locations or conditions.  
The KEGG pathway for malaria (Figure 3.6) highlights evidence of regulation relating to 
many of the critical components in the development of CM. For example, during malaria infection 
and regulated by miR-146a and miR-193b, there is increased production of inflammatory cytokines 
such as IFN-g and TNF, with the latter responsible for fever observed in patients (Kwiatkowski et al., 
1993); as well as the recruitment of macrophages, and increased nitric oxide production, thus 
disrupting neuronal function (Clark et al., 1991; Clark et al., 1992; Kwiatkowski et al., 1993; Miller 
et al., 2002). Activation of the toll-like receptor pathway through the TLR2/4-mediated interaction of 
pRBC with MyD88+ dendritic cells (regulated by miR-146a, miR-150, and miR-486), leads to 
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increased TGFb2 production (regulated by miR-193b and miR-335) and eventually, 
immunosuppression. Increased IFN-g production stimulates platelet MV release (Faille et al., 2009a). 
CD40 (regulated by miR-486), and Thrombospondin 1/2 (regulated by miR-328, miR-335, and miR-
193b) interact with CD40L (regulated by miR-146a) on platelets and PfEMP1 on pRBC respectively 
(Baruch et al., 1996; Treutiger et al., 1997; Henn et al., 1998; Slupsky et al., 1998; Piguet et al., 2001; 
Schofield and Grau, 2005). In the case of leucocytes, Integrin Beta 2 (regulated by miR-146a) (Grau 
et al., 1993; Faille et al., 2009b) interacts with ICAM1 (regulated by miR-146a), which is also 
expressed on the vascular endothelium during infection. These interactions involving platelets, 
pRBC, and leucocytes, as well as the regulation of IFN-g and TNF (regulated by miR-146a and miR-
467a respectively), gives further evidence for the accumulation of all three cell types within the brain 
microvasculature. Furthermore, there is evidence that this accumulation leads to vascular obstruction 
and haemorrhaging as seen in CM, with imminent death resulting if left untreated. 
As the usefulness of individual control miRNA has been contested, due to the variability of 
their abundance in different sample and tissue types (Reid et al., 2011; Benz et al., 2013; Mahdipour 
et al., 2015), particular attention was paid to the use of controls for data normalisation. Interestingly, 
using only U6 as a control in our study, miR-150 showed increased abundance in CM mouse brains, 
replicating the findings of El-Assaad et al.(El-Assaad et al., 2011). Given the criticism against specific 
controls – particularly U6, we examined our results using multiple controls, including U6 or not, and 
found that U6 provided no negative impact on the consistency of results, in line with previous studies 
examining extracellular vesicles (Rice et al., 2015; Crossland et al., 2016). However, we observed 
that the combination of four candidate controls was more consistent with global normalisation, as 
used in the OpenArray analysis, making it the most reliable normalisation strategy for our subsequent 
RT-qPCR analysis. Notably, no statistical significance was observed overall in the variation in 
abundance of the selected control miRNA across all samples. Therefore, the use of these four controls 
was the most robust way to analyse a sample range of this variety and number, to minimise the risk 
of false positives and increase the stringency of RT-qPCR analysis. 
Only 2 of the 7 miRNA tested were confirmed to be significantly dysregulated in MV upon 
verification. This may be the consequence of a change made between the methodology of the 
OpenArray and RT-qPCR analyses – that is, the required starting amount of RNA. The OpenArray 
analysis required a far greater starting amount of RNA (10x) and thus was performed on pooled 
groups of mice. RT-qPCR analysis was instead performed on samples from a single mouse, also 
allowing us to better evaluate the biological variability. This difference between the two analyses 
might, partially, explain the discrepancies between the results and further prove the importance of 
verification by RT-qPCR in our experimental design. 
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Of importance to our work are the recent improvements in the understanding of the role of 
miRNA in the regulation of molecular and cellular networks associated with inflammation 
(Zampetaki et al., 2012; de Candia et al., 2014; Marques-Rocha et al., 2015). Consequentially, 
miRNA potential as biomarkers of inflammatory processes and infectious diseases has become 
increasingly evident (de Candia et al., 2014; Marques-Rocha et al., 2015). In this context, further 
investigations of miRNA contained in MV (such as miR-146a and miR-193b) or circulating in the 
MV-free plasma (such as miR-467a) could reveal novel candidate markers for the early diagnosis of 
CM. Indeed, the evaluation of their abundance in human paediatric samples as well as functional 
studies using in vitro CM models to establish their cellular source and targets, will help to understand 
the clinical potential of these miRNA and their role in CM pathogenesis. In investigating for the first 
time the miRNA content of murine MV during CM, our results indicate that the content of plasma 
MV is affected during the severe infection and should be considered in the understanding of CM 
pathogenesis. 
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Supplementary Figure 3.1: Non-significant relative expression of chosen miRNA targets in MV, 
MV-free plasma, and brain tissue from NI, NCM, and CM CBA mice. Dot plots show non-
significant changes in miRNA expression levels measured for MV, MV-free plasma, and brain tissue 
from NI, NCM, and CM conditions, expressed as normalised values as compared to the expression 
of a panel of control miRNA in each case. The horizontal line denotes the mean value, and the error 
bars denote SEM. A nonparametric Kruskal-Wallis test was carried out, together with post hoc tests, 
as before. 
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Supplementary Table 3.1: Pathways significantly regulated by miRNA of interest. The list of 
significantly differentially expressed miRNA from the OpenArray analysis was analysed using 
miRPath software to determine the significantly regulated pathways they controlled. The KEGG 
pathway identification and p-value of each pathway is shown, as well as the number of genes within 
each pathway controlled by a number of miRNA from our list of miRNA of interest. 
# KEGG pathway p-value # genes # miRNA 
1 Prion diseases (mmu05020) 2.22e-20 7 5 
2 Lysine degradation (mmu00310) 8.61e-6 16 7 
3 Valine, leucine and isoleucine degradation (mmu00280) 0.015 14 5 
4 Estrogen signalling pathway (mmu04915) 0.015 20 8 
5 Regulation of actin cytoskeleton (mmu04810) 0.025 41 8 
6 Neurotrophin signalling pathway (mmu04722) 0.038 25 6 
7 Renal cell carcinoma (mmu05211) 0.042 15 4 
8 Pyruvate metabolism (mmu00620) 0.042 11 5 
9 Fatty acid metabolism (mmu01212) 0.042 11 5 
10 Dorso-ventral axis formation (mmu04320) 0.042 9 5 
11 Gap junction (mmu04540) 0.042 14 5 
12 Terpenoid backbone synthesis (mmu00900) 0.042 8 6 
13 GABAergic synapse (mmu04727) 0.042 19 6 
14 Chagas disease (African trypanosomiasis) (mmu05142) 0.042 21 6 
15 Central carbon metabolism in cancer (mmu05230) 0.042 12 6 
16 Bacterial invasion of epithelial cells (mmu05100) 0.042 16 7 
17 Toxoplasmosis (mmu05145) 0.042 22 8 
18 Protein processing in endoplasmic reticulum (mmu04141) 0.042 37 9 
19 Steroid biosynthesis (mmu00100) 0.048 3 3 
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Supplementary Table 3.2: Functions of significantly differentially expressed miRNA of interest. 
The list of significantly differentially expressed miRNA from the OpenArray analysis was analysed 
using miRPath software to determine their proposed roles and downstream targets. The directional 
change in regulation of each miRNA in CM as compared to NI MV is shown. These ten miRNA were 
chosen for further study based on their identified roles in the literature: eight are significantly 
differentially expressed, and two were selected from the populations of miRNA unique to each 
biological group. Here, p-value thresholds of significance as defined previously. 
miRNA of 
interest 
Change in 
abundance  
in CM 
Pathways involved, or known roles 
hsa-miR-146a Up 
Regulates IL-1β in cytokine-induced tolerance1; serum indicator for 
dengue infection2; suppresses cellular immune response during 
Japanese encephalitis3; induces apoptosis4; associated with 
Alzheimer’s disease5 
Genes in malaria pathway: suppresses CD40LG6, CXCL87,8, 
IFNɣ9, TLR210, TLR411, and ITGB212 
hsa-miR-150 Up 
In CM mouse brains13, monocytes14 monocyte-derived 
microvesicles15, T cell exosomes16, and platelets17; promotes 
proliferation and apoptosis18; immune suppression function19; altered 
during immune response and disease conditions20 such as ulcerative 
colitis21 
hsa-miR-205 Up 
Regulates apoptosis22,23, VEGF-mediated promotion of ovarian 
cancer cell invasion24, biomarker for cervical cancer25 and influenza 
B26, potential extracellular vesicle-derived biomarker for pulmonary 
TB27 
hsa-miR-328 Down 
Down-regulated in H. pylori-associated gastric cancer28; regulation 
of ATP-binding cassette transporter ABCG229, increased function of 
macrophages and neutrophils during infection30, inhibits 
proliferation31 
Genes in malaria pathway: increases Thbs132 
hsa-miR-335* Down 
Regulates Parkinson’s disease susceptibilityError! Hyperlink 
reference not valid., reduced in , ulcerative colitis34, osteoarthritis35, 
Crohn’s disease36, and during HIV infection37 
Genes in malaria pathway: increases Thbs1 and Thbs232, and 
TLR4 
hsa-miR-486 Up 
Regulates normal erythropoiesis and enhances growth38; targets 
NFκβ39 and PIK3R140, characterised in serum exosomes41,42, 
including in hypoxic states, increased in Huntington’s disease43 and 
MS patients44 
Genes in malaria pathway: suppresses CD4045 and TLR246 
mmu-miR-10b Up 
Related to brain pathology in Huntington’s43 and Parkinson’s 
diseases47, part of hypoxic signature of miRNA in glioblastoma48, 
identified in exosomes49; upregulated by proinflammatory 
cytokines50 
Genes in malaria pathway: suppresses IL12A46 
mmu-miR-16* Up Role in embryo implantation51 
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mmu-miR-21* Up 
Important role in induction of asthmatic inflammation52 and seizure 
deterioration in epilepsy53; upregulated during Toxoplasma 
infection54 
mmu-miR-193b Down 
Inhibits TGFβ2 signalling pathway55, induces IL10-expressing 
monocytes56, characterised in PBMC’s57, role in monocyte-
macrophage differentiation58, potential sepsis biomarker59, down-
regulated in Alzheimer’s disease60 and ALS61 
Genes in malaria pathway: increases Thbs1 and Thbs262, and 
TGFβ263 
mmu-miR-215 Up Promotes apoptosis
64, hypoxia-induced65, inflammatory mediator in 
cystic fibrosis lung epithelial cells66, identified in exosomes67 
mmu-miR-297a* Up No published results 
mmu-miR-467a Down Regulates apoptosis
68 and cell survival69 
Genes in malaria pathway: increases TNF70 
mmu-miR-685 Up No published results 
mmu-miR-1949 Up Potential inducer of bladder cancer71 
hsa-miR-590-5p Only in  NI 
Potential biomarker in coronary artery disease72, modifies cell 
proliferation, differentiation and migration through TGFb signalling 
pathway73, biomarker for dengue2 and Alzheimer’s disease 
patients74, identified in monocytes75, and in T cells during MS76 
rno-miR-450 Only in CM Inflammatory marker in diabetes
77, targets interferon regulatory 
factor 2 in lung cancer78 
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Abstract 
 
Cerebral malaria is the most severe manifestation of infection with Plasmodium, however its 
pathogenesis is still not completely understood. microRNA (miRNA) have been an area of focus in 
infectious disease research, due to their ability to affect normal biological processes, and have been 
shown to play roles in various viral, bacterial and parasitic infections, including malaria. The 
expression of miRNA was studied following infection of CBA mice with either Plasmodium berghei 
ANKA (causing CM), or Plasmodium yoelii 17XNL (causing severe but non-cerebral malaria 
(NCM). Using microarray analysis, miRNA expression was compared in the brain of non-infected 
(NI), NCM and CM mice. Six miRNA: miR-19a-3p, miR-19b-3p, miR-27a-5p, miR-142-3p, miR-
223-3p, and miR-540-5p, were significantly dysregulated between NCM and CM mice, and these 
miRNA are significantly involved in several pathways relevant to CM, including the TGF-b and 
endocytosis pathways. Dysregulation of these miRNA during CM specifically compared with NCM 
suggests that these miRNA, through their regulation of downstream targets, may be vitally involved 
in the neurological syndrome. Our data implies that, at least in the mouse model, miRNA may play a 
regulatory role in CM pathogenesis. 
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Introduction 
 
Malaria is a serious and sometimes life-threatening disease transmitted by the bite of female 
Anopheles mosquitoes. In 2015 alone, the disease led to an estimated 429,000 deaths, with sub-
Saharan Africa the most heavily affected with 90% of this count. Malaria is most severe in children 
under five years old, who account for 70% of all death (WHO, 2016). Features of the life-threatening 
disease typically consist of metabolic acidosis, severe anaemia, and cerebral malaria (CM), with the 
latter eventuating in approximately 1% of cases worldwide, equal to 1 million people (WHO, 2016). 
CM is an often fatal complication of malaria infections, and the most severe manifestation of the 
infection, characterised by unarousable coma and unconsciousness, often leading to death, or the 
occurrence of neurological sequelae in survivors (Bangirana et al., 2016). Currently the only 
treatment options for CM are a combination of immediate intensive care and anti-malarial 
medications (Sahu et al., 2015), however resistance is increasingly common, and access to adequate 
medical care in time is not. Non-cerebral malaria (NCM) is another manifestation of severe malaria, 
resulting in severe anaemia and respiratory distress, and can be caused by other strains of 
Plasmodium, including P. vivax (WHO, 2012). 
Of particular pertinence to this study, the pathology of CM is not currently completely 
understood, though several proposed hypotheses have been proposed. The pathogenicity associated 
with CM is understood to involve parasitised red blood cells (pRBC), endothelial cells, various 
adhesion molecules and cytokines, platelets, monocytes, and microvesicles released from many 
different cell types, including several involved in the pathogenesis of CM (Wassmer et al., 2003; 
Medana and Turner, 2007; Moxon et al., 2011; Wassmer et al., 2011a). Within brain microvessels, 
and in response to the parasite itself, sequestration occurs – that is, the cytoadherence of pRBC, 
platelets, and monocytes to endothelial and intravascular cells (Wassmer et al., 2003; Moxon et al., 
2011; Wassmer et al., 2011a). This accumulation of cells within the vessels, mediated by adhesion 
markers such as ICAM-1, VCAM-1, and E-selectin, can trigger changes in the function and viability 
of the cerebral endothelium, destruction of microcirculatory blood flow, and hypoxia, leading to 
blood brain barrier dysfunction and, consequently, several of the clinical manifestations observed in 
CM (Medana and Turner, 2007; Moxon et al., 2011; Wassmer et al., 2011a). The loss of blood-brain 
barrier integrity also results in increased permeability, leading to increased cerebral oedema, as 
observed in patients (Seydel et al., 2015; Mohanty et al., 2017). Parasite infection, as stated 
previously, induces the overproduction of cytokines, such as TNF, lymphotoxin, and IFN-ɣ, and this 
also results in alterations of the cerebral endothelium, upregulation of adhesion molecules, EC 
apoptosis, and further mediation of cytokine and chemokine release (El-Assaad et al., 2014b). In 
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recent times, microRNA (miRNA) have also been investigated as to their role in normal conditions 
and deregulation in a number of diseases, including malaria. 
miRNA are small, single-stranded non-coding RNA that have been widely demonstrated to 
be able to regulate the expression of at least one third of the human genome and play a critical role in 
a variety of normal biological processes, including cell differentiation, apoptosis, development, and 
metabolism (Bartel, 2004). Changes in miRNA expression have also been identified in a range of 
diseases, including viral, bacterial, and parasitic infections (Ding and Voinnet, 2007; Hakimi and 
Cannella, 2011; Eulalio et al., 2012), including malaria. MiRNA expression changes in the liver and 
brain have been studied during malaria infections using the murine model (El-Assaad et al., 2011; 
Chamnanchanunt et al., 2015; Barker et al., 2017), and within circulating microvesicles (Mantel et 
al., 2016; Moro et al., 2016), investigating the effect of Plasmodium infection on miRNA signatures 
within these tissues and cells. They found that certain miRNA were down or upregulated, including 
miR-16, miR-27a, miR-150, and miR-451, in response to infection, and that blocking some of these 
protects mice against the development of the infection. The effect of anti-malarial treatment on this 
expression has also been tested, with miRNA expression changes being reversed in some cases (Al-
Quraishy et al., 2012; Cohen et al., 2015; Dkhil et al., 2017). These studies provide supporting 
evidence of the roles that miRNA can play in the pathogenesis of, resistance to, and protective 
immune response against malarial infection. 
However, the exact mechanism of action of miRNA during infection, and whether they play 
either a pathogenic or a protective role, or a combination of the two, is still not completely understood. 
Therefore, there is still a need for further research in this area. Our study examines the role of miRNA 
within brain tissue during experimental cerebral or non-cerebral malaria, and in non-infected mice in 
comparison. We show that, after infection, there are changes in specific miRNA in the brain tissue 
which could provide prospective avenues of research into further understanding CM pathogenesis 
and how to treat or prevent it. 
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Materials and Methods 
 
i. Mice 
All mice were handled according to approved protocols of the University of Sydney Animal Ethics 
Committee (protocol number 2015/832). 7-10-week-old female CBA mice (Animal Resource Centre, 
Perth) were housed under pathogen-free conditions, fed a commercial rodent pellet diet, and had 
access to water ad libitum. For experimental comparisons, three groups of five mice were included: 
non-infected (NI), Plasmodium berghei ANKA-infected (PbA, CM), and Plasmodium yoelii 17XNL-
infected (Py, NCM). PbA infection of CBA mice leads to fatal disease with cerebral pathology during 
the neurological phase, between day 6 and day 14 post-infection (p.i.) (Rae et al., 2004). Mice 
surviving beyond this point are defined as NCM: i.e. Py infection leads to a fatal but non-cerebral 
syndrome due to hyperparasitaemia and severe anaemia, 14 or more days post infection. 
 
ii. Plasmodium inoculation 
All infections were initiated by intraperitoneal injection of 1 x 106 PbA/Py pRBC, as previously 
described (Grau et al., 1986). Parasitaemia was monitored by counting pRBC in Diff-Quick-stained 
thin blood smears on day four p.i. and every 1-2 days after this, for the duration of the infection. Mice 
were assessed using a clinical evaluation score, and CM diagnosed if mice presented with ruffled fur, 
severe motor impairment (ataxia, hemiplegia, or paraplegia) or convulsions and was given a score of 
3 or 4 as described previously (Potter et al., 2006). This diagnosis was then confirmed by 
histopathology, i.e. presence of leucocyte and pRBC adherence to endothelium, haemorrhages, and 
oedema surrounding vessels. Py-infected mice without any of the symptoms mentioned above were 
classified as NCM. 
 
iii. Brain tissue preparation 
At the time of CM for PbA-infected mice, all groups of mice were sacrificed as detailed above and 
brain tissue was collected from infected (CM and NCM), and NI mice. Samples were placed 
immediately in RNAlater (Life Technologies) in a 1:5 volume ratio for complete submersion. 
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iv. RNA extraction 
Total RNA including miRNA was isolated using Ambion mirVanaTM miRNA Isolation Kit (Life 
Technologies). The concentration and purity of total RNA was determined using a NanoDrop-1000 
spectrophotometer (only RNA samples with A260/A280 and A260/A230 ratios above 2.0 and 1.8, 
respectively, were included into subsequent miRNA profiling studies). To that end, 100 ng of total 
RNA was reverse transcribed using the microRNA reverse transcription (RT) reaction kit by 
following manufacturer’s protocol. 
 
v. cDNA synthesis and preamplification 
To increase the quantity of desired cDNA before performing PCR and to significantly increase the 
ability to detect low abundance transcripts, a pre-amplification step was performed as per the 
manufacturer’s recommendation. The preamplified product was diluted 40 times by mixing 4 µl of 
the preamplified product with 156 µl of 0.1x Tris-EDTA buffer, pH 8.0, and the mix was loaded onto 
the OpenArray rodent panel using the Accufil system, and run using a QuantStudio 12K Flex PCR 
(Life Technologies). 754 rodent miRNA were amplified in each sample. All reactions were performed 
in duplicate, and each technical replicate was analysed on two different OpenArray® Panels. 
 
vi. OpenArray analysis 
Resulting Crt values were filtered to exclude low-quality reactions with an amplification score below 
1.1, following recommendations of Life Technologies technicians, where Crt is defined as the PCR 
cycle number at which the fluorescence meets the threshold in the amplification plot. miRNA with a 
Crt value ˃29 were considered unamplified. This Crt cut-off was chosen since OpenArray® reactions 
are carried out in small volumes (33 nL); a single molecule is more concentrated in a smaller reaction 
volume and amplifies sooner than it would from regular microplate qPCRs. More concretely, single 
copy numbers will produce, on average, a Crt value of 29 with TaqMan® assays (McAlinden et al., 
2012). Furthermore, for large scale miRNA expression profiling studies, it has been demonstrated 
that global normalisation outperforms the normalisation strategy that makes use of small RNA 
controls (Mestdagh et al., 2009). Consequently, raw Crt values were normalised using global 
normalisation of each pool separately, as per recommendations. After global normalisation, technical 
replicates differing by more than 0.5 standard deviations were excluded from the analysis, and 
average ΔCt values were estimated for the remaining results. Finally, miRNA which were not 
amplified in more than 50% of samples were considered to be lowly expressed and, therefore, also 
excluded from the analysis. Using these criteria, 395 miRNA were filtered out leaving 359 miRNA 
in the final data analysis. 
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vii. Statistical analyses 
Differences between experimental groups were assessed by Kruskal-Wallis with Dunn post-hoc test, 
and p-values were adjusted for multiple testing using the Benjamini-Hochberg method. The results 
were calculated using the ΔΔCt method (Livak and Schmittgen, 2001), and fold change (FC) was 
calculated using the 2-ΔΔCt method, and then data were log2-transformed. Those miRNA with 
expression differences among the three study groups (as determined by Kruskal-Wallis test and 
corresponding post-hoc tests) were included in hierarchical clustering, which was performed using 
Euclidean distance, complete linkage and z-score normalisation. A Venn diagram was generated to 
show the number of miRNA that were significantly dysregulated among the three study groups. P-
values of <0.05 (two-sided) were considered significant. All data were analysed using SPSS Statistics 
20 (IBM Corporation), GraphPad Prism version 5.02 (GraphPad Software) and RStudio. 
 
viii. Pathway analysis 
DIANA-mirPath v3.0 was used for analysing the combinatorial effect of dysregulated miRNA on 
target pathways, with a False Discovery Rate (FDR) of 5%. DIANA mirPath is a powerful tool to 
analyse the combinational effects of miRNA on signalling pathways (Vlachos et al., 2015). This 
bioinformatics software performs an enrichment analysis of the input datasets by comparing the set 
of dysregulated miRNA to all available biological pathways provided by the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (Kanehisa and Goto, 2000). It should be taken into account that, to this 
end, we used TarBase (Sethupathy et al., 2006) that houses a manually curated collection of 
experimentally proven miRNA targets. Classic miRNA target prediction algorithms were not used 
due to their intrinsic high false positive rates (Vlachos and Hatzigeorgiou, 2013). The combinatorial 
effect of co-expressed miRNA in the modulation of a given pathway is taken into account by the 
simultaneous analysis of multiple miRNA. The significantly influenced pathways (P <0.05) were 
identified. 
 
The datasets generated and analysed during the current study are available from the corresponding 
author on reasonable request. 
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Results 
 
Clustering analysis shows miRNA expression in NCM mice is more closely related to NI than 
CM mice. The changes in miRNA expression in the brain of NI, NCM and CM mice were examined. 
Unsupervised hierarchical clustering separated the samples into two main clusters confirming 
homogeneity of the miRNA expression profiles within each group. Whilst all the CM mice were 
placed in one cluster, the other cluster was constituted by the other two experimental groups, NI and 
NCM mice (Figure 4.1). According to this clustering method, the relative expression of dysregulated 
miRNA in NCM mice was more closely related to the NI group than to CM mice. Regarding the set 
of dysregulated miRNA, two main clusters were identified, the first one gathering those miRNA that 
were upregulated in CM mice whereas those downregulated were included in the second cluster. 
 
  
Figure 4.1. Hierarchical clustering of dysregulated miRNA based on Euclidean distance 
measure and complete linkage with Z score normalised gene expression. Each row represents one 
microRNA and each column represents one sample. Red rectangles represent missing values. NI: 
non-infected; NCM: Plasmodium yoelii-infected mice; CM: Plasmodium berghei ANKA-infected 
mice. 
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Six miRNA of interest are significantly differentially expressed between NCM and CM mice. A 
total of 16 miRNA showed differential expression among the three groups, as determined by Kruskal-
Wallis analysis and subsequent post-hoc tests. We found twelve miRNA to be significantly 
dysregulated between NI and CM mice: miR-18a-5p, miR-19a-3p, miR-20b-5p, miR-21-5p, miR-
27a-5p, miR-142-3p, miR-152-3p, miR-155-5p, miR-193a-5p, miR-218-1-3p, miR-411-5p, and miR-
543 (Figure 4.2). Two miRNA were significantly dysregulated between NI mice and NCM mice: 
miR-19b-3p and miR-101-3p; and six miRNA between NCM and CM mice: miR-19a-3p, miR-19b-
3p, miR-27a-5p, miR-142-3p, miR-223-3p, and mmu-miR-540-5p. Three miRNA: miR-19a-3p, 
miR-27a-5p, and miR-142-3p were significantly upregulated in CM mice compared with NI as well 
as NCM, with NCM being an intermediate in this expression comparison. The Venn diagram 
presenting the number of significantly dysregulated miRNA regarding the three experimental groups 
is shown in Figure 4.2. 
 
 
Figure 4.2. Venn diagram showing the number of miRNA that were significantly dysregulated 
in the brain of NI, NCM and CM mice. P-values of <0.05 (two-sided) were considered significant. 
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Sixteen miRNA are significantly dysregulated amongst NI, NCM, and CM mice. For those 
dysregulated miRNA between the three groups, the log2 (fold change) was calculated (Table 4.1), and 
graphed in Figure 4.3 together with the calculations regarding the significance described above. Of 
those miRNA significantly dysregulated in CM vs. NI mice, miR-18a-5p, miR-19a-3p, miR-20b-5p, 
miR-21-5p, miR-27a-5p, miR-142-3p, and miR-155-5p were increased 0.60-2.24-fold, and miR-152-
3p, miR-193a-5p, miR-218-1-3p, miR-411-5p, and miR-543 were decreased 0.32-0.92-fold. miR-
101-3p was increased 1.17-fold, and miR-19b-3p was decreased 0.46-fold in NCM vs. NI mice. 
Finally, in comparing NCM vs. CM mice, miR-19a-3p, miR-19b-3p, miR-27a-5p, miR-142-3p, and 
miR223-3p were increased 0.44-1.44-fold, and miR-540-5p was decreased 0.87-fold in CM mice. 
 
 
Figure 4.3. Box plots show miRNA expression levels measured in the three study groups, 
expressed as normalised values using global normalisation. The horizontal line denotes the 
median value, the box encompasses the upper and lower quartiles, whiskers show the range, and the 
plus symbol denotes the mean. A nonparametric Kruskal-Wallis test was carried out. If the Kruskal-
Wallis test was significant, post hoc tests were carried out, to adjust p-values for multiple testing 
using the Benjamini-Hochberg method. The results of these are denoted in the plot with horizontal 
bars and asterisks (*, P = 0.01-0.05; **, P <0.01). These data represent results of duplicate 
experiments, with 5 animals in each group. 
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Table 4.1. Fold change of significantly dysregulated miRNA within the brain between biological 
conditions. 
miRNA Kruskal-Wallis  
test 
Log2 FC, with Dunn’s + Benjamini-Hochberg Post-Hoc tests 
NI vs. NCM NI vs. CM NCM vs. CM 
miR-18a-5p <0.01  1.61  
miR-19a-3p <0.05  0.93 0.77 
miR-19b-3p <0.05 -0.46  0.44 
miR-20b-5p <0.05  1.55  
miR-21-5p <0.05  0.60  
miR-27a-5p <0.05  1.37 1.09 
miR-101-3p <0.05 1.17   
miR-142-3p <0.01  1.17 1.19 
miR-152-3p <0.05  -0.34  
miR-155-5p <0.05  2.24  
miR-193a-5p <0.05  -0.87  
miR-218-1-3p <0.05  -0.92  
miR-223-3p <0.05   1.44 
miR-411-5p <0.05  -0.51  
miR-540-5p <0.05   -0.87 
miR-543 <0.05  -0.32  
 
Significantly dysregulated miRNA in CM compared with NCM mice play roles in pathways 
consistent with the cerebral syndrome of malaria. We then examined more closely the differences 
in miRNA expression between CM and NCM, in order to identify miRNA with potential roles 
specifically in the cerebral syndrome. Those miRNA that were upregulated in CM mice in 
comparison with NCM mice as determined by post-hoc comparisons, as seen in Figure 4.3 (miR-19a-
3p, miR-19b-3p, miR-27a-5p, miR-142-3p and miR-223-3p) were analysed the DIANA-mirPath v3.0 
software identified 16 pathways in mice as significantly enriched (P < 0.05) (Table 4.2). The pathway 
relating to endocytosis (3rd in the list, P = 6.28E-7), as well as the FoxO (6th, P = 0.0004) and TGF-β 
signalling (10th, P = 0.007), and adherens junctions (13th, P = 0.01) pathways were among the most 
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significantly regulated by our list of miRNA of interest. This is particularly interesting as the 
endocytosis, FoxO signalling and adherens junctions pathways are all intrinsically linked to the TGF-
b signalling pathway, as they share common elements. Two of these miRNA upregulated in CM mice 
(miR-19a-3p and miR-19b-3p) target 28 of the genes involved in the FoxO signalling pathway, 16 of 
the genes participating in the TGF-β signalling pathway, and 20 of the genes participating in the 
adherens junctions pathway. Furthermore, these same miRNA, along with miR-27a-5p, have shown 
to target 50 different genes involved in endocytosis. 
When analysing the combinatorial effect of those miRNA upregulated in CM mice (when 
compared to NCM mice) to target pathways in humans, 37 pathways were identified by the software 
as significantly enriched (P <0.05), including 12 of those also significantly enriched in mice. Of these, 
the FoxO (6th, P = 2.86E-7) and TGF-β signalling (14th, P= 0.0001), and adherens junctions (26th, P = 
0.001) pathways remained as significantly enriched as identified in mice, although the number of 
experimentally proven targets of these molecules of interest is generally higher in humans than in 
mice in the Tarbase database. Specifically when analysing target pathways in humans, three of the 
miRNA upregulated in CM mice (miR-19a-3p, miR-19b-3p and miR-223-3p) target 43 of the genes 
involved in the FoxO signalling pathway, whilst miR-19a-3p, miR-19b-3p and miR-27a-5p regulate 
the expression of 23 of the genes participating in the TGF-β signalling pathway, and miR-27a-5p and 
miR-142-3p regulate the expression of 18 genes participating in the adherens junctions pathway. 
Additionally, other notable pathways identified included apoptosis (P = 0.020) and Wnt signalling (P 
= 0.022) pathways. 
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Discussion 
 
This study provides the first large-scale analysis of miRNA expression in experimental 
malaria and reveals that Plasmodium infection induces the dysregulation of a specific set of miRNA 
in the brain. That set included 12 miRNA found to be dysregulated in CM compared with NI mice, 
and 6 miRNA dysregulated in CM compared with NCM mice. The latter set likely play important 
roles in CM, and includes several molecules that are widely associated with inflammatory responses. 
For instance, miR-223 was found to be overexpressed in rheumatoid arthritis (Shibuya et al., 2013), 
osteoarthritis (Okuhara et al., 2012), and inflammatory bowel disease (Fasseu et al., 2010), among 
others. Furthermore, miR-223 actively participates in infection processes, regulating the 
differentiation of several key players of the innate immune response and therefore, likely plays an 
important role in the early stages of infection (Haneklaus et al., 2013). 
Clustering analyses suggested that dysregulated miRNA may represent a miRNA fingerprint 
of CM, therefore able to distinguish between individuals with and without cerebral complications 
during a malaria infection. Consequently, the levels of expression of this set of miRNA should be 
further analysed in blood samples from patients with CM and compared to NCM patients, in order to 
confirm their usefulness as biomarkers of CM in humans. The utility of miRNA as biomarkers of 
infection has been widely demonstrated in several parasitoses, including schistosomiasis (He et al., 
2013), filarial infections (Tritten et al., 2014), and toxoplasmosis (Jia et al., 2014). Among the set of 
miRNA dysregulated in CM mice, miR-223 has been defined as a potential biomarker of infection 
with Schistosoma japonicum (He et al., 2013). 
Regarding the relationship between miRNA and malaria, a recent study has demonstrated that 
intrinsic miRNA levels play a significant role in malaria resistance (La Monte et al., 2012), proving 
that miRNA activity may be utilised to defend host cells against complex eukaryotic pathogens, not 
only against viruses as previously demonstrated (Lecellier et al., 2005). LaMonte et al. showed that 
miR-223, among others, strongly reduces the growth of P. falciparum in erythrocytes carrying a 
variant haemoglobin allele (HbS), which causes sickle cell disease. The authors indicated that the 
antimalarial activity of erythrocyte miRNA requires their entry and subsequent modification of 
parasite mRNA. Consequently, it is possible that the upregulation of at least miR-223 in CM mice 
may be a targeted anti-parasitic immune response, and that miRNA could be used as valuable targets 
for new therapeutic interventions in malaria – a method already being explored in other diseases. 
 
 
 
CHAPTER 4 | Brain microRNA in cerebral malaria 
 148 
Our study also shed light on the range of miRNA molecules simultaneously involved in 
regulating several signalling pathways in CM. Bioinformatics tools indicated that hsa-miR-19a-3p, 
which was upregulated in CM mice compared to NCM mice, can regulate the expression of at least 
14 out of the 38 genes involved in the TGF-β signalling pathway, as well as many other genes 
involved in other significantly associated pathways. 
TGF-β is a superfamily of cytokines, known to regulate cell differentiation, proliferation, 
apoptosis and pro- and anti-inflammatory immune responses (Lutz and Knaus, 2002). TGF-β is 
considered a pivotal regulator of the mammalian response to malaria parasite infection, having been 
described as maintaining “immunological balance” during infection (Omer et al., 2000). In our study, 
we found that two miRNA upregulated in CM compared with NCM mice have been experimentally 
demonstrated to target 16 genes from the TGF-β signalling pathway, which could lead to a miRNA-
mediated downregulation of their corresponding mRNAs, subsequently altering this pathway, as is 
consistent with previous findings (more detailed information in Figure S4.1 and Table S4.1) (Omer 
and Riley, 1998). Similarly, low levels of TGF-b1 have been shown to contribute to increased disease 
severity in mice (de Kossodo and Grau, 1993) and humans (Perkins et al., 1999). Therefore, we 
suggest that the paramount relevance of the TGF-β signalling pathway in malaria infections is, at 
least partly, due to the action of these miRNA. 
The most significant relationship was found between miRNA upregulated in CM mice and 
the endocytosis pathway. Endocytosis is a mechanism for cells to remove nutrients, plasma 
membrane proteins, and lipids from the cell surface into the cell interior, by phagocytic or pinocytic 
methods (Conner and Schmid, 2003). This relationship is of particular interest due to the known role 
of microvesicles (submicron vesicles released from cell types involved in CM) in CM, where a 
significant overproduction is observed in cerebral infection cases only, and not in NI or NCM 
conditions (Combes et al., 2005). Microvesicles have their effect on target tissues through the process 
of endocytosis into these target cells, therefore it is poignant that this pathway should be the most 
significantly regulated by our miRNA of interest. This link supports existing evidence of the role of 
microvesicles in CM in effecting change within the brain in response to infection (El-Assaad et al., 
2014b). Particularly, recognition of the expression of phosphatidylserine on the surface of 
microvesicles is crucial for phagocytic endocytosis and the subsequent clearance of microvesicles, 
providing evidence of a potential protective role played by miRNA in the brain. 
The KEGG pathway analysis also showed relationship between miRNA upregulated in CM 
mice and the FoxO signalling pathway. The FoxO family of transcription factors is central to the 
integration of growth factor signalling, oxidative stress and inflammation (Hedrick et al., 2012), by 
regulating the expression of several antioxidant enzyme genes, including superoxide dismutase (sod), 
and catalase (cat) (Kahle et al., 2009; Storz, 2011). Recently, it was shown that these antioxidant 
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enzyme genes were altered at the transcriptional level during Plasmodium infection, indicated by the 
gradually diminished expression of superoxide dismutase-1 (sod-1), sod-2, sod-3 and catalase genes 
(Linares et al., 2013). This family of transcription factors also regulates the expression of genes in 
cellular physiological events including apoptosis and glucose metabolism and, considering that 
impaired glucose production caused by the inhibition of gluconeogenesis is a frequently encountered 
complication in falciparum malaria (Thien et al., 2006), the possible relationship among miRNA, the 
FoxO signalling pathway and glucose concentration should be addressed in the future. 
This set of miRNA is involved in the assembly/disassembly of adherens junctions which, 
together with tight junctions, ensure the integrity of vascular endothelial cells forming a barrier that 
plays a crucial role in the health and integrity of the blood-brain barrier (BBB). Disruption of the 
BBB is a hallmark of immune mediated neurological disorders, including CM (El-Assaad et al., 
2014a). More concretely, during malaria infection, the endothelium becomes activated leading to 
leakage associated with the disruption of endothelial cell junctional proteins (Adams et al., 2002). 
However, the relationship of miRNA with the disruption of the BBB is almost unknown, but may be 
linked to the Vascular Endothelial cadherin (VE-cad), a component of the adherens junction complex 
that has emerged as an important regulator of endothelial cell-cell adhesion (Dejana et al., 2008). It 
has been shown that, in the presence of high levels of miR-142a-3p (also upregulated in CM mice in 
our study), VE-cad (cdh5) levels are suppressed, decreased levels of which are known to compromise 
endothelial cell-cell adhesion thus leading to loss of vascular integrity and remodelling (Lalwani et 
al., 2012). Furthermore, another component of adherens junctions, β-catenin, has been found to be 
targeted in humans by two miRNA that are also found upregulated in CM mice (miR-142-3p and 
miR-27a-5p). Strikingly, β-catenin has also been shown to regulate FoxO function under conditions 
of oxidative stress (Essers et al., 2005), indicating cross-talk between both pathways. 
It is clear that dysregulation of these miRNA during CM specifically compared with NCM 
suggests that they, through their regulation of downstream targets, may be vitally involved in the 
neurological syndrome. Collectively, these findings may help to decipher which and how miRNA are 
connected to some of the processes that have been historically implicated in CM pathogenesis, such 
as excessive pro-inflammatory cytokine production (Clark and Rockett, 1994; Grau and de Kossodo, 
1994), loss of endothelial barrier function (Beare et al., 2009; Dorovini-Zis et al., 2011), and 
endothelial dysregulation (Wassmer et al., 2011b). Nevertheless, how our miRNA of interest are 
regulating these pathways should be analysed more thoroughly in the future due to the complexity of 
the interactions of these miRNA with their numerous mRNAs targets within these pathways. 
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Supplementary Figure 4.1-4. DIANA mirPath analysis of five upregulated miRNA in CM mice. 
Genes targeted by more than one miRNA are shown in orange boxes whereas genes targeted by one 
miRNA are highlighted in yellow boxes. Numbers in italics represent that several genes whose 
protein products play a similar role are targeted by these upregulated miRNA, detailed below. 
Supplementary Figure 4.1: DIANA mirPath analysis predicted that 16 genes involved in TGF-β 
signalling pathway are targeted by two miRNA from this group. 1: Ppp2ca and Ppp2r1b. 
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Supplementary Figure 4.2: DIANA mirPath analysis predicted that 50 genes involved in the 
endocytosis pathway are targeted by three miRNA from this group. 1: Ap2b1 and Ap2a2; 2: Wwp1, 
Nedd4l, Traf6, Mdm2 and Nedd4; 3: Asap2, Arfgap3, Agap1, Asap1 and Arap2; 4: Arfgef1, Arfgef2 
and Psd3; 5: Arf3, Arf6; 6: F2r and Adrb1; 7: Grk5, Grk4 and Adrbk1; 8: Stam and Stam2; 9: Vps37b 
and Vps37a. 
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Supplementary Figure 4.3: DIANA mirPath analysis predicted that 28 genes involved in the FoxO 
signalling pathway are targeted by two miRNA from this group. 
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Supplementary Figure 4.4: DIANA mirPath analysis predicted that 20 genes involved in the 
adherens junctions’ pathway are targeted by two miRNA from this group. 1: Pvrl1, Pvrl3. 
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Supplementary Table 4.1. Description of those genes targeted by miRNA upregulated in PbA-
infected mice in comparison with Py-infected mice within significantly upregulated pathways 
Pathway Protein miRNA targeting the 
protein 
Protein function  
TGF-β 
signalling 
pathway 
Tgfb3 miR-19a-3p, miR-19b-3p Binds to the type II TGF-β receptor, which 
then binds to the type I TGF-β receptor1 
Inhbb miR-19b-3p Encodes the activin/inhibin βB subunit of 
activins and inhibins, belonging to the 
TGF-β super-family2 
 Tnf miR-19a-3p, miR-19b-3p Encodes TNF, which can induce the 
transcription of I-Smads (Smad6/Smad 7)3 
 Tgfbr2 miR-19a-3p, miR-19b-3p Encodes the TGFβRII receptor, which 
phosphorylates and activates TGFβRI4 
 Acvr1b miR-19a-3p, miR-19b-3p Encodes the Activin A receptor type 1b 
protein, which is a transmembrane serine/ 
threonine kinase receptor and is essential 
for signalling5 
 Acvr2a miR-19b-3p Codes for an Activin receptor type II that is 
able to bind Activin ligands6 
 Bmpr2 miR-19a-3p, miR-19b-3p Encodes the BMP type-II receptor, which 
appears to bind exclusively to BMP 
ligands7 
 Bmpr1a miR-19a-3p, miR-19b-3p Encodes the BMP type IA receptor for bone 
morphogenetic proteins (BMPs)8 
 Smad2 miR-19a-3p, miR-19b-3p  The intracellular signals for the activins and 
TGF-βs are mediated through the 
phosphorylation of Smad27 
 Smad4 miR-19a-3p, miR-19b-3p Forms heterotrimeric complexes with two 
R-Smads, which are translocated to the 
nucleus9 
 Ppp2ca miR-19a-3p, miR-19b-3p Encodes the catalytic subunit of a serine 
phosphatase PP2A, which binds to type I 
receptors9 
 Ppp2r1b miR-19a-3p, miR-19b-3p Encodes the β isoform of the A subunit of 
the serine/threonine protein phosphatase 2A 
(PP2A), which binds to type I receptors10 
 Zfyve9 miR-19a-3p, miR-19b-3p Encodes SARA, which functions as a linker 
protein between type I activin/TGF-β 
receptors and SMAD2/3 to stimulate 
SMAD phosphorylation11 
 Sp1 miR-19a-3p, miR-19b-3p Cooperates with Smad2, Smad3 and Smad4 
to induce p15Ink4B transcription in response 
to TGF-β12 
 Id3 miR-19a-3p, miR-19b-3p Id proteins are important parts of signalling 
pathways involved in development, cell 
cycle and tumorigenesis13 
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Endocytosis Tgfb3 miR-19a-3p, miR-19b-3p Encodes a member of the TGF-β family of 
proteins14 
 Tgfbr2 miR-19a-3p, miR-19b-3p Encodes a cell-surface receptor for TGF-β15 
 Tfrc miR-19a-3p, miR-19b-3p Encodes a membrane receptor for 
transferrin16 
 Kit miR-19b-3p Encodes receptor tyrosine kinases, such as 
the EGFRs17 
 Smad2 miR-19a-3p, miR-19b-3p SARA/Smad2 complex allows signalling 
and recycling18 
 Zfyve9 miR-19a-3p, miR-19b-3p Encodes SARA protein, which facilitates 
signal transduction by promoting the 
association of SMAD2 and SMAD3 with 
receptor complexes19 
 Cblb miR-19a-3p, miR-19b-3p Encodes Cbl, which mediates the 
internalisation of many receptors17 
 Sh3glb1 miR-19b-3p Encodes endophilins, which induce 
membrane curvature and help in the fission 
of clathrin-coated buds from the 
membrane17 
 Epn2 hsa-miR-27a-5p Encodes epsin, which, along with EPS15, 
might bind to monoubiquitylated EGFRs to 
move EGFRs out of lipid rafts17 
 Eps15 miR-19b-3p EPS15 and epsin might bind to 
monoubiquitylated EGFRs to move EGFRs 
out of lipid rafts17 
 Cltc miR-19a-3p, miR-19b-3p 
 
Encodes a major subunit of clathrin, which 
serves as the vesicle coat protein involved 
in intracellular trafficking and endocytosis20 
 Ap2a2 miR-19b-3p Encodes the adaptor protein-2 (AP2), 
mediates the endocytosis of cargo proteins17 
 Ap2b1 miR-19a-3p, miR-19b-3p Encodes one of the two large chain 
components of the clathrin assembly 
protein complex 2, which is important for 
protein transport21 
 Wwp1 miR-19a-3p, miR-19b-3p Encodes a ubiquitin ligase that targets 
proteins for degradation or other cellular 
fates22 
 Traf6 miR-19a-3p, miR-19b-3p Encodes a ubiquitin ligase that participates 
in signal transduction of both the TNF 
receptor superfamily and the interleukin-1 
receptor/Toll-like receptor superfamily23 
 Nedd4 miR-19a-3p, miR-19b-3p Plays a crucial role in ubiquitination of 
many plasma membrane proteins24 
 Nedd4l miR-19a-3p, miR-19b-3p Encodes Nedd4-2, which binds and 
regulates a number of membrane proteins to 
aid in their internalisation and turnover25 
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 Mdm2 miR-19a-3p, miR-19b-3p Encodes an E3-ubiquitin ligase that 
promotes the proteasomal degradation of 
the cell-cycle regulator p5326 
 Arf6 miR-19a-3p, miR-19b-3p Controls the redelivery to the plasma 
membrane27 
 Ldlr miR-19b-3p Encodes a membrane receptor for low-
density lipoprotein (LDL) particles, which 
constitutes a clathrin-dependent endocytosis 
cargo protein28 
 F2r miR-19a-3p, miR-19b-3p Encodes G-protein coupled receptors 
(GPCR) phosphorylated by GPCR kinases 
(GRKs), allowing β-arrestins to bind to the 
GPCR27 
 Adrb1 miR-19b-3p Encodes the β1-adrenergic receptor, a G-
protein coupled receptor (GPCR)29 
 Dab2 miR-19a-3p, miR-19b-3p Encodes the protein Disabled-2 (Dab2), 
which is capable of direct interaction with 
LDL receptors30 
 Grk4 miR-19b-3p Encodes a GPCR kinase (GRK) that 
phosphorylates GPCR, allowing β-arrestins 
to bind to the GPCR27 
 Grk5 miR-19a-3p, miR-19b-3p As above27 
 Adrbk1 miR-19a-3p, miR-19b-3p As above31 
 Arrb1 miR-19b-3p Encodes β-arrestin that binds to the GPCR, 
preventing G-protein recruitment and 
thereby terminating signalling27 
 Rab11b miR-19b-3p Signalling molecule required for fusion 
back to the plasmatic membrane32 
 Eea1 miR-19a-3p, miR-19b-3p Encodes the early endosomal antigen 1 
(EEA1), recruited to membranes by 
phosphatidylinositol 3-phosphate and Rab5-
GTP, together facilitating early endosome 
fusion32 
 Usp8 miR-19a-3p, miR-19b-3p Encodes the UBPY protein, which can 
deubiquitinate cargos and direct them to 
different fates18 
 Stam miR-19a-3p, miR-19b-3p In early endosomes, STAM forms a ternary 
complex with HRS and EPS15 that 
interacts with EGFRs17 
 Stam2 miR-19a-3p, miR-19b-3p A regulator of receptor signalling and 
trafficking that interacts directly with Hrs33 
 Eea1 miR-19a-3p, miR-19b-3p Encodes an effector of the small GTPase 
Rab5 that controls early-endosome fusion 
dynamics17 
 Chmp4b miR-19a-3p, miR-19b-3p Encodes a member of the family of small 
coiled-coil proteins named CHMP 
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implicated in playing roles in multivesicular 
body sorting34 
 Chmp1a miR-19b-3p As above34 
 Chmp2a miR-19a-3p, miR-19b-3p As above34 
 Vps4b miR-19a-3p, miR-19b-3p Encodes a protein responsible for the 
disassembly of ESCRT-III35  
 Rab31 miR-19a-3p, miR-19b-3p Encodes Rab22, required for recycling back 
out of the plasmatic membrane32 
 Arf3 miR-19a-3p, miR-19b-3p Small GTPase required for the integrity of 
recycling endosomes and the recycling 
pathway36 
 Arf6 miR-19a-3p, miR-19b-3p Signalling molecule required for recycling32 
 Vps37a miR-19b-3p Encodes the protein Vps37, which together 
with Tsg101, Vps28 and Mvb12, forms the 
ESCRT-I complex37 
 Vps37b miR-19b-3p As above18 
 Cav1 miR-19b-3p Encodes caveolin-1, shown to be important 
for the formation of caveolae17 
 Src miR-19a-3p, miR-19b-3p Its activation leads to plasmatic membrane 
ruffling and corresponding 
macropinocytosis32 
 Agap1 miR-19b-3p Encodes an endosome-associated ARF-
GAP protein that affects the actin 
cytoskeleton38 
 Asap1 miR-19a-3p, miR-19b-3p Belongs to a family of multifunctional 
scaffold proteins that regulate membrane 
trafficking and actin remodelling39 
 Asap2 miR-19a-3p, miR-19b-3p Encodes an Arf-GAP that has been reported 
to bind proteins that function as part of the 
endocytic machinery40 
 Arfgap3 miR-19a-3p, miR-19b-3p A GTPase-activating protein that associates 
with the Golgi apparatus and regulates the 
vesicular trafficking pathway41 
 Arap2 miR-19b-3p Encodes an ArfGAP implicated in the 
regulation of actin and cell motility42 
 Arfgef1 miR-19a-3p, miR-19b-3p Encodes a protein responsible for the 
activation of Arf GTPases43 
 Arfgef2 miR-19a-3p, miR-19b-3p Encodes the brefeldin A-inhibited GEF2 
protein (BIG2), required for vesicle and 
membrane trafficking from the trans-Golgi 
network44 
 Psd3 miR-19a-3p, miR-19b-3p Encodes a guanine nucleotide exchange 
factor for the small GTPase ARF6, which 
regulates membrane trafficking and the 
actin cytoskeleton45 
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Abstract 
 
Cerebral malaria (CM) is a severe neurological complication that develops following 
Plasmodium infections in approximately one percent of cases. However, we still do not completely 
understand the pathogenesis of this syndrome. One of the barriers in our understanding is the 
challenge of examining tissue such as the brain, that has a complex architecture and presents both 
marked and subtle changes during CM. In this study, we have performed confocal microscopy of 
thick sections of brain tissue by combining the analysis of several previously described key players 
of the pathogenesis. We propose here a novel approach to observe and quantify aberrant 
morphological changes in the brain during CM. Our data shed light on the relative distribution of 
leucocyte, platelet, and parasitised red blood cell sequestration, combined with adhesion molecule 
expression and tissue hypoxia development in order to further elucidate the pathogenic mechanisms 
responsible for the development of CM. 
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Introduction 
 
Cerebral malaria is a severe complication of malaria infections caused predominantly by 
Plasmodium falciparum, leading to 1 million deaths annually (WHO, 2016). The fine 
pathophysiological mechanisms underlying the neurological syndrome of cerebral malaria (CM) have 
been examined extensively; however, the aetiology is still unclear. Therefore, examining the brain 
tissue to further elucidate pathological mechanisms is crucial for our continued understanding and 
improved ability to treat this severe syndrome. CM has been linked to many contributing factors, 
including increased parasitaemia, sequestration of red and white blood cells in the vasculature, and 
increased cytokine circulation, however none of these factors is a prerequisite of CM, nor are they 
unique to the neurological syndrome (Combes et al., 2006). Several hypotheses have been put forward 
regarding the specific pathogenic mechanisms by which the CM occurs, and it is now generally 
agreed that a combination of these is the closest understanding we have at the current time (Berendt 
et al., 1994; Clark and Rockett, 1994; Grau and de Kossodo, 1994; Nacer et al., 2014; Pai et al., 2014; 
Mohanty et al., 2017; Phillips et al., 2017; Wassmer and Grau, 2017). 
Our current understanding of CM pathogenesis encompasses the roles of circulating immune 
cells and molecules, and effects on the surrounding parenchymal tissue associated with the 
breakdown of the blood-brain barrier (Penet et al., 2005; Medana and Turner, 2006; Rénia et al., 
2012). Several parasite molecules, such as Plasmodium falciparum erythrocyte membrane protein 1 
(PfEMP1), have been shown to facilitate parasite invasion of red blood cells (RBC) and their adhesion 
to the endothelium (Schofield and Grau, 2005; Maier et al., 2009). Many circulating cells have been 
shown to contribute to CM pathogenesis in patients, and in the experimental mouse model, including 
RBC and parasitised RBC (pRBC), platelets, T cells, and monocytes – and demonstrate sequestration 
within the brain microvasculature. In fact, a key histological difference between CM patients and the 
experimental model is that, while pRBC, leucocytes and platelets are all observed sequestered in brain 
microvessels the ratio of cells accumulating is different – adult CM features pRBC accumulation, 
whereas the paediatric syndrome and the experimental model demonstrates sequestration of various 
white blood cell subtypes (Jerusalem et al., 1983; Polder et al., 1991; Porta et al., 1993; Belnoue et 
al., 2008; Amante et al., 2010; Hawkes et al., 2013). However, several studies have now demonstrated 
the similarities in histopathology observed in the paediatric CM syndrome and the experimental 
mouse model, validating its continued use in studying this syndrome (Hochman et al., 2015; 
Strangward et al., 2017). 
This intravascular sequestration of circulating cells is facilitated by and triggered by increased 
cytokines and adhesion markers, such as TNF, IFN-g, and ICAM-1 (Belnoue et al., 2003; Hunt and 
Grau, 2003; van der Heyde et al., 2006; Medana and Turner, 2007; Combes et al., 2010; Hochman et 
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al., 2015). Many of these cells, including platelets and parasitised or normal RBC, have been shown 
to bind to the endothelium and to each other, following activation of the endothelium, leading to 
blood vessel blockage, alterations at the level of the blood brain barrier, and subsequent 
haemorrhaging and death, if untreated (Adams et al., 2002). Blockage of the microvasculature has 
been suggested to be the mechanism by which hypoxia develops in affected areas of the brain and 
central nervous system in experimental CM (Penet et al., 2005; Hempel et al., 2011). 
Most neuropathological observations in humans are limited to post-mortem analyses of brain 
tissue (Newton and Krishna, 1998). Therefore, alternatives, such as animal models have been 
indispensable in further research into understanding the pathology of CM. The murine model of CM, 
using Plasmodium berghei ANKA (PbA) infection in susceptible mouse strains such as CBA or 
C57BL/6, has been useful to study CM pathology in real-time, and replicates many aspects of 
pathology observed in the human syndrome and discussed above (Hunt and Grau, 2003; Hunt et al., 
2010; Riley et al., 2010; Craig et al., 2012). In fact, specifically depleting certain cytokines or cells, 
including monocytes or T cells, during infection prevents CM, however this success is dependent on 
the timing of depletion and, to some degree, the mouse strain used (Chang et al., 2001; van der Heyde 
et al., 2005; Schumak et al., 2015). 
The brain tissue has a highly sophisticated architecture containing intricate vascular structures, 
cells deriving from the immune system, and multiple neuronal and glial cell types. The nature of this 
complex architecture presents basic challenges in the approach taken to study CM in depth, at the 
tissue scale. Fluorescence microscopy-based approaches have been used to study circulating and 
tissue-resident cells in the brain and other tissues for many years. However, recently, new and 
improved techniques of optical imaging, such as 2-photon microscopy, and clearing techniques, 
combined with the increased availability of transgenic parasites and reporter mice with fluorescently 
tagged cell types, have allowed tissue sections of increasing size to be examined, up to whole tissues 
or whole organisms, through ex vivo or intravital imaging (Becker et al., 2012; Ke et al., 2013; 
Kuwajima et al., 2013; Pai et al., 2014; Susaki et al., 2014; Susaki et al., 2015). As the technology 
continues to improve, so does the speed and resolution at which this imaging can take place. 
In this study, confocal microscopy and computational image analysis were used to 
simultaneously preserve and analyse the cellular organisation and spatial relationships between 
elements in the brain microvasculature during CM development. Specifically, we aimed to detect 
morphological changes during CM, and perform comprehensive analysis across thick sections of 
brain tissue to further elucidate the spatial relationship between these changes. We examine, for the 
first time, the relative distribution of leucocyte, platelet, and pRBC sequestration, colocalised with 
adhesion molecule expression and leading to the development of hypoxia in the surrounding 
parenchyma during CM.  
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Methods 
 
i. Mice 
7-10-week-old C57BL/6 mice were obtained from the Animal Resource Centre (Perth) and housed 
under pathogen-free conditions, as per approved protocols of the University of Sydney Animal Ethics 
Committee (protocol number 2015/832). For experimental comparisons, two biological groups of 
mice were used: non-infected, and CM, caused by infection with either Plasmodium berghei ANKA 
(PbA), or PbG (transgenic parasite, expressing GFP) (Lundie et al., 2008). As previously described, 
C57BL/6 mice are susceptible to PbA/PbG infection and succumb to CM during the neurological 
phase, between day 6 and day 14 post-infection (p.i.) (Lundie et al., 2008; El-Assaad et al., 2014). 
 
ii. Plasmodium inoculation 
All infections were initiated by intraperitoneal (i.p.) injection of 1 x 106 PbA or PbG-pRBC, as 
previously described (Grau et al., 1986; Lundie et al., 2008). PbG-infected mice were provided with 
pyrimethamine solution (section iii) instead of normal drinking water for the duration of the infection 
to select for transgenic parasites (Lundie et al., 2008). Parasitaemia was monitored by counting pRBC 
in Diff-Quick-stained thin blood smears (ProSciTech) by light microscopy on day four p.i. and every 
1-2 days after this, for the duration of the infection. Mice were assessed using a clinical evaluation 
score, and CM diagnosed if mice presented with ruffled fur, severe motor impairment or convulsions, 
representative of a score of 3 or 4 as described previously (Potter et al., 2006), and sacrificed at this 
time. 
 
iii. Pyrimethamine solution 
As previously described, pyrimethamine powder (5-4-chlorophenyl-6-ethyl 2,4-pyrimidinediamine) 
(Sigma Aldrich) was dissolved in DMSO (Sigma Aldrich) while stirring on a vortex, to a final 
concentration of 7 mg/mL, diluted 100 times in normal tap water, and finally adjusted to pH 3.5-5.0 
(with 1M HCl) (Janse et al., 2006). 
 
iii. Antibodies and reagents 
Fluorochrome-labelled antibodies detected against anti-CD3 (Abcam), CD11b (Ebioscience), 
CD41/GPIIbIIIa (Abcam), CD54/ICAM-1 (Santa Cruz) were used to identify cells and adhesion 
molecules. Fluorescent dyes included wheat germ agglutinin (WGA, ThermoFisher Scientific), and 
hypoxyprobe-1 (pimonidazole hydrochloride, reductively activated in hypoxic cells where the partial 
pressure pO2 is < 10mm Hg at 37°C, Hypoxyprobe Incorporated). Further details can be found in 
Table S5.1. 
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iv. Immunohistochemistry 
Hypoxyprobe-1 (60 mg/kg) was administered i.p. under anaesthesia one hour prior to sacrifice, and 
WGA-594 (100 µg/mL) was administered intravenously (i.v.) in mice 15 minutes prior to sacrifice. 
Mice were sacrificed and brain harvested, before being fixed overnight at 4°C in 4% 
paraformaldehyde (PFA, Sigma Aldrich) in phosphate buffered saline (PBS). The tissue was then 
washed and sectioned on a vibratome to a thickness of 100-200 µm. Sections in the range of 1000-
2000 µm down from the dorsal surface of the brain were used for this study. Sections were then 
permeabilised with 0.1% Triton X-100 (Amresco) and blocked with 1% bovine serum albumin (BSA, 
Sigma Aldrich) for 30 minutes at room temperature, and then stained. Primary antibodies were 
conjugated as per the manufacturer’s specifications to using Antibody Labelling kits specific for 
Alexa Fluor 488 and 647 (ThermoFisher Scientific). Sections were incubated on a shaker in 
conjugated antibodies and an anti-pimonidazole mouse IgG1 monoclonal antibody (HPI) for 24 hours 
at room temperature. Finally, a goat anti-mouse Alexa Fluor 405 secondary antibody was applied 
overnight at room temperature, to complete the hypoxyprobe staining, before tissue clearing. 
 
v. Tissue clearing 
Cubic reagent 1 was prepared as previously described, with 25% wt% urea and 25% wt% N,N,N’,N’-
tetrakis(2-hypoxypropyl)ethylenediamine (Sigma Aldrich), and 15% wt% Triton X-100 (Susaki et 
al., 2014). Sections were incubated in reagent 1 for 30 minutes at room temperature before imaging. 
 
v. Microscopy 
Spectral imaging was performed with samples immersed in cubic reagent 1, on a Zeiss LSM 710 
META system using emissions from four lasers (405 nm, 488 nm, 568 nm, and 633 nm) and 20x 
W/0.8N.A. apochromat or 63x oil objectives. This system allows a 32-point emission spectrum to be 
recorded at each point in the image. Z-series image stacks were collected with a 1024 x 1024-pixel 
image size, and as 1.7 µm optical sections as determined by the depth of focus of the objective. 
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vi. Data analysis 
Post-acquisition image analysis was carried out using Volocity (Perkin-Elmer) and Fiji on the original 
data files. Fluorescence intensity-based approaches were used to quantify the overall signal intensity 
of each channel using the mean signal from the whole section measured per section, per mouse, with 
an n of 7-16 samples per group. This was done by creating a region of interest (ROI) surrounding the 
specific staining we were interested in measuring, by using a fluorescence threshold above the 
background staining level. We then used this ROI to determine the area of staining within the original 
images. Due to the combination of antibodies needed for hypoxyprobe staining – that is, the 
secondary antibody is a mouse anti-pimonidazole antibody, thus requiring an anti-mouse tertiary 
antibody for fluorophore staining – some non-specific binding was observed in this channel, despite 
the inclusion of blocking steps. This background staining was specifically observed in the vessels, 
where the dye was originally injected. Therefore, the strongest signal (appearing within the vessels 
within this channel only), was removed for comparisons, by subtracting the vessel channel from this 
channel. 
 
vii. Statistical analysis 
Comparison of two groups was conducted using a Mann-Whitney test (not normally distributed), and 
three groups were compared using a non-parametric Kruskal-Wallis test with Dunn’s post hoc test. 
Depending on the group size, statistical calculations were performed using a non-parametric Kruskal-
Wallis test, and Dunn’s post hoc test to correct for multiple comparisons, or a Mann-Whitney test 
(not normally distributed). The result of the statistical analyses is signified as * = 0.05-0.01,                  
** = 0.01-0.0001, *** = < 0.0001. All results were analysed using GraphPad Prism version 5.02 
(GraphPad Software). 
  
CHAPTER 5 | 3D microscopy of brain during CM 
 176 
Results 
 
As more and more research has focussed on the immunohistochemical analysis of increasingly 
larger tissue sections up to whole-mounts, various methods have arisen to alleviate the issues facing 
this type of analysis. The barriers present in this type of research have been explored in great detail, 
including how to optimise fixation methods, antibody penetration, tissue permeabilisation and 
transparency, sample preparation and mounting, and imaging for tissues of this size. We tested several 
methods and list below some of the steps we took to optimise our protocol for imaging large sections 
of brain tissue, including steps that have previously been shown to be successful but did not enhance 
our approach (Figure 5.1). In developing this protocol, we considered two main criteria: firstly, 
efficiency of staining and transparency of tissue with preservation of fluorescence for microscopy-
based analysis approaches; and secondly, reproducibility for comparative analysis of multiple 
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Protocol design. Graphical summary of the alternatives tested in each step of the protocol 
designed for the present study. 
 
Sample preparation: fixation and post-fixation options 
Protocols for whole tissue or whole-mount imaging often use perfusion fixation to preserve 
the tissue as a whole in one go – that is, the mouse is perfused i.v. with a fixative prior to removing 
the tissue of interest. The alternative is a much slower perfusion that occurs with immersion fixation, 
where the tissue is instead submerged in the fixative. However, it has also been shown that perfusion 
Step 1: fixation 
Immersion or perfusion 
                                       ☑                ✖ 
 
Step 2: post-fixation 
Second fixation   Dehydration   Permeabilisation   Blocking 
              ✖                     ✖                      ☑                    ☑ 
 
Step 3: antibody staining 
Injection or incubation 
                                      ☑                ☑ 
             Vessel label / All other labels 
                      (24 hours at room  
                   temperature) 
 
Step 4: tissue clearing 
ClearT2     Clarity     SeeDB     Cubic 
                    ✖         ✖           ✖            ☑ 
                     (reagent 1 only) 
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fixation is not necessary to preserve tissue morphology and, in fact, may have a negative impact on 
probe penetrance in later staining (Zukor et al., 2010). Indeed, our results demonstrated that perfusion 
fixation, despite the slow rate of fixative applied, negatively affected our staining, and resulted in a 
decreased signal in injected dyes, compared with immersion fixation. Conversely, we found 
immersion fixation to adequately preserve the tissue and elements of the pathology for our analysis. 
Several additional measures have been suggested to modify the sample preparation process, 
thereby better preserving the tissue structure and increasing the chances of complete antibody 
penetration. As criticism has been levelled at the method of immersion fixation, and the potential for 
tissue to be incompletely, or inconsistently fixed, one method assessed was a second fixation step, 
following sectioning on the vibratome. Sectioned samples were immersed in 1% PFA for 1 hour at 
room temperature, however this did not assist the process and in fact, negatively affected tissue size. 
Several measures were assessed at the post-fixation stage, including a dehydration step, by immersing 
the samples in ice-cold ethanol for 30 minutes; permeabilisation using triton; and blocking to reduce 
background staining, using BSA. The dehydration provided no additional benefit in our protocol, 
however, the permeabilisation and blocking increased the penetration and quality of antibody 
labelling and were incorporated into our protocol. 
 
Antibody penetration optimisation 
As antibody penetration was a concern in thick tissue samples, the typical antibody staining 
protocols, where samples are incubated for a few hours or less, did not achieve the required 
penetration, and simply extending the antibody staining time, without any other methodological 
changes had limited success as, over time, the likelihood of contamination of the sample increased. 
To increase antibody penetration in sections of 100-200 µm thickness, we assessed increasing the 
time and temperature at which the samples were stained, testing staining times of 1-48 hours, and 
temperatures of 4-37°C. It was found that 24 hours at room temperature per antibody, on a shaker, 
was the optimal staining time and temperature for samples of this thickness, such that the tissue was 
sufficiently labelled without too much background fluorescence. We also assessed the i.v. injection 
of antibodies prior to sacrificing mice, in labelling the tissue, and circumventing the issue of antibody 
penetration completely. An increased concentration of antibody is required for i.v. injection compared 
with that used to incubate fixed tissue sections (~10x), as previously shown (Sim et al., 2015). 
Injection of the antibody provided excellent staining, despite the much larger volume required for 
this process, and therefore, we decided to inject the WGA, as this stain was critical in assessing the 
spatial relationship of all other elements, and was used as a framework for all other analysis. 
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Assessment of tissue clearing methods 
Thick tissue sections are intrinsically difficult to image, due to the obscuring effects of light 
scatter deeper within the tissue in question. Therefore, we assessed a number of different clearing 
methods, in order to turn the brain tissue transparent and increase the depth at which we could 
examine the tissue microscopically. We assessed four methods of tissue clearing, namely: SeeDB (Ke 
et al., 2013), ClearT2 (Kuwajima et al., 2013), Clarity (Chung and Deisseroth, 2013) and Cubic 
(Susaki et al., 2014). 
 
Figure 5.2: Confocal imaging of WGA488-labelled mouse brain. 200 µm brain sections were stained with 
WGA488 and examined on a confocal microscope, with the YZ plane shown here. A Uncleared tissue was 
compared with tissue cleared using either the B ClearT2 or C SeeDB method. 
 
Firstly, the clearT2 method – a mixture of increasing concentrations of formamide and 
polyethylene glycol – did not satisfactorily clear the whole tissue. Compared to uncleared brain tissue, 
which we were able to image to a depth of approximately 70 µm, clearT2 did not increase the depth 
at which were able to image the brain (Figure 5.2A and B). Additionally, we wanted to assess clearing 
methods involving less toxic compounds. 
Secondly, the seeDB (See Deep Brain) protocol – a water-based, increasing fructose gradient 
optical clearing protocol – only provided partial brain clearing, and the size of the brain also increased 
(Figure 5.3). However, despite only achieving partial clearing, the depth of imaging was good and 
we were able to image to a depth of approximately 100 µm (Figure 5.2C). Nevertheless, we continued 
testing other clearing methods, because this method required the solutions of increasing glucose 
concentration to be changed every 8-24 hours for a period of several days, and the solutions 
themselves were incredibly viscous and challenging to use. 
The third protocol we assessed was the clarity method, which utilised a hydrogel to remove 
lipids from the tissue, but leave its structure intact. However, as with the SeeDB protocol, this 
protocol required several days of clearing, and the solutions were difficult to manage, and we did not 
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succeed in clearing the brain tissue with this method. We did not assess other commonly used clearing 
methods, such as Scale (Hama et al., 2011) and BABB (Dodt et al., 2007) due to previously published 
criticisms against the tissue swelling and incomplete clearing that occurred in both of these protocols 
(Ke et al., 2013). 3Disco (Ertürk et al., 2012), and DBE (Becker et al., 2012) have been shown to be 
suitable clearing methods, efficiently preserving tissue size; however some concerns have been raised 
regarding the quenching of fluorescent proteins, and the protocols themselves required several days 
(1-2 for DBE, and 2-5 for 3Disco), in comparison to the modified cubic protocol we implemented 
(Susaki et al., 2015; Liu et al., 2016). 
 
 
Figure 5.3: Optical clearing using SeeDB or Cubic. a) 200 µm brain sections were cleared using increasing 
concentrations of fructose as per the SeeDB clearing protocol. Note that, over time, the brain swelled a little 
in size, and was only partially cleared. b) 200 µm brain sections were cleared using the cubic clearing protocol. 
Complete tissue clearing can be observed within one minute of incubation at room temperature, with no 
structural change to the brain tissue. 
 
The cubic protocol prescribed by Susaki et al. is based on hydrophilic reagents that effectively 
clear the tissue through lipid removal, as well as preserving fluorescence and tissue size (Susaki et 
al., 2014; Tainaka et al., 2014; Susaki et al., 2015). Several clearing methods are based upon the 
premise of lipid removal, as lipids are thought to be mainly responsible for light scattering in tissue 
samples. The cubic reagents are derived from Scale-related compounds, as this protocol also 
functions to remove lipids, and this protocol involves ScaleCUBIC-1 (reagent 1) and ScaleCUBIC-2 
(reagent 2). According to the protocol, reagent 1 removes lipids from the tissue, turning it transparent, 
while reagent 2 matches the refractive indices of the sample and the reagent, further reducing light 
scattering. Using reagent 1, we effectively turned the 100-200 µm thick brain sections transparent, in 
a matter of seconds, with no effect on the size of the tissue (Figure 5.3). Surprisingly, in contrasting 
to the findings of Susaki et al., we found that reagent 2 did not enhance to the transparency of the 
tissue – in fact, the tissue was returned it to its original opaque state, similarly to incubation in PBS. 
Therefore, we continued using cubic reagent 1 for our subsequent analyses. Samples were not 
mounted on slides due to their thickness, but instead imaged in a dish of cubic reagent 1 with a 
coverslip and a drop of PBS on top, using an upright confocal microscope. 
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Application of established protocol to investigate cerebral malaria pathogenesis 
 Using the established protocol detailed above, we pursued our original aim of imaging the 
brain three-dimensionally in order to learn more about the pathogenesis of CM, by examining the 
accumulation and distribution of monocytes, T cells, platelets and pRBC, combined with ICAM-1 
and hypoxyprobe expression in the brain of infected mice at the time of CM, compared with healthy 
mice. All images shown here are at a magnification of 20x and examine axial brain slices to the depth 
of 2500 – 3500 µm in the brain. 
Firstly, we examined platelets, ICAM-1 expression and tissue hypoxia in relation to the brain 
microvessels. In healthy, non-infected control mice, there was no specific platelet or ICAM-1 
expression, and faint, diffuse hypoxyprobe staining (Figure 5.4C-E). 
 
Figure 5.4: Maximum intensity projection of a four-channel 3D image collected from a 100 µm-thick 
section of non-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood vessels, c) 
anti-CD41 (green, Alexa Fluor 488) labelling platelets, d) anti-CD54 (cyan, Alexa Fluor 647) labelling ICAM-
1 staining, and e) hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 40 µm. 
 
When we compared this with PbA- (Figures 5.5-8) and PbG-infected mice (Figures 5.9-10), 
we observed focal areas of ICAM-1 upregulation and platelet accumulation in post-capillary venules 
(Figure 5.5, circled). WGA demonstrated a diffuse blurred staining pattern around the vessels, 
indicating its leakage out of the vessel into the surrounding parenchyma (Figures 5.5 and 5.7B, 
arrowhead). This is also clearly observed in 3D reconstructions of the same areas shown in Figure 
5.5 and 5.7A (Figures 5.6 and 5.8, respectively). Finally, we observed focal hypoxyprobe staining 
surrounding vessels and co-localised platelet and hypoxyprobe expression (circled), with ICAM-1 
upregulation on some cells surrounding vessels (Figure 5.7B, arrowhead). 
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Figure 5.5: Maximum intensity projection of a three-channel 3D image collected from a 100 µm-thick 
section of PbA-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) anti-CD41 (green, Alexa Fluor 488) labelling platelets, and 
c) anti-CD54 (cyan, Alexa Fluor 647) labelling ICAM-1 staining, with WGA labelling blood vessels in red 
(Alexa Fluor 594). Scale bar = 40 µm. 
 
 
Figure 5.6: Three-dimensional reconstruction of PbA-infected mouse brain, triple-stained as per Figure 
5.5. 
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Figure 5.7A and B: Two maximum intensity projections of four-channel 3D images collected from two 
100 µm-thick sections of PbA-infected mouse brain. a) Max projection of merged channels, with XZ and 
YZ views displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood 
vessels, c) anti-CD41 (green, Alexa Fluor 488) labelling platelets, d) anti-CD54 (cyan, Alexa Fluor 647) 
labelling ICAM-1 staining, and e) hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 
40 µm. 
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Figure 5.8: Three-dimensional reconstruction of PbA-infected mouse brain, labelled as per Figure 5.7A. 
 
Likewise, in PbG-infected mice where pRBC, identified by the GFP-tagged parasite, were 
examined instead of platelets, we observed vascular damage in the form of vessel leakage and micro-
haemorrhages (Figure 5.9, white arrowhead). At several sites of vessel leakage, extravasated pRBC 
could be observed, which is most uncommon during this vascular pathology, as usual normal RBC 
extravasate while pRBC are sequestered in the brain microvessels (Figure 5.9, yellow arrowheads). 
As in PbA-infected mice, ICAM-1 was found to be upregulated and localised to cells accumulating 
within post-capillary venules, particularly at sites of pRBC sequestration (Figures 5.9 and 5.10, 
circled). Additionally, we observed large numbers of sequestered pRBC with hypoxyprobe 
expression limited to the tissue surrounding those areas (Figure 5.10). 
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Figure 5.9: Maximum intensity projection of a three-channel 3D image collected from a 100 µm-thick 
section of PbG-infected mouse brain. a) Max projection of merged channels. Separate channels were 
obtained for b) GFP-tagged parasites (green), and c) anti-CD54 (cyan, Alexa Fluor 647) labelling ICAM-1 
staining, with WGA labelling blood vessels in red (Alexa Fluor 594). Scale bar = 40 µm. 
 
 
Figure 5.10: Maximum intensity projection of a four-channel 3D image collected from a 100 µm-thick 
section of PbG-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood vessels, c) 
GFP-tagged parasites (green), d) anti-CD54 (cyan, Alexa Fluor 647) labelling ICAM-1 staining, and e) 
hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 40 µm. 
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We also searched for the presence of CD3+ T cells in the brain of infected mice. We found 
evidence of T cell accumulation in the microvasculature in less than one in 100 vessels examined 
(Figure 5.11). It should be noted that, although relatively few T cells could be located in the tissue of 
infected mice, those that were identified also accumulated at the site of pRBC sequestration within 
post-capillary venules (Figure 5.11, circled). 
 
 
Figure 5.11: Maximum intensity projection of a three-channel 3D image collected from a 100 µm-thick 
section of PbG-infected mouse brain. a) Max projection of merged channels. Separate channels were 
obtained for b) GFP-tagged parasites (green), and c) anti-CD3 (cyan, Alexa Fluor 647) labelling CD3+ T cells, 
with WGA labelling blood vessels in red (Alexa Fluor 594). Scale bar = 40 µm. 
 
We then examined CD11b+ monocyte accumulation in PbA- and PbG-infected mice 
compared with non-infected controls, in relation to platelet or pRBC accumulation, and hypoxyprobe 
expression. As before, we found monocytes and platelets distributed evenly throughout the tissue of 
control mice, i.e. no focal accumulation, and faint hypoxyprobe expression (Figure 5.12). 
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Figure 5.12: Maximum intensity projection of a four-channel 3D image collected from a 100 µm-thick 
section of non-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood vessels, c) 
anti-CD41 (green, Alexa Fluor 488) labelling platelets, d) anti-CD11b (cyan, Alexa Fluor 647) labelling 
monocytes, and e) hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 40 µm. 
 
We detected co-localised platelet and monocyte accumulation within the cerebral 
microvasculature of PbA-infected mice, typically localised to branch points (Figures 5.13 and 5.14, 
circled). Branch points were also commonly sites where vessel leakage was observed (Figures 5.13 
and 5.14, white arrowheads). This was also clearly observed in 3D reconstructions of the same areas 
shown in Figure 5.14 and 5.15 (Figures 5.16A and B, respectively). Furthermore, extravasated 
platelets could be observed (Figure 5.13, yellow arrowheads). Similar to the ICAM-1 upregulation 
and platelet accumulation previously described, numerous monocytes were observed accumulating 
in post-capillary venules, with hypoxyprobe staining in adjacent areas, indicating tissue hypoxia 
development. Monocytes were found to be co-localised with pRBC accumulation in PbG-infected 
mice – similar to their co-localised accumulation with platelets in PbA-infected mice – in both cases 
leading to hypoxia in the tissue surrounding the blocked vessels (Figure 5.15). 
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Figure 5.13: Maximum intensity projection of a three-channel 3D image collected from a 100 µm-thick 
section of PbA-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) anti-CD41 (green, Alexa Fluor 488) labelling platelets, and 
c) anti-CD11b (cyan, Alexa Fluor 647) labelling monocytes, with WGA labelling blood vessels in red (Alexa 
Fluor 594). Scale bar = 40 µm. 
 
  
Figure 5.14: Maximum intensity projection of a four-channel 3D image collected from a 100 µm-thick 
section of PbA-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood vessels, c) 
anti-CD41 (green, Alexa Fluor 488) labelling platelets, d) anti-CD11b (cyan, Alexa Fluor 647) labelling 
monocytes, and e) hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 40 µm. 
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Figure 5.15: Maximum intensity projection of a four-channel 3D image collected from a 100 µm-thick 
section of PbG-infected mouse brain. a) Max projection of merged channels, with XZ and YZ views 
displayed. Separate channels were obtained for b) WGA (red, Alexa Fluor 594) labelling blood vessels, c) 
GFP-tagged parasites (green), d) anti-CD11b (cyan, Alexa Fluor 647) labelling monocytes, and e) 
hypoxyprobe (blue, Alexa Fluor 405), labelling hypoxic areas. Scale bar = 40 µm. 
 
 A                        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: A) Three-dimensional reconstruction of a PbA-infected mouse brain, labelled as per Figure 
5.14. B) Three-dimensional reconstruction of a PbG-infected mouse brain, labelled as per Figure 5.15. 
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Interestingly, when the mean signal intensity of the channels relating to the various 
pathological elements was analysed (Figure 5.17), hypoxia was significantly increased in both PbA- 
(P = 0.0034) and PbG-infected mice (P = 0.0186), though PbG-infected mice showed broader 
distribution in the extent of hypoxia, potentially due to the wider ranges of parasitaemia in these mice 
(data not shown). Measuring the mean signal intensity of platelet staining in non-infected and PbA-
infected mice, we found a significant increase in platelets in PbA-infected vs. NI mice (P < 0.0001). 
This too was seen in monocyte expression, where a small but significant increase was observed in 
monocytes in PbA- (P = 0.0312) and PbG-infected mice (P = 0.0140). By contrast, ICAM-1 showed 
a dramatic increase in expression in both PbA- (P = 0.0003) and PbG-infected mice (P = 0.0422). 
 
 
Figure 5.17: Comparison of signal intensity between and within biological groups. The mean signal 
intensity of the labelling for each of the pathological elements tested, was measured and compared between 
biological groups in order to gain more information about the changes in these elements in response to 
Plasmodium infection. 
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Discussion 
 
In recent years, the role of leucocytes, including CD4+ and CD8+ T cells, monocytes, and 
macrophages in driving the onset of neurological signs in experimental CM has been explored in 
great detail (Belnoue et al., 2002; Belnoue et al., 2003; Pai et al., 2012; Cabrales et al., 2013; Pai et 
al., 2014; Borges da Silva et al., 2015; Shaw et al., 2015). However, the exact intricacies of cell-cell 
interactions, as well as the contribution of other elements of pathology in leading to the neurological 
syndrome are still not fully established. We therefore undertook a comprehensive spatial analysis of 
the relative distribution and extent of accumulation of platelets, monocytes, pRBC, T cells, and 
ICAM-1 positive cells, and hypoxic regions in the brain of Plasmodium-infected mice. 
Our studies show that significant numbers of pRBC, platelets, monocytes, but low numbers 
of T cells were observed arrested in the cerebral microvasculature of mice during experimental CM, 
in line with previous findings (Belnoue et al., 2002; Hunt and Grau, 2003; Amante et al., 2010; Pai 
et al., 2014; Strangward et al., 2017). This is typical of the pathology observed during CM, where the 
crucial role but relative paucity of T cells compared with other leucocytes such as monocytes, has 
been reported (Renia et al., 2006; Shaw et al., 2015). Platelets too have been reported to accumulate 
in the cerebral microvasculature in patients (Grau et al., 2003) and in experimental CM (Grau et al., 
1993; van der Heyde et al., 2005). Finally, pRBC sequestration has been identified in both human 
and mouse CM, despite differences in presentation and distinct mechanisms of accumulation (Hearn 
et al., 2000; Dende et al., 2015; Strangward et al., 2017). 
While T cells make up 50% of peripheral blood mononuclear cells in normal mice, compared 
with monocytes representing 10% of this population, this ratio changes following Plasmodium 
infection. Here, we show that monocytes were the most numerous white blood cells sequestered in 
the vasculature of PbA and PbG-infected mice, corroborating results found in the experimental mouse 
model of CM (Grau et al., 1991; Strangward et al., 2017) and paediatric CM as well (Pongponratn et 
al., 1991; Porta et al., 1993; Hochman et al., 2015). Additionally, areas of hypoxia were most often 
seen surrounding these areas of vessel blockage or haemorrhaging, in some cases. More specifically, 
confocal microscopy of thick brain sections revealed that micro-haemorrhages commonly occurred 
at branch points of microvessels. This is most likely due to the slow flow rate at these points, leading 
to increased likelihood of any cell accumulation occurring at that site. The resulting increased 
pressure and vascular resistance leads to damage to the blood brain barrier also at those sites (Cabrales 
et al., 2013). Furthermore, this localised accumulation could cause a reduced flow rate in those areas 
(Penet et al., 2005; Dondorp et al., 2008; Beare et al., 2009; Cabrales et al., 2010), and this reduced 
flow rate could, in turn, promote further cell accumulation in those areas. Although a consensus has 
not been reached concerning the occurrence of disturbances in cerebral blood flow during CM, or 
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whether these disturbances are restricted to blood vessels with smaller diameter (Clavier et al., 1999; 
Nacer et al., 2012), nevertheless, the majority of those studies did discover a reduced flow rate. 
Primary blood flow disturbances lead to brain oedema development (Murr et al., 1993; Jha, 
2003), which can also trigger an increase in intracranial pressure and a reduction in cerebral blood 
flow. There are two types of cerebral oedema: firstly, vasogenic oedema refers to cerebral oedema in 
which the BBB is compromised, allowing an influx of fluid into the brain, and is the most common 
type of oedema (Hemphill, 2001). In contrast, cytotoxic oedema does not involve endothelial 
dysfunction or changes in vascular permeability and, instead, is the result of extracellular water 
entering cells, causing them to swell (Hemphill, 2001). Both these types of oedema occur 
concurrently in CM, together leading to reduced flow rate (Newton and Warrell, 1998; Pongponratn 
et al., 2003; Jambou et al., 2010). Furthermore, the combination of increased intracranial pressure, 
due to oedema and leading to reduced cerebral blood flow, and haemorrhaging has been shown to be 
linked with coma especially in paediatric patients with CM (Newton et al., 1998; Pongponratn et al., 
2003). 
In our study, an increase in adhesive properties in the vessels of infected compared with 
healthy mice (as demonstrated by the significant upregulation of ICAM-1) lead to the enhanced 
accumulation and sequestration of circulating cells, including platelets and monocytes particularly 
(Grau et al., 1991; Rudin et al., 1997; Nacer et al., 2014). The co-localised endothelial ICAM-1 
overexpression and pRBC or platelet sequestration indicates an increase in the adhesive properties of 
the cells themselves, increasing the numbers of cells adhering not only to the vessel walls, but also to 
each other, to increase the obstruction of vessels (Rowe et al., 2009; Shikani et al., 2012; Strangward 
et al., 2017). ICAM-1 upregulation was also observed on cells surrounding vessels: these may be 
pericytes or perivascular macrophages, both of which have been identified previously in CM (Polder 
et al., 1992; Brown et al., 1999). Monocyte and T cell accumulation was also shown to occur in 
regions of platelet or pRBC accumulation. This is consistent with previous findings, highlighting the 
role of T cells and other leucocytes in promoting further leucocyte sequestration as well as pRBC 
accumulation (Amante et al., 2010; Shaw et al., 2015; Ioannidis et al., 2016). Our work further 
demonstrated focal areas of hypoxia surrounding these plugged vessels. 
We observed an increase in accumulation and sequestration of circulating cells, leading to 
partial or complete vessel blockage and, subsequently, increased cranial pressure and vascular 
resistance (Mishra and Newton, 2009; Cabrales et al., 2013). This cascade of events clearly 
contributed to the number of haemorrhages observed in the brain of infected mice. Indeed, the damage 
to circulation, due to micro-haemorrhages and vessel blockage, could clearly be seen affecting the 
surrounding tissue, in the form of an increased amount of hypoxia detected (Medana et al., 2001; 
Hackett et al., 2015). Additionally, these sites of haemorrhaging enabled extravasation of pRBC to 
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occur – a phenomenon rarely observed during this vascular pathology. Indeed, in CM most micro-
haemorrhages consist of the extravasation of normal RBC, while pRBC remain sequestered 
intravascularly (Dorovini-Zis et al., 2011; Nacer et al., 2012). Furthermore, the brain tissue was 
increasingly hypoxic surrounding these sites of pRBC accumulation and, consistent with previous 
findings from our lab, are also likely to be the outcome of cerebral sequestration (Hempel et al., 
2011). In contrast with these findings, however, we found that no particular area of the brain was 
affected more than others by the development of hypoxia – instead, this development was dependent 
on manifestations of cerebral complications in the microvasculature alone, diffuse throughout the 
tissue. 
 Altogether, our observations were consistent with a model in which damage to the blood-
brain barrier and vascular leakage are caused by accumulation of adherent monocytes, platelets, and 
parasitised RBC, leading to widespread hypoxia in the surrounding tissue, and this is ultimately 
responsible for disease and death during experimental CM. Furthermore, our findings in experimental 
CM were consistent with the similarities in histopathology identified by previous studies in this model 
and in patients, further validating the use of the mouse model as a pre-clinical model to study and 
increase our understanding of CM pathogenesis (Strangward et al., 2017).  
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Appendix 
 
Supplementary table 5.1: Detection of cell-, adhesion molecule-, and hypoxia-specific markers 
Name of antibody 
(clone) 
Conjugate/ 
Secondary 
Supplier Initial 
concentration 
Working 
concentration 
Diluent 
CD3 Alexa647 Abcam 0.2 mg/mL 10 µg/mL 1% BSA 
CD11b (M1/70) Alexa647 Ebioscience 1 mg/mL 10 µg/mL 1% BSA 
CD41 (MWReg30) Alexa488 Abcam 1 mg/mL 10 µg/mL 1% BSA 
CD54 (M-19) Alexa647 Santa Cruz 200 µg/mL 10 µg/mL 1% BSA 
Hypoxyprobe-1 
(pimonidazole 
hydrochloride) 
Mouse IgG1  
(a-pimonidazole) 
Alexa405 
(Rabbit a- 
mouse) 
Hypoxyprobe 
Incorporated 
(HPI) 
100 mg 
 
 
60 µg/mL 
60 mg/kg 
 
 
0.6 µg/mL 
PBS 
 
 
1% BSA 
Wheat Germ 
Agglutinin (WGA) Alexa594 
ThermoFisher 
Scientific 1 mg/mL 100 µg/mL PBS 
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Abstract 
 
Current treatment of severe malaria and the syndrome of cerebral malaria (CM) is directed primarily 
at the parasite and has low efficacy in advanced infection, as occlusion of the brain microvasculature 
by accumulating host blood cells produces increasing neurological damage. In a preclinical mouse 
model of CM, we identified Ly6Chi monocyte-derived Ly6Clo monocytes as the main pathological 
population and successfully targeted these cells with immune-modifying particles (IMP), preventing 
CM in 50% of Plasmodium berghei ANKA-infected mice in early treatment from D3 post infection. 
Two doses of a novel combination of IMP and anti-malarial artesunate treatment administered upon 
appearance of neurological signs of CM resulted in 88% survival. Combination treatment effectively 
addressed three major pathological hallmarks, namely parasitaemia, circulating microvesicle 
numbers and the accumulation of Ly6Clo monocytes in the brain microvasculature, as well as 
resulting in robust immunity to re-infection, suggesting a viable alternative for current CM 
treatments.  
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Introduction 
 
Severe malaria is caused by the mosquito-borne parasite, Plasmodium falciparum. The most 
recent WHO estimates indicate some 212 million cases of malaria worldwide in 2015, with an 
estimated 429,000 individuals globally dying from severe malaria, principally in Africa and Asia 
(WHO, 2016). Severe malaria consists of several lethal complications, including grave metabolic 
abnormalities, acute respiratory distress syndrome and cerebral malaria (CM). CM is associated with 
cerebral blood vessel occlusion by localised collections of adherent, parasitised red blood cells 
(pRBC), platelets, inflammatory monocytes, and T cells; resulting in focal areas of brain ischaemia, 
and progressing to blood-brain barrier breakdown and vascular leakage (Pongponratn et al., 1991; 
Porta et al., 1993; Pongponratn et al., 2003; Idro et al., 2005; Hochman et al., 2015; Wassmer and 
Grau, 2017). In addition, these accumulating cells release increased numbers of submicron 
‘microvesicles’ (MV), which are associated with inflammation, apoptosis and neurological 
complications in both patients and the preclinical model mouse of CM (Combes et al., 2005; Pankoui 
Mfonkeu et al., 2010). Patients with CM present with delirium, seizures, and coma. Similar vascular 
involvement in the lungs can also lead to malaria-associated acute respiratory distress syndrome. Both 
syndromes are, in most cases, lethal without treatment. 
Current treatments almost exclusively target the parasite. The WHO recommended treatment 
for severe malaria is parenteral artesunate for 24 hours, followed by two days of artemisinin-based 
combination therapy (Sahu et al., 2015; WHO, 2015). However, overall mortality remains at 10-20% 
and this is projected to increase with the emergence and spread of malarial parasites carrying 
artemisinin resistance genes (Lu et al., 2017). Furthermore, current treatments do not address the 
immune-associated cerebral blood vessel occlusion which is a major cause of neurological damage 
at the time of disease presentation. 
A preclinical mouse model of CM, reproducing more than 25 clinical, biochemical, 
pathophysiological, histopathological and immunological features of human disease (Hunt and Grau, 
2003; Hunt et al., 2010; Riley et al., 2010; Craig et al., 2012) has been used to assess diverse 
intervention strategies, notably those aiming at a down-modulation of the immunopathological 
response (Schofield and Grau, 2005; Achtman et al., 2012). Monocytes represent a major source of 
cytokines and chemokines in CM pathogenesis (Stanisic et al., 2014) and intravascularly sequestered 
monocytes have been identified in both human (Pongponratn et al., 1991; Porta et al., 1993; Grau et 
al., 2003; Hochman et al., 2015) and mouse CM (Grau et al., 1987). The pathological involvement of 
these cells is emphasised by the abrogation of the syndrome in Plasmodium berghei ANKA (PbA)-
infected mice after clodronate liposome-mediated depletion or CCR2 antibody treatment (Pai et al., 
2014; Schumak et al., 2015). However, these treatments are only effective at the time of infection or 
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earlier, and neither solely targets inflammatory monocytes, while both deplete potentially anti-
parasitic and/or other immunomodulatory cells (Schmidt-Weber et al., 1996; Boros et al., 2010; 
Shantsila et al., 2011). We have previously demonstrated that immune-modifying particles (IMP) 
selectively modulate circulating inflammatory Ly6Chi monocytes in a variety of diseases without 
obtunding a robust immune response (Getts et al., 2014). Monocytes phagocytosing IMP in the 
bloodstream are sequestered in the spleen and thus prevented from migrating to inflammatory foci. 
IMP treatment was more effective than anti-CCR2 antibody (Getts et al., 2008) or clodronate 
treatment (Getts et al., 2008) van Vreden, unpublished data) in a murine model of WNV encephalitis, 
in which the accumulation of Ly6Chi monocytes in the brain parenchyma is uniformly lethal. Here, 
we further confirm the role of monocytes in the pathogenesis of CM. We report the efficacy of IMP 
treatment both in early infection and at the clinical onset of neurological signs in a lethal preclinical 
murine CM model. Critically, the novel combination of IMP treatment with artesunate, resulted in 
88% survival, while artesunate alone rescued only 56% of animals. Moreover, this treatment approach 
produced robust immunity against re-challenge in this model. 
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Materials and methods 
 
i. Mice 
7-12-week-old CBA/J mice were obtained from the Animal Resource Centre (Perth) and kept under 
specific pathogen-free conditions with ad libitum access to food and water. Permission for all 
experiments was obtained from the University of Sydney Animal Ethics Committee (protocol 
#2015/832). 
 
ii. Plasmodium infection 
Cerebral malaria (CM) was induced by intraperitoneal injection of 1 x 106 Plasmodium berghei-
ANKA (PbA)-pRBC, as previously described (Grau et al., 1986). Mice were assessed using a 
previously described clinical evaluation score (Potter et al., 2006b) and diagnosed with CM based on 
presentation with disease signs including ruffled fur, severe motor impairment or convulsions 
(clinical score 3-4). Parasitaemia was monitored by counting erythrocytes in Diff-Quick-stained thin 
blood smears (ProSciTech) by light microscopy on D4 post infection (p.i.) and every 1-2 days after 
this, for the duration of the infection. 
 
iii. Intravenous delivery of immune-modulatory particles 
500 nm carboxylated immune-modulatory particles (IMP) consisting of polylactic-co-glycolic acid) 
(PLGA) were obtained from Polysciences. IMP were diluted in sterile PBS to a concentration of 4.26 
x 109 particles/200 µL and administered intravenously. 
 
iv. Administration of anti-malarial treatments 
Quinine hydrochloride dihydrate, chloroquine disphosphate and artesunate (from Artemisia annua) 
were obtained from Sigma Aldrich. All anti-malaria drugs were diluted in sterile PBS to a 
concentration of 50 mg/kg in a 200 µL volume and administered intraperitoneally. 
 
v. Longitudinal studies 
Longitudinal studies were performed to assess survival in treated compared to non-treated mice. Mice 
treated from an early time point received IMP daily from D3-10 p.i., and three doses of quinine 
treatment from D14 p.i. Alternatively mice were treated at first signs of neurological CM signs and 
received IMP, artesunate or chloroquine, or a combination of IMP and either artesunate or 
chloroquine in two doses separated by 24 hours. 
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vi. Cross-sectional studies 
Cross-sectional studies were performed to assess the effect of treatment on histopathology and 
cellular infiltration at certain time points. This analysis took place at D10 p.i. in mice treated from 
D3 p.i. onwards and mice treated from onset of signs were sacrificed 36 hours after initial treatment. 
 
vii. Flow cytometry 
Mice were anaesthetised, perfused with 50 mL of sterile PBS and the brain and spleen were collected. 
The organs were processed into single cell suspension as previously described (Getts et al., 2008). 
Live cell numbers were determined by counting with trypan blue exclusion. Cells were incubated 
with anti-CD16/32 and LIVE/DEAD Fixable Blue Stain (Invitrogen) and subsequently stained with 
a cocktail of fluorescently labelled antibodies containing markers including BUV395 CD11b (Becton 
Dickinson), BUV737 B220 (Becton Dickinson), BV650 Ly6G (Biolegend), BV785 CD11c 
(Biolegend), PerCP CD45 (Biolegend), FITC CD3e (Biolegend), PE Ly6C (Biolegend), PE/Cf594 
CD80 (Becton Dickinson), APC NK1.1 (Biolegend), APC/Cy7 CD86 (Biolegend). Expression of cell 
surface markers was measured using the FACSDiva program on a fluorescence-activated cell sorter 
(FACS) LSR II (Becton Dickinson). Acquired data was analysed using FlowJo (Tree Star Inc., 
Ashland, OR). Quality control gating based on forward and side scatter and LIVE/DEAD staining 
was applied to exclude debris, doublets, and dead cells. Populations of interest were identified by 
fluorescence and quantified based on the percentage of the population and total cell counts. 
 
viii. viSNE/tSNE analysis 
Visualisation of stochastic nearest neighbour embedding (viSNE) was applied to compensated 
populations of interest, exported from FlowJo. These files were loaded into Matlab R2014b using the 
cyt v3 tool, subsampled and transformed. Selected markers were used to perform a bh-tSNE analysis 
on the transformed data, resulting in a 2D plot, which can be overlaid with a heat map of marker 
expression (Amir el et al., 2013). 
 
ix. Histology 
Brain, lung, and spleen tissue was preserved in neutral-buffered formalin for 24 hours, and 70% 
ethanol for 48 hours before being processed for histopathology. Tissue was dehydrated overnight, 
embedded in wax, sectioned with a microtome, mounted on slides, and stained using standard 
haemotoxylin and eosin protocols. Histopathology was examined using the scoring system previously 
defined (Potter et al., 2006a). 
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x. Cell sorting and adoptive transfer 
The bone marrow of PbA-infected mice was isolated and processed into single cell suspension on D7 
p.i. and incubated with fluorescently labelled antibodies against CD45, CD11b, Ly6C and Ly6G. 
Ly6Chi CD11b+ inflammatory monocytes were sorted on an Influx cell sorter using the FACSDiva 
Program (Becton Dickinson). These cells were labelled with membrane dye PKH26 (Invitrogen) 
according to the manufacturers’ protocol and injected intravenously into PbA-infected recipients in 
200 µL sterile PBS on D7 p.i. Recipients were sacrificed 12 hours post-transfer and the brain and 
spleen were isolated and processed for flow cytometry, as described above. 
 
xi. Microvesicle enumeration 
Mouse venous blood was collected by retro-orbital puncture under anaesthesia in 0.129 mol/L sodium 
citrate (ratio of blood to anticoagulant 4:1). Samples were centrifuged at 1500 g for 15 min at room 
temperature. Harvested platelet-poor plasma samples were further centrifuged at 18000 g for 5 min, 
twice, to achieve platelet-free plasma. Platelet-free plasma was centrifuged at 18000 g for 45 min, 
supernatant removed and retained, and then the pellet centrifuged for a further 45 min at 18000 g in 
a solution of sodium citrate and PBS (ratio of citrate to PBS 1:3) to pellet microvesicles. Total MP 
numbers were quantified by detection of phosphatidylserine using FITC-Annexin V (Beckman 
Coulter) labelling, as previously described. Samples were acquired on a Gallios flow cytometer 
(Beckman Coulter) and analysed using Kaluza (Beckman Coulter) (El-Assaad et al., 2014). 
 
xii. Statistical analysis 
GraphPad Prism 7 (GraphPad Software) was used to graph data and perform statistical analyses. 
Survival data was compared using the Mantal-Haenszel log-rank test. Comparison of two samples 
was conducted using an unpaired two-tailed Student’s t-test, and three or more samples were 
compared using a one-way ANOVA with a Tukey-Kramer post-test. The outcome of statistical 
analyses is represented as p £ 0.05 significant (*), p £ 0.01 strongly significant (**), p £ 0.005 very 
significant (***) and p £ 0.001 extremely significant (****). 
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Results 
 
Accumulating Ly6Clo cells are derived from infiltrating monocytes and are distinct from 
microglia. 
The brains of PbA-infected mice were analysed by flow cytometry at the time of clinical CM on D8 
p.i. and showed that T cells, B cells, neutrophils, DC, and NK cells were numerically minor 
populations, while monocytes constituted ~80% of accumulating leucocytes in the central nervous 
system and, therefore, present great potential as a therapeutic target (Figure 6.1A). Clustering analysis 
using visualisation of Stochastic nearest Neighbour Embedding (viSNE) was applied to further 
characterise the CD11b+ population in the brain. viSNE analysis creates a two-dimensional figure in 
which the position of each cell is determined by its relation to other cells, based on the expression of 
all fluorescent and scatter markers in a multi-dimensional flow cytometric analysis, thus resulting in 
the grouping of cells with similar expression patterns. The myeloid CD11b+ population in the brains 
of non-infected and PbA-infected mice on D8 p.i. consisted of three separate populations (Figure 
6.1B). To compare expression of any marker between populations, the viSNE output can be 
represented as an expression heat map (Figure 6.1C). CD11b+ populations in the brains of non-
infected mice were dominated by a population with low expression of Ly6C, as indicated by the blue-
coloured cell clusters identified as microglia (Figure 6.1B, population 1). In the brains of PbA-
infected mice, this microglial population was proportionately (but not numerically) less prominent 
due to the increase in other cell types, with separate Ly6Clo and Ly6Chi myeloid populations, here 
defined as populations 2 and 3, respectively (Figure 6.1B). Of the other markers measured on these 
cells, CCR2, CD45, MHC-II, and CD80 were expressed at very low levels by microglia, but at high 
levels in the Ly6Clo (population 2) and Ly6Chi monocytes (population 3) (Figure 6.1C). The identified 
microglial population was reduced in infected mice compared with non-infected mice; however, 
Ly6Clo and Ly6Chi monocytes were both dramatically increased in infected mice, with the Ly6Clo 
cells being most numerous (Figure 6.1D). We hypothesised that Ly6Clo monocytes accumulating in 
the vasculature of the brain were derived from Ly6Chi inflammatory monocytes recruited from bone 
marrow. We therefore performed an adoptive transfer: bone marrow-derived Ly6Chi monocytes were 
isolated from D8 PbA-infected mice, labelled with PKH26 and injected into a separate group of 
infected mice at the time of CM. We showed that these transferred cells acquired a Ly6Cint profile in 
the brain within 12 hours after transfer, progressing to a Ly6Clo profile at 24 hours after transfer. 
Conversely, Ly6Cint and Ly6Clo monocytes increased over time following adoptive transfer 
(Figure 6.1E). Finally, the identified microglial population had an even lower Ly6C expression 
profile. 
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Figure 6.1. The major infiltrating Ly6Clo population is derived from Ly6Chi monocytes. 
A Flow cytometry was used to determine the proportional size of specific populations in the brains of non- and 
PbA-infected mice on D8 p.i. Numbers were determined by multiplying organ cell counts by the percentages 
obtained in FlowJo. These data represent three separate experiments with a total n of 7-9 mice per group. B 
Populations formed by viSNE analysis on the CD11b+ population in flow cytometry data of the brains of non- and 
PbA-infected mice on D8 p.i. C Heat-map of relative expression of Ly6C, CD45, CCR2, CX3CR1, F4/80, MHC-
II, CD80, and CD86 on these populations. D Numerical representation of CD11b+ populations in the brains of non- 
and PbA-infected mice identified by viSNE, gated in FlowJo. E CD11b+Ly6G-Ly6Chi inflammatory monocytes 
were isolated from the bone marrow of PbA-infected mouse donors on D7 p.i., labelled with PKH26 fluorescent 
dye, and injected into matched recipients on D7 p.i. Brains of recipient mice were processed 12 or 24 hours later, 
on D8/9 p.i., and adoptively transferred PKH26+ cells were identified and their Ly6C expression determined. F 
CD11B+Ly6G- populations separated based on their Ly6C expression 24 hours after transfer. Data represents two 
independent experiments with a total n of 6 mice per group. 
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IMP reduce monocyte infiltration and increase survival in a mouse model of CM. 
Since immune-modifying particles (IMP) have been shown to target circulating Ly6Chi monocytes 
(Getts et al., 2014), we administered these particles intravenously (i.v.) into PbA-infected mice daily 
from D3-D10 p.i. This IMP treatment resulted in a 48% survival, while all mock-treated mice 
succumbed to CM (Figure 6.2A). Surviving mice did not develop clinical signs of CM, as reflected 
in the lower cumulative incidence of CM, and a significantly lower average clinical score on D8 p.i., 
compared to mock-treated controls (Figure 6.2B, C). Surviving IMP-treated mice were then given 
three daily doses of quinine to abrogate the development of anaemia following the cerebral phase 
(Figure 6.2A, arrows). Increased survival in IMP-treated, PbA-infected mice was associated with a 
dramatic reduction in the proportions of Ly6Chi and Ly6Cint cells, which returned to levels similar to 
those in non-infected brains (Figure 6.2D). Furthermore, histology of the brain vasculature and lung 
tissue showed that sequestration of pRBC and leucocytes, invariably seen in PbA-infected mice, was 
abrogated in PbA-infected, IMP-treated mice (Figure 6.2E). In the lungs of these mice, there was a 
marked reduction of typical alveolar septal thickening, due to cellular infiltrates. Notwithstanding the 
clear reduction in clinical and histological signs of inflammation, IMP treatment did not result in 
reduced parasitaemia (Figure 6.2F). When quinine treatment was commenced after IMP treatment, 
this resulted in survival past the typical phase of anaemia development in the first month; these mice 
survived for more than one year. 
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Figure 6.2. IMP treatment increases survival of PbA-infected mice. 
A Survival of mice over time post PbA infection, comparing IMP treatment from D3-10 p.i. with untreated controls, 
and non-infected mice. The acute phase of mortality, observed during the second week post PbA-infection, is 
denoted by the blue box, and the arrows annotate initiation of IMP and quinine treatments. B Cumulative incidence 
of the neurological syndrome in PbA-infected mice, with or without IMP treatment. C Average clinical score on 
D8 p.i. in PbA-infected mice receiving different treatments, shown as mean ± SEM. Data represents 3 separate 
experiments with a total n of 21-36 mice per group. D Dot plots of myeloid CD11b+ cells in the brains of non-
infected and PbA-infected mice with or without IMP treatment, on D10 p.i. E Representative haematoxylin and 
eosin-stained brain and lung sections from non-infected mice and PbA-infected mice with or without IMP treatment 
on D8-10 p.i. Scale bars are equal to 100 µm or 20 µm for 10x and 40x images, respectively. F Peripheral blood 
parasitaemia levels in treated and untreated infected mice. Data represents 3 separate experiments with a total n of 
21-36 mice per group. Q is indicative of the time-points at which quinine treatment was given. 
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IMP and artesunate synergise to ameliorate CM and increase survival in PbA-infected mice. 
The data clearly show that IMP therapy addresses an underlying monocyte-driven pathology in 
animals suffering CM. However, the requirement for additional anti-parasitic treatment following 
IMP-mediated survival prompted us to combine IMP treatment with the anti-malarial drug, 
artesunate, as recommended for severe malaria by WHO (2015). Specifically, two doses of artesunate 
and IMP in combination, 24 hours apart, were administered from the onset of signs of CM – between 
D6 and 8 p.i. Artesunate or IMP treatment alone resulted in 56% and 10% survival, respectively, 
while the combination of artesunate and IMP resulted in a considerably increased survival rate of 
88% (Figure 6.3A). The synergistic effect of combining artesunate and IMP treatment was evident in 
the lower cumulative incidence and the reduced average clinical score on D8 p.i. (Figures 6.3B and 
C). Interestingly, treatment combining IMP and chloroquine – an alternative anti-malarial therapy – 
upon development of CM signs, also had a strong protective effect against CM (Figure 6.3D), despite 
the lower efficacy of chloroquine treatment alone, compared to artesunate (Waknine-Grinberg et al., 
2010). As expected, mice treated with artesunate alone or in combination with IMP showed a 
substantial reduction in parasitaemia, while mice treated only with IMP required additional anti-
malarial treatment to achieve long-term survival (Figure 6.3E). We also investigated the number of 
plasma MV in these groups, since increased numbers of MV are linked to increased cellular adhesion 
and cerebral pathology in mice and humans (Combes et al., 2005; Pankoui Mfonkeu et al., 2010), and 
blocking their release protects against CM (Penet et al., 2008). Circulating MV numbers were 
significantly decreased in mice treated with IMP, either alone or in combination with artesunate, but 
not in mice treated with artesunate alone (Figure 6.3F). 
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Figure 6.3. IMP and artesunate combination treatment upon CM presentation increases survival 
A Survival of mice over time post PbA infection, comparing IMP, artesunate or a combination treatment from D7 
p.i. with untreated controls. The acute phase of mortality, observed during the second week post PbA-infection, is 
denoted by the blue box. B Cumulative incidence of the neurological syndrome between D6 and D14 p.i. in PbA-
infected mice receiving different treatments. C Average clinical score on D8 p.i. in PbA-infected mice receiving 
different treatments, shown as mean ± SEM. D Survival of mice over time post-PbA infection, comparing treatment 
from D7 p.i. with IMP alone or in combination with chloroquine, with untreated mice. Data represents 3 separate 
experiments with a total n of 5-11 mice per group. E Peripheral blood parasitaemia levels in treated and untreated 
infected mice. Percentage parasitaemia was significantly lower on D9 p.i. in all treatment conditions was observed. 
Parasitaemia shown as mean ± SEM. Data represents 3 separate experiments with a total n of 17-23 mice per group. 
F Number of circulating microvesicles per microlitre of platelet-free plasma in non-infected mice, and in PbA-
infected mice, comparing IMP, artesunate or a combination treatment from D7 p.i. with untreated controls. All data 
presented as mean ± SEM. Data represents 1 experiment with a total n of 3-7 mice per group. 
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Histological examination of mice treated with artesunate and IMP in combination showed no 
evidence of cerebral haemorrhage and only few vessels with cell sequestration on D8 p.i. (Figure 
6.4A). In fact, the sequestration of pRBC and leucocytes typically seen in PbA-infected mice was 
significantly reduced to near healthy levels in mice receiving each of the three treatments (Figure 
6.4B). The few nucleated cells visible in the vessels of NI and treated mice are endothelial cells, as 
indicated by their flattened nuclei, as opposed to the sequestered leucocytes visible in infected 
untreated mice. No specific area of the brain was chosen for this examination, as this is typically a 
diffuse pathology, with instances of sequestration and haemorrhaging observed throughout the tissue. 
Similarly, alveolar wall thickening and cellular infiltrates were more reduced in the lungs of this 
group than in mice treated with IMP or artesunate alone (Figure 6.4A). Consonant with this, flow 
cytometry showed that the combination of artesunate and IMP reduced total monocyte numbers to 
0.58x106 per brain, i.e. by >60% (Figure 6.4C). Of these subsets, Ly6Chi and Ly6Cint monocytes were 
reduced to 0.09x106 and 0.14x106, respectively. Interestingly, Ly6Clo monocytes showed the largest 
reduction to 0.35x106 in these animals (Figure 6.4D). The corresponding improvement in clinical 
signs of CM and the reduction in these cell subtypes emphasises the pathological nature of monocyte 
accumulation in CM. 
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Figure 6.4. Treatments result in reduced pathology and monocyte infiltration in the brains of PbA-infected 
mice. 
A Representative haemotoxylin and eosin brain and lung sections from non-infected mice, and PbA-infected mice 
with no treatment, or treatment with IMP, artesunate, or a combination of the two, on D8-10 p.i. Scale bars are equal 
to 100 µm or 20 µm for 10x and 40x images, respectively. B The percentage of vessels with sequestration in the 
brains of from non-infected mice, and PbA-infected mice with no treatment, or treatment with IMP, artesunate, or 
a combination of the two, on D8-10 p.i., was quantified (n = 3-6). C-D Flow cytometry was used to gated and 
enumerate total CD45+ cells (B) and specific CD11b+ populations with differential Ly6C expression (C) in the brain 
36 hours after initial treatment. Flow cytometry data represent three separate experiments with a total n of 7-9 mice 
per group. 
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Successfully treated mice are immune to PbA reinfection. 
Since these treatments evidently cured CM and afforded long-term survival, we wished to determine 
whether they conferred immunity. We therefore assessed the effect of rechallenging the survivors 
with PbA. Remarkably, reinfected mice presented with minimal clinical signs and parasitaemia, 
compared to naïve PbA-infected mice (Figure 6.5A, B). All surviving mice were found to be immune 
to reinfection, regardless of the treatment protocol administered during the primary infection (Figure 
6.5C). 
 
 
Figure 6.5. Treated PbA-infected mice are protected during reinfection 
A-B Clinical scores (A) and parasitaemia (B) in previously successfully IMP-treated mice, reinfected on D35 p.i., 
compared to naïve PbA-infected mice. All data presented as mean ± SEM. Data represents 3 separate experiments 
with a total n of 5-16 mice per group. C Survival of all previously successfully treated mice over time post PbA 
reinfection, compared with untreated controls. The acute phase of mortality, observed during the second week post-
PbA-infection, is denoted by the blue box. 
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Discussion 
 
In this study, we have shown that a novel combination of IMP and artesunate significantly 
prevented lethality and even cured the syndrome when administered at the onset of CM. This 
combined treatment also reduced clinical signs of CM in mice infected with PbA. Protection was 
associated with down-regulation of two key cellular responses to infection, i.e., monocyte 
accumulation and circulating MV numbers in the vasculature. This treatment has enabled us to 
explore for the first time the cellular changes within the brain during the late stages and resolution of 
CM. 
The CM syndrome is characterised by a dysregulated immune response associated with 
sequestration of cells in the brain microvasculature. The main subset we found in the brain during 
CM presented a CD11b+ Ly6Clo phenotype. viSNE analysis demonstrated a group of Ly6Clo cells in 
the brains of PbA-infected mice, with high MHC-II expression, and distinguished them from 
microglia, that expressed lower levels of MHC-II. Compared with Ly6Clo microglia, these Ly6Clo 
cells instead expressed the same level of MHC-II as the Ly6Chi monocytes from which they are 
presumably derived, echoing previous work identifying phenotypic and functional similarities 
between Ly6Clo and Ly6Chi monocytes (Auffray et al., 2007; Shi and Pamer, 2011). Adoptive transfer 
of Ly6hi monocytes into recipient mice with CM demonstrated down-regulated Ly6C expression on 
80% of these cells collected from the brain 12 hours after transfer, confirming this hypothesis. These 
results suggest that the accumulation of Ly6Clo monocytes in the CM brain can be prevented by 
targeting Ly6Chi monocytes prior to their localisation in the brain and their subsequent differentiation 
to a Ly6Clo phenotype, thus reducing pathology in CM. This aligns with previous work showing that 
monocytes accumulating in the microvasculature of the brain acquire the features of tissue 
macrophages without transmigrating across the blood-brain barrier (Grau et al., 1987). 
In contrast to brain parenchymal changes in other neuroinflammatory diseases, such as West 
Nile virus infections where many Ly6Chi and few Ly6Clo can be found (Getts et al., 2014), the most 
prevalent subset in the brains of PbA-infected mice was the Ly6Clo population. Likewise, in influenza 
virus A-associated inflammation, Ly6Clo monocytes have been shown to be the predominant pro-
inflammatory population, rather than their Ly6Chi counterparts (Stifter et al., 2016). Furthermore, 
Ly6Clo monocytes have previously been shown to adhere to the luminal surface of endothelial cells 
(Shi and Pamer, 2011), perhaps indicating their proportionately larger role in a neuropathology such 
as CM, where endothelial dysfunction is a key feature of pathology (Combes et al., 2010). 
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The current recommended treatment approach for CM consists of artemisinin-based 
combination therapy (WHO, 2015). With this best practice treatment, which does not address the 
pathological contribution of the immune response in CM, there is nevertheless a substantial mortality 
in patients (Sahu et al., 2015). In mouse models, artemisinin derivatives generally have to be 
administered before the onset of signs and for as long as 14 days in order to prevent CM (Gumede et 
al., 2003). There are few published examples of successful treatment at the development of signs, one 
of which administered artemether, reducing the number of leucocytes in the brain vasculature 
(Clemmer et al., 2011). Other investigators utilised twice daily artemisone treatment combined with 
chloroquine on D6-8 p.i. which reduced pro-inflammatory and increased anti-inflammatory cytokines 
by D12 p.i. (Waknine-Grinberg et al., 2010; Guiguemde et al., 2014). However, in these studies, 
between 5 and 14 doses of treatment were required to abrogate CM. In contrast, the combination of 
artesunate and IMP, administered at the onset of neurological signs, effectively abrogated CM with 
only two doses given daily over 48 hours. Aside from its anti-parasitic effects, artesunate has been 
shown to down-regulate TNF production (Golenser et al., 2006). When given in combination with 
IMP, this treatment resulted in both IMP-mediated reduction of circulating Ly6Chi monocytes prior 
to their sequestration and Ly6C down-regulation in the microvasculature, leading to reduced Ly6Clo 
monocyte numbers in the brains of treated mice. 
Furthermore, mice receiving IMP, alone or in combination with artesunate, showed the largest 
reduction in circulating MV levels. These MV are derived from monocytes, as well as other cells, 
both in mice (Combes et al., 2005) and human patients (Pankoui Mfonkeu et al., 2010) and are 
associated with CM neuropathology. Reduced MV numbers here may be due to a reduction in the 
number of cells they originate from or to a diminished activation status of the cells generating them 
(Wassmer et al., 2005; Penet et al., 2008). The anti-TNF properties of artesunate alone are not 
effective in reducing circulating MV levels in infected mice. Indeed, TNF is just one of many agonists 
triggering MV release (Latham et al., 2014), therefore this may explain why artesunate by itself, 
though effective in reducing cell accumulation, does not reduce circulating MV production. In 
contrast, IMP treatment, alone or in combination with artesunate, was highly effective in suppressing 
circulating MV. As MV express surface markers from their cell of origin, and a high percentage of 
cells in the vasculature have been identified as monocytes, a substantial proportion of circulating MV 
are monocyte-derived (El-Assaad et al., 2014), and may carry MARCO, the macrophage associated 
receptor shown to be the conduit through which IMP bind to inflammatory monocytes (Getts et al., 
2014). IMP-mediated MV reduction may thus contribute to the efficacy of this therapy. 
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While the numbers of adherent leucocytes, including monocytes, in brain vessels were limited 
in early stages of infection, these numbers increased significantly in mice displaying severe clinical 
signs (Pai et al., 2014). Thus, early IMP treatment on D3 p.i. largely prevented this intravascular 
monocyte accumulation and protected approximately half of the mice against CM. Furthermore, in 
mice showing clinical signs on D7 p.i., at which point most monocytes were already present in the 
brain and had down-regulated Ly6C expression, the efficacy of IMP treatment alone was evidently 
reduced. However, IMP treatment combined with anti-malarial compounds, either chloroquine or 
artesunate, at this time point dramatically improved survival. Notably, although chloroquine alone 
has low efficacy in treating mice with CM signs (Waknine-Grinberg et al., 2010), IMP treatment 
combined with either chloroquine or artesunate resulted in similar survival of over 80%. Considering 
the anti-TNF effect of artesunate and the reduction of inflammatory monocytes by IMP, the success 
of combination treatment highlights the substantial contribution of the myeloid lineage in driving and 
mediating the pathogenesis of CM. Finally, after being successfully cured of CM, all mice challenged 
with PbA were completely protected from reinfection. 
Taken together, our data show the importance of the synergy between monocyte diversion by 
IMP and anti-parasitic/anti-inflammatory effects of artesunate in vivo. Indeed, this combination 
treatment conferred almost complete protection against CM in mice with clinically evident CM with 
two daily doses and no follow-up treatment. The late stage success of this combination therapy in 
mice suggests a potential avenue for translation in treating paediatric CM. More broadly, the 
therapeutic potential of immune modulation during infectious diseases warrants further investigation. 
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Discussion 
 
In this work, we have explored the complex network of cellular, subcellular, and molecular 
elements contributing to cerebral malaria (CM) development. We have investigated the particular 
combination of these elements and assessed their role in the pathogenesis of the neurological 
syndrome. This work has expanded on the role of microvesicles (MV) associated with CM onset, 
providing strong evidence that the content of these MV contributes to their pathogenic role. Our 
results highlight the relationship between the expression of microRNA (miRNA) in MV and in the 
brain. We have examined further morphological features associated with the pathogenesis of CM. 
Finally, we have proposed a novel and highly effective treatment to prevent CM, even when 
administered at the onset of clinical signs. 
The significant increase in circulating subcellular MV, as well as the accumulation of many 
cells from which they are derived, is a hallmark and driving force in the development of murine and 
human CM (Belnoue et al., 2002; Deininger et al., 2002; Grau et al., 2003; Wassmer et al., 2003; 
Combes et al., 2004; Combes et al., 2005; Amante et al., 2010; Franke-Fayard et al., 2010; Pankoui 
Mfonkeu et al., 2010; Ponsford et al., 2012; El-Assaad et al., 2014b; Pai et al., 2014). These 
accumulating cells, including adherent parasitised red blood cells (pRBC), leucocytes, and platelets, 
both respond to and stimulate the release of inflammatory mediators, including cytokines and 
adhesion markers (Grau et al., 1987; Pongponratn et al., 1991; Patnaik et al., 1994; Lou et al., 1997; 
Hearn et al., 2000; Rogerson, 2003; van der Heyde et al., 2006; McQuillan et al., 2011; Grau and 
Craig, 2012; Dunst et al., 2017; Wassmer and Grau, 2017). These cells are a part of the vascular 
endothelial lesion in the brain, the formation of which ultimately leads to vessel obstruction, impaired 
circulation, endothelial damage, haemorrhaging, and tissue hypoxia, all of which have been identified 
as contributing factors in either human or mouse CM development, or both (MacPherson et al., 1985; 
Pongponratn et al., 1991; Hunt and Grau, 2003; Schofield and Grau, 2005; Hunt et al., 2006; Hansen 
and Schofield, 2010; Hempel et al., 2011; Grau and Craig, 2012; Hansen, 2012). 
The work in this thesis proposes that, in vivo, miRNA encapsulated in MV and expressed in 
the brain tissue during infection function to regulate pathways and inflammatory cells implicated in 
CM pathogenesis. MiR-146a and miR-193b in MV, and miR-19a-3p, miR-19b-3p, miR-27a-5p, miR-
142-3p, miR-223-3p, and miR-540-5p in the brain were altered in PbA-infected mice, coinciding with 
the onset of the neurological syndrome. In addition, in vivo investigation of the interactions and 
spatial relationship between elements of CM pathology revealed monocytes, platelets, T cells, pRBC, 
and ICAM-1-positive cells accumulating within the cerebral microvasculature of P berghei-infected 
mice. For the first time, we simultaneously characterised changes in several pathological elements 
using confocal microscopy of thick brain sections. We also found monocytes to be the most numerous 
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cell type accumulating in the brain of mice at CM onset and therefore targeted these therapeutically. 
Remarkably, late-stage administration of a combination of a subcellular therapeutic, immuno-
modulatory particles (IMP), shown to target monocytes and artesunate, a commonly used antimalarial 
medication, resulted in almost complete protection, as well as a sterile immunity upon reinfection. 
More specifically, in Chapter 3, using microarray and RT-qPCR techniques in our in vivo 
mouse model of CM, we studied the nucleic acid contents of MV. That is, we assessed the 
contribution of miRNA as active contributors to the dysregulated immune response seen in CM. We 
characterised, for the first time, the miRNA cargo of MV during experimental CM in order to better 
understand the pathogenesis. We demonstrated clear differences in miRNA abundance within 
circulating MV during experimental CM as compared with non-infected and non-CM conditions, 
with significantly altered levels of miR-146a and miR-193b detected in CM MV in both the 
microarray screening and RT-qPCR validation stages. These miRNA interact with mRNA to affect 
the downstream production of proteins involved in apoptosis, cytokine regulation, and recruitment of 
inflammatory cells. Furthermore, we demonstrated a separate set of miRNA significantly 
dysregulated in brain tissue, supporting the hypothesis that miRNA are selectively packaged in MV 
during CM. Although the miRNA content of extracellular vesicles has been studied previously 
following Plasmodium infection (Mantel et al., 2016; Moro et al., 2016; Yang et al., 2017), none of 
these studies has examined MV in CM. Mantel et al. studied human RBC-derived exosomal miRNA 
in vitro, Yang et al. examined plasma-derived exosomal miRNA in the mouse model, and Moro et al. 
studied plasma MV rather than exosomal miRNA in pregnant women with placental malaria, but not 
CM specifically. Our study highlights, for the first time, the potential of MV-encapsulated miRNA, 
in this mouse model of CM, to play a regulatory role in the pathogenesis of severe malaria. 
In Chapter 4, using the same microarray technique as in Chapter 3, we undertook a detailed 
analysis of the miRNA content in brain tissue. While the miRNA changes within the brain during 
CM have previously been explored in our laboratory (El-Assaad et al., 2011), only particular miRNA 
of interest had been examined. Our study provides the first unbiased and exhaustive analysis of brain 
miRNA expression in experimental CM and reveals that PbA infection induces the dysregulation of 
a specific set of miRNA compared with non-infected and non-CM conditions. We established a 
miRNA fingerprint differentiating mice with CM from non-CM, and this group of miRNA specific 
to the neurological syndrome were shown to regulate pathways related to the differentiation of several 
key players in innate immune responses and malaria resistance (La Monte et al., 2012; Haneklaus et 
al., 2013). Furthermore, this group of significantly dysregulated miRNA controlled pathways such as 
TGF-β signalling, endocytosis, FoxO signalling, and adherens junctions. These results highlight the 
potential role of CM-specific miRNA changes, through downstream regulation of mRNA and 
proteins, of contributing to the neurological syndrome. 
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In both Chapters 3 and 4, we examined the miRNA content of brain tissue, however we found 
distinct miRNA to be differentially significantly expressed in CM, non-CM and non-infected mice 
between these two experiments. One way to explain this discrepancy is that, although only a few 
selected miRNA were tested in Chapter 3 by RT-qPCR, a comprehensive analysis of all known 
murine miRNA was performed in Chapter 4 by microarray. In Chapter 3 using RT-qPCR analysis, 
miR-205, miR-215, and miR-467a were found to be significantly increased in the brain of mice with 
CM compared with non-infected mice. None of these miRNA were found to be significantly 
differentially expressed in the arrays examined in Chapter 4, though they were all similarly increased. 
Furthermore, RNA samples tested in these analyses were isolated using different protocols for 
Chapters 3 and 4 – total RNA was isolated using the RNAzol protocol in Chapter 3, as opposed to 
the Ambion mirVana miRNA isolation kit in Chapter 4. This may further explain why these three 
miRNA were not shown to be significantly dysregulated in Chapter 4 as they were in Chapter 3. 
 Having established that miRNA may participate in the development of CM, either contained 
in circulating plasma MV or in brain tissue, in Chapter 5 we investigated further the interactions of 
pathological elements of CM at the cellular level, by performing thorough morphological analyses of 
the brain. We undertook a comprehensive spatial analysis of the relative distribution and numbers of 
platelets, monocytes, pRBC, T cells, ICAM-1 positive cells, and hypoxic regions in the brain of 
Plasmodium-infected mice. Platelets, pRBC, ICAM-1-positive cells, and numerous monocytes were 
found to accumulate at branch points of vessels. This accumulation was associated with vascular 
leakage and haemorrhaging, leading to widespread hypoxia in the surrounding tissue and ultimately, 
to disease and death during experimental CM. Altogether, our observations are consistent with 
previous reports (Schofield and Grau, 2005; Medana and Turner, 2007; Schofield, 2007; Amante et 
al., 2010; Franke-Fayard et al., 2010; Hempel et al., 2011; Nacer et al., 2014). 
 Having shown the significant increase in monocytes in the brain of mice with CM, we 
evaluated the therapeutic efficacy of modulating their accumulation using IMP in Chapter 6. These 
IMP have previously been shown to target Ly6Chi monocytes in other diseases (Getts et al., 2014), 
therefore their effect was investigated in our experimental model of CM. IMP treatment alone 
prevented the cerebral syndrome in 48% of PbA-infected mice when administered early in infection 
(D3 p.i.), but was less effective when given at the onset of the neurological syndrome (D7 p.i.), 
resulting in only 10% protection. At this same late stage, IMP combined with the anti-malarial, 
artesunate, resulted in a remarkable 88% protection, compared with 56% in mice treated with 
artesunate alone. The synergy between IMP and artesunate dramatically reduced clinical signs, 
monocyte numbers, and MV numbers in PbA-infected mice. These results are in agreement with 
previous studies demonstrating the critical role of monocytes in both human (Pongponratn et al., 
1991; Porta et al., 1993; Grau et al., 2003; Hochman et al., 2015) and mouse CM (Grau et al., 1987). 
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This combined treatment has enabled us to explore, for the first time, the cellular changes within the 
brain during successful late treatment of CM, resulting in complete immunity upon reinfection. Our 
work suggests that this combination therapy can modulate the inflammatory response and, 
particularly given its late-stage success, could be envisaged as a treatment for paediatric CM. 
 
Critical assessment/analysis and future directions 
 
Chapter 3 
We have explored the miRNA content of MV in detail and now further characterisation of their 
downstream effect during CM is needed. Though target prediction is possible with miRNA data alone, 
there is redundancy in miRNA expression and activity on target pathways. Therefore, to distinguish 
the effect of miRNA expression signatures associated with CM more specifically, matched mRNA 
and protein studies could be utilised, for example RNA sequencing and protein array techniques. This 
way, meaningful insights into the interactions between miRNA-mRNA pairs and miRNA-protein 
pairs could be established, leading to more accurate downstream target prediction and detection of 
measurable effects on gene expression. To confirm the importance and specific roles of identified 
miRNA of interest within MV or brain tissue, antagomirs (functioning to silence targeted miRNA) 
or miRNA mimics (increasing their level of expression) could be introduced into the in vivo model, 
and their effects assessed. In order to test the relevance of these findings to human CM, this 
assessment could also be carried out in an existing in vitro system modelling the BBB (Penet et al., 
2008; Combes et al., 2010). 
 
Chapter 4 
As with our previous miRNA study, further examination of how our chosen miRNA of interest are 
regulating pathways implicated in CM pathogenesis is needed to fully grasp their contribution to the 
syndrome. This is particularly important due to the complex nature of the interactions between these 
miRNA and their numerous mRNA targets in these pathways. Paired miRNA-mRNA data would 
allow greater specificity in identifying downstream targets, and measurable effects of these 
molecules. To this end, RNA sequencing could also be applied to this project to match miRNA data 
with mRNA expression and gain useful insights into their interactions. However, before this, the 
miRNA identified in this work need to be further validated by RT-qPCR. Blood samples have been 
taken from these mice, as well as the brain samples tested. As circulating miRNA often reflect the 
changes in the tissue, this analysis could present an opportunity to assess the suitability of these 
miRNA as biomarkers of disease, or more specifically, of neurological complications. 
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Chapter 5 
As this tissue clearing protocol has now been set up to image the pathogenic elements of CM, the 
work can be scaled up in several ways. Additional known elements contributing to pathology, 
including additional adhesion markers, leucocyte subsets and MV produced from these cell types 
could also be examined, to broaden the assessment of pathology. Furthermore, although non-infected 
mice and mice with CM – either PbA- or PbG-infected – have been examined, adding a more detailed 
examination of the brain of mice with non-CM would strengthen this analysis, to highlight features 
unique to the cerebral syndrome. The brain of PbA- or PbG-infected mice could also be assessed 
earlier in infection, before the development of detectable neurological signs. Next, as the system is 
efficient in imaging thick brain sections, the most natural way of enhancing this analysis would be to 
gradually move towards whole-mount imaging, followed by in vivo live imaging with reporter mice, 
reducing or eliminating the need for labelling steps completely. In this way, we would be able not 
only to gain a greater spatial perspective of these elements, but also to observe their interactions and 
kinetics in real time, through analysis of greater numbers of mice, in order to reach statistical 
significance. Finally, depletion studies have been utilised to highlight the pathogenic importance of 
the elements we have explored. However, the intricacies of these interactions have still not been fully 
explored, and this imaging system provides an opportunity to examine this more closely in real time. 
Further to this, the imaging protocol we have established allows for the possibility to assess treatment 
strategies in abrogating CM pathology, by targeting particular elements such as monocytes, as 
discussed in Chapter 6. 
 
Chapter 6 
In order to understand more the exact mechanisms by which IMP and artesunate combined 
treatment is abrogating CM and leading to immunity in successfully treated mice, several strategies 
could be implemented. Firstly, further testing of the adoptive transfer model needs to be carried out, 
in order to assess the exact target of the IMP, and further elucidate the exact mechanisms by which 
they are having an effect. In other studies, using these particles therapeutically, it has been shown that 
Ly6Chi monocytes are specifically targeted (Getts et al., 2014), however Ly6Clo monocytes were the 
most numerous in our study. Adoptive transfer will allow us to determine whether the Ly6Clo 
population we observe in the brain of treated mice simply consists of Ly6Chi monocytes that are 
downregulating their Ly6C expression due to some stimulus in CM. Once this has been assessed, the 
immunity induced in successfully treated mice needs to be explored further. Specifically, the in vivo 
role, function, and specificity of CD8+ and CD4+ T cells, as well as B cells in malarial immunity 
needs to be defined. The role of dendritic cells and other antigen-presenting cells will also need to be 
assessed (Karunarathne et al., 2016). 
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Conclusions 
There is still no explanation of why only approximately one percent of P. falciparum-infected 
patients develop CM. Better understanding of the events underlying CM pathogenesis may help to 
guide the increased specificity of therapeutic interventions, improve the management of this 
syndrome, and ultimately improve mortality rates. We have addressed some of these aspects in this 
thesis, including the role of nucleic acids such as miRNA, the regulation of gene expression, the 
spatial interactions of inflammatory cells resulting in oxygen deprivation in tissues, and adjunct 
therapies targeting some of the most numerous inflammatory cells. 
 One of the major challenges in combating severe malaria is a swift diagnosis, as the syndrome 
develops rapidly and the symptoms resemble those of other neurological conditions, such as 
meningitis (Misra et al., 2011). Currently, CM diagnosis requires detection of asexual forms of P. 
falciparum in the blood, as well as neurological symptoms such as impaired consciousness. However, 
this diagnosis presents challenges in and of itself, as not all patients demonstrate symptomatic 
infections and, in some cases, the parasite may be absent or present in undetectable levels in the 
bloodstream, due to increased sequestration and subsequent removal from circulation (Silamut et al., 
1999; Newton et al., 2000; Idro et al., 2005; van der Heyde et al., 2006). Furthermore, greater 
sensitivity is needed in testing for the parasite in the bloodstream, however more sensitive equipment 
is not always widely available in areas where prevalence is highest (Misra et al., 2011; WHO, 2016). 
Examination of CSF is often necessary to exclude other encephalopathies, though this is quite an 
invasive procedure. Therefore, it is crucial to establish reliable diagnostic and prognostic biomarkers. 
MV have previously shown potential as biomarkers in diagnosis and as indicators of treatment 
success, due to their increase during CM and their association with disease severity (Combes et al., 
2004; Pankoui Mfonkeu et al., 2010; Nantakomol et al., 2011). Particularly, MV have been shown to 
contain proteins, lipids, and nucleic acids, and express surface antigens from their cell of origin and 
circulate in the blood, propagating signals and triggering systemic effects related to the severity of 
infection (El-Assaad et al., 2014b; Tiberti et al., 2016). In fact, in our study of the plasma MV during 
experimental CM (Appendix), we demonstrated that infection impacts the MV-encapsulated 
proteome. Furthermore, the specific changes occurring during CM may relate to the pathogenic 
mechanisms of the syndrome and add to our understanding of its development (Tiberti et al., 2016). 
The fine molecular mechanisms by which MV influence cellular processes are still under 
investigation; however, it is clear that they are active players in CM development.  
MV derived from injured organs have been shown to contain miRNA with great potential as 
valuable biomarkers to aid in determining the site, type, and extent of pathology in several diseases 
(Muralidharan-Chari et al., 2010; Fleissner et al., 2012). Therefore, the miRNA contents of MV, as 
well as tissue-resident miRNA, could be further assessed for their potential as biomarkers of CM. It 
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is clear from our miRNA analyses that the abundance of relevant miRNA is affected by Plasmodium 
infection and specifically CM, and that these miRNA actively participate in pathways consistent with 
CM. Notably, several of our MV-encapsulated miRNA of interest have already been identified as 
biomarkers of other diseases, such as sepsis and prion infections (Giza and Vasilescu, 2010; 
Bellingham et al., 2012; Tacke et al., 2014). Furthermore, targeted therapy could be directed towards 
miRNA contributing to pathology (Rupaimoole and Slack, 2017). 
 Examining brain pathology more closely, our work investigating the 3D morphology of 
various pathological elements of CM was consistent with previously demonstrated histopathological 
signs in humans and mice (Riley et al., 2010; Hempel et al., 2011). The validity of the mouse model 
in replicating the human syndrome and its usefulness in studying CM has been greatly debated (Hunt 
et al., 2010; White et al., 2010; El-Assaad et al., 2014a). However, our study and others have shown 
that the accumulation of both red and white blood cells within the cerebral vasculature is common to 
the human (Patnaik et al., 1994; Coltel et al., 2004; Idro et al., 2005; Ponsford et al., 2012; Hawkes 
et al., 2013) and murine syndromes (Hearn et al., 2000; van der Heyde et al., 2006; Ryg-Cornejo et 
al., 2013; Pai et al., 2014). Therefore, the mouse syndrome, as a pre-clinical model, represents an 
invaluable tool to assess the clinical potential of novel therapeutics before translation into human 
clinical trials, at least in paediatric CM (Hochman et al., 2015). 
 The work in this thesis, together with previous studies, suggests that monocytes are an 
important target in CM therapy (Wassmer et al., 2003; Pai et al., 2014; Hochman et al., 2015). Further 
to this, administration of specific monoclonal antibodies to deplete Ly6Chi monocytes in vivo was 
shown to attenuate brain inflammation and immune cell recruitment to the brain circulation (Schumak 
et al., 2015). Our work, too, supports the efficacy of IMP in preventing the onset of CM by targeting 
monocytes, and as a suitable candidate for a combination therapy with antimalarial medications in 
paediatric CM. Once the first clinical symptoms are detected, the syndrome rapidly develops, leading 
to deterioration in the health of patients. Therefore, the efficacy of this combination therapy at this 
point in the disease could potentially increase the likelihood of successful treatment, decreasing 
mortality in those patients, or neurological sequelae in survivors (Bartoloni and Zammarchi, 2012). 
 The body of work presented in this thesis has served to further support the existing hypotheses 
concerning the pathogenesis of CM, while also indicating several candidates as novel players in the 
development of the syndrome. The rapidly expanding area of miRNA research presents novel 
opportunities to establish much-needed biomarkers for CM, and target them in relation to their role 
in exacerbating the syndrome. This work further supports the dysregulated accumulation of 
inflammatory cells, particularly monocytes, and their role in CM. Finally, we propose a novel and 
effective treatment strategy for eliminating CM at a late stage and highlight the potential of this 
therapy to be effective in treating paediatric CM.  
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Exploring experimental cerebral 
malaria pathogenesis through the 
characterisation of host-derived 
plasma microparticle protein 
content
Natalia Tiberti1,2, Sharissa L. Latham2, Stephen Bush3, Amy Cohen2, Robert O. Opoka4, 
Chandy C. John5,6, Annette Juillard2, Georges E. Grau2,7 & Valéry Combes1,2,7
Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection responsible 
for thousands of deaths in children in sub-Saharan Africa. CM pathogenesis remains incompletely 
understood but a number of effectors have been proposed, including plasma microparticles (MP). MP 
numbers are increased in CM patients’ circulation and, in the mouse model, they can be localised within 
inflamed vessels, suggesting their involvement in vascular damage. In the present work we define, for 
the first time, the protein cargo of MP during experimental cerebral malaria (ECM) with the overarching 
hypothesis that this characterisation could help understand CM pathogenesis. Using qualitative and 
quantitative high-throughput proteomics we compared MP proteins from non-infected and P. berghei 
ANKA-infected mice. More than 360 proteins were identified, 60 of which were differentially abundant, 
as determined by quantitative comparison using TMTTM isobaric labelling. Network analyses showed 
that ECM MP carry proteins implicated in molecular mechanisms relevant to CM pathogenesis, including 
endothelial activation. Among these proteins, the strict association of carbonic anhydrase I and S100A8 
with ECM was verified by western blot on MP from DBA/1 and C57BL/6 mice. These results demonstrate 
that MP protein cargo represents a novel ECM pathogenic trait to consider in the understanding of CM 
pathogenesis.
Malaria infection caused by Plasmodium protozoan parasites still represents a major worldwide health problem 
affecting more than 200 million people and being responsible for the death of 600,000 of them, according to 
the latest WHO estimations1. Cerebral malaria (CM) is the most fatal malaria complication and affects mainly 
children under the age of 5 in sub-Saharan Africa2. CM prompt diagnosis remains difficult2 and despite availa-
ble treatment, 15–20% of patients die, while 10–15% of cured patients will suffer from long-term neurological 
deficits3.
The pathological mechanisms of this complex neurological syndrome are still to be fully deciphered. The best 
described processes of CM pathogenesis include the sequestration of parasitized red blood cells (pRBC) in the 
brain microvasculature and an excessive activation of the immune response with production of pro-inflammatory 
cytokines4. An additional important feature is the increased number of microparticles (MP) in patients’ circula-
tion. MP are submicron extracellular vesicles (100–1000 nm in size) released through a mechanism of outward 
blebbing of the plasma membrane by potentially all host cell types under physiological conditions or follow-
ing stress and apoptosis5. Due to their process of formation, MP expose on their surface negatively charged 
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phosphatidylserine residues and cellular markers specific to their cell of origin6. Importantly, they contain pro-
teins, nucleic acids and lipids derived from the cytoplasm of the parent cell that they can convey to target cells, 
thus playing an important role in the intercellular communication and exchange of biological information7 as 
already shown in cancers, neurological disorders and cardiovascular diseases8–10. Interestingly, the proteomics 
characterisation of the cargo of plasma MP released under specific pathological conditions has already been 
found useful to identify new disease biomarkers and to propose new pathophysiological features11,12.
In CM patients, an increased number of MP originating from platelets, endothelial cells, monocytes and red 
blood cells has been shown in different clinical cohorts, where a significant correlation with the disease severity 
was proven13–15. Studies in the murine model of CM (experimental cerebral malaria – ECM), consisting of sus-
ceptible mouse strains (DBA/1, CBA and C57BL/6) infected with the Plasmodium berghei ANKA (PbA) para-
site16, significantly contributed to further demonstrating that MP are not merely inert cellular products but active 
players in CM progression17,18. Indeed, similarly to human CM, increased numbers of cell-specific MP have been 
detected in ECM18 and mice showing a reduced release of MP (ABCA1−/− or pantethine-treated) are protected 
from the cerebral syndrome17,19. Additionally, adoptively transferred ECM plasma MP localised in inflamed ves-
sels, elicited breakdown of the blood brain barrier and brain pathology similar to ECM18.
Although an important role of circulating MP in CM pathogenesis is now generally accepted20,21, the mech-
anisms through which these vesicles carry out their biological functions still need to be deciphered and their 
protein cargo is yet to be described. In this context, we hypothesized that the protein content of circulating 
host-derived MP produced during CM might be of central importance in the pathogenesis of this syndrome. 
To closely follow the development of the neurological syndrome, we took advantage of the well-established CM 
mouse model and we investigated the protein content of MP produced during ECM using high-throughput qual-
itative and quantitative proteomics and network analyses. Two selected ECM-MP proteins, carbonic anhydrase 
1 (CA-I) and S100A8, were further verified on a larger number of samples and their abundance was proven to be 
increased within plasma MP specifically released during the infection.
Results
Experimental design. To obtain quantitative information on the protein cargo of MP released during dif-
ferent infection conditions we used the Tandem Mass TagTM (TMT) isobaric labelling technology (ThermoFisher 
Scientific).
To set up an efficient quantitative protocol to analyse plasma MP proteins obtained from individual mice, the 
TMTzero (TMT0) labelling approach was first applied. MP from one non-infected (NI) and one PbA-infected 
mouse (experimental cerebral malaria – ECM) were used. The lists of identified proteins were considered as 
“qualitative datasets”.
The protocol established with the TMT0 was then translated to the TMTsixplex (TMT6) format. To increase 
the number of tested samples, two parallel experiments were performed comparing plasma MP proteins from 
non-infected mice (NI, n = 4), PbA-infected mice at day 3 post-infection (d3 pi, n = 4) and PbA-infected mice at 
d8 post-infection when all the signs of cerebral malaria are detected (ECM, n = 4).
Qualitative and quantitative proteomics results were then compared and evaluated in the context of CM 
pathogenesis through gene ontology and network analyses, and further verified by western blot (WB) for two 
selected proteins, carbonic anhydrase I (CA-I) and S100A8 on two different mouse strains.
A graphical representation of the experimental design used in the present study is depicted in Fig. 1.
MP visualisation by scanning electron microscopy (SEM) and counting by flow cytometry. To 
demonstrate the efficiency of our purification method, plasma MP from a NI mouse were imaged by SEM (Fig. 2). 
Figure 2A and C clearly show that the predominant population of purified vesicles has a size range compatible to 
that of MP (0.1–1 μ m); only a minimal contamination of larger elements, which might correspond to cell debris 
or platelets, was visualised.
When counted by flow cytometry in PFP samples, the number of Annexin V+ MP/μ L in ECM PFP was 2.5 
and 2.1 times higher than in NI and d3 pi PFP, respectively (Supplementary Figure S1).
Proteomics analyses. TMT0 qualitative experiment. In the TMT0 experiment we identified 184 NI MP 
proteins and 164 ECM MP proteins (2 unique peptides, FDR ≤ 1%, Fig. 3A).
The complete lists of identified proteins together with the identification details are reported in Supplementary 
MS Information-Identification. The percentage of TMT tagging – calculated as the proportion of peptides having 
a TMT0 at the N-terminus within the total identified peptides – was ≥ 97% in both samples, demonstrating the 
feasibility of the approach.
The comparison of the identified proteins between the two samples showed that 44% of the identifications 
were shared, 32% were only identified in the NI sample and 24% only in the ECM sample.
TMT6 quantitative experiments. In the two TMT6 quantitative experiments (TMT6-1 and TMT6-2), 314 proteins 
were overall identified with at least 2 unique peptides and FDR ≤ 1%. The good technical efficiency of the TMT6 
experiments was evaluated through the percentage of labelled peptides (≥ 94%) and the distribution, across the 
6 tags, of the mean relative intensity obtained for the spiked bovine beta-lactoglobulin (coefficient of variation – 
CV < 20%).
Considering the two TMT0 and the two TMT6 experiments together, we globally identified 368 murine plasma 
MP proteins (2 unique peptides, FDR ≤ 1%) (Fig. 3B).
Quantitative information was obtained for 221 and 240 proteins in the TMT6-1 and TMT6-2 experiments, 
respectively and, of these, 67% were commonly quantified in the two experiments. Among all quantified proteins 
(TMT6-1 + TMT6-2), 60 were significantly different in abundance (Mann-Whitney U test, p ≤ 0.001) according to 
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IsoQuant statistics and the calculated ratio threshold of 2.1 for increased proteins and 0.5 for decreased proteins 
(Fig. 3C,D and Supplementary MS information-Quantification). When the ECM/d3 pi ratio was considered, 38 
proteins had significantly increased and 7 significantly decreased abundance. Thirty-one proteins were increased 
in ECM compared to NI MP, 26 of which had also higher abundance in ECM compared to d3 pi, and 12 proteins 
had an ECM/NI ratio ≤ 0.5. Finally, for the comparison d3 pi/NI, 8 proteins were significantly decreased and none 
were significantly increased, indicating that this is likely too early a time point in the infection to detect differ-
ences in MP cargo. This is in agreement with previous results on the number and phenotype of circulating MP 
Figure 1. Experimental design. Graphical summary of the experimental design applied in the present 
study. PFP = platelet free plasma; MP = microparticle; SEM = scanning electron microscopy; NI = non-
infected; d3 pi = day 3 post-infection; ECM = experimental cerebral malaria (d8 post-infection). The mouse 
image was obtained at Pixabay.com.
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in ECM18. The complete list of proteins whose abundance in MP was significantly affected during the infection is 
reported in Fig. 3D.
When Plasmodium berghei proteins were searched, two proteins - intra-erythrocytic P. berghei-induced 
structures protein 1 and merozoite surface protein-1 - were detected (2 unique peptides, FDR ≤ 1%) in 
the TMT0 ECM sample, after exclusion of all peptides also matching murine proteins (Supplementary MS 
information-Identification). In all other samples, no parasite protein could be identified with sufficient 
confidence.
The mass spectrometry data have been deposited to the ProteomeXchange Consortium (http://proteome cen-
tral.proteomexchange.org)22 via the PRIDE partner repository23 with the dataset identifier PXD003772.
Gene Ontology analysis. All murine plasma MP proteins identified in our proteomics experiments 
(n = 368) were subjected to Gene Ontology (GO) analysis. For each GO category (i.e., biological process – BP, 
molecular function – MF and cellular component – CC), the top-10 most represented GO terms are reported in 
Fig. 4.
As shown, the majority of plasma MP proteins were involved in localisation processes and in response to stim-
ulus, with the immune and inflammatory responses appearing among the top 10 BP, probably as a contribution 
of proteins whose expression was induced by the infection. Considering the CC terms, the identified proteins 
were highly significantly associated with the cytoskeleton, the plasma membrane and vesicles. Finally, the MF 
GO terms showed that the proteins identified from murine plasma MP have important active roles, being highly 
significantly associated with binding and regulatory activities.
Network and upstream regulator analyses. To highlight proteins associated with the ECM pathological 
state, a list comprising all those significantly overabundant in ECM MP compared either to d3 pi or to NI (n = 42) 
and all proteins uniquely identified in the TMT0 ECM MP sample (n = 21) was created (ECM-associated proteins, 
Table 1). Similarly, a list of NI-associated proteins (n = 43) comprised 16 proteins significantly overabundant in 
NI MP, compared either to d3 pi or to ECM MP, and 27 only identified in NI MP (Supplementary Table 1).
The 63 ECM-associated proteins were analysed with IPA Ingenuity to highlight significantly represented net-
works and predicted upstream regulators. The top two molecular networks are reported in Fig. 5A and B and 
for each the most interesting significant molecular functions were selected. The network with the highest score 
involved 18 molecules of the experimental dataset and was associated (p < 0.0001) with molecular functions 
affecting the quantity of blood cells and of reticulocytes, and RBC morphology. The second network, involving 13 
Figure 2. Murine plasma MP visualized by Scanning Electron Microscopy. Plasma MP purified from a non-
infected DBA/1 mouse have been imaged with a Zeiss Ultra FESEM. (A,C) Magnification x4000. The majority 
of the visualized vesicles have size corresponding to MP (0.1–1 μ m - yellow arrowheads), while only one bigger 
element (white arrowheads) was visualised on each image probably corresponding to small aggregates of MP 
or microplatelets. (B,D) Visualisation of plasma MP at a higher magnification, × 23920 and 52160, respectively. 
Numbers beside arrowheads indicate the measured vesicle diameter expressed in μ m.
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molecules of the dataset, was significantly associated (p < 0.0001) with the activation of myeloid cells, leukocyte 
migration and inflammation of endothelial cells.
The upstream regulator analysis predicted, with high significance, that tumour necrosis factor (TNF), amyloid 
precursor proteins, MYC, erythroid transcription factor (GATA 1) and transforming growth factor beta (TGFβ ) 
were highly likely to regulate the expression of the proteins found to be associated with ECM MP. The detailed 
results of the upstream regulator analysis are reported in Fig. 5C.
The same analysis was performed on the list of NI-associated proteins (n = 43) and the top two networks were 
significantly associated with lipid metabolism and with haemostasis (Supplementary Figure S2).
CA-I and S100A8 verification by western blot. To verify our results, two proteins – carbonic anhydrase 
1 (CA-I) and S100A8 - were selected, based on their biological functions and proteomics results, for further eval-
uation on a larger number of newly collected samples from DBA/1 mice (n = 16). CA-I (identified with 6 peptide 
spectral matches - PSM, 4 unique peptides and 17.31% sequence coverage) was quantified in both TMT6-1 and 
-2 experiments as overabundant in ECM MP compared to both NI (ECM/NI = 2.9 and 2.4, respectively) and d3 
pi MP (ECM/d3 pi = 3.7 and 2.7, respectively). S100A8 was uniquely identified in ECM MP (3 PSM, 3 unique
peptides and 54.55% sequence coverage).
As shown in Fig. 6, CA-I abundance was confirmed to be significantly higher in ECM MP (n = 8) compared 
to NI samples (n = 8) (t-test, p < 0.0001). A 10 kDa band corresponding to S100A8 protein was detected in all 
8 ECM samples but in only 1 out of 8 NI MP, confirming proteomics results where it was only identified in 
PbA-infected MP. Unfortunately, to the best of our knowledge, a housekeeping protein for plasma MP has not 
been described yet. When the abundance of γ -actin was assessed on the same samples, a more intense signal 
was detected in NI samples indicating that actin is not an adequate loading control due to the high variability 
Figure 3. Identification and quantification results. (A) Proteins identified in the plasma MP from a non-
infected mouse (NI) and a PbA-infected mouse at the stage of experimental cerebral malaria (ECM) (TMT0 
experiment). The two samples shared 44% of the identifications. Only proteins identified with minimum 2 
peptides and FDR ≤ 1% have been considered. (B) Comparison of the proteins identified in the pooled NI – d3 
pi – ECM samples (TMT6#1 and TMT6#2 experiments) and those identified in the individual NI and ECM 
samples (TMT0 experiment). Globally, 368 murine plasma microparticle proteins have been identified.  
(C) Quantitative results obtained from the two TMT6 experiments. Proteins differentially abundant in MP 
were defined as having a p-value < 0.001 and a ratio ≥ 2.1 or ≤ 0.5. (D) Heat map showing the level of expression 
of the proteins found to be significantly differentially abundant for the three computed ratios, i.e. ECM/d3 pi, 
ECM/NI and d3 pi/NI, in the two quantitative experiments. nd = non differential proteins.
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in protein composition of plasma MP, but also showing that our experiments were not biased towards a higher 
amount of proteins loaded in ECM samples (Supplementary Figure S3).
S100A8 and CA-I were also assessed in the platelet-free plasma (PFP) and MP-free plasma (MFP) of 10 out 
of the 16 samples (Supplementary Figure S4). CA-I was expressed in both PFP and MFP but no difference was 
observed between the 2 types of samples (PFP vs. MFP, Wilcoxon matched-pairs signed rank test) nor between 
groups (NI vs. ECM, Mann-Whitney U test). Interestingly, S100A8 was detected in only 2 out of 5 ECM PFP (and 
in the corresponding MFP) and in none of the NI samples.
To exclude the possibility of an association between the obtained results and the DBA/1 genotype, CA-I and 
S100A8 were assessed by WB in MP and PFP samples from C57BL/6 mice (n = 4 NI, n = 4 PbA-infected - ECM) 
(Supplementary Figure S5). CA-I was significantly more abundant in both MP and PFP samples from ECM mice 
compared to NI, while S100A8 was only detected in ECM MP, confirming the results obtained by both proteom-
ics and WB in the DBA/1 model. S100A8 was not detected in the PFP of C57BL/6 mice, both NI and ECM.
Finally, the two proteins were also assessed in MP isolated from PFP obtained from children suffering either 
from CM or from asymptomatic malaria (AM), as well as from healthy community controls (CC) (n = 7 in each 
group) (Supplementary Figure S6). S100A8 was significantly (one-way ANOVA, p = 0.006) more abundant in 
MP from CM patients compared to both AM and CC (Dunnet’s multiple comparison post-test, p = 0.0069 and 
p = 0.0134, respectively). CA-I was not significantly different between the three groups, however its abundance in 
CM MP was almost double than in AM MP (mean CM/mean AM = 1.9).
Discussion
Host-derived plasma microparticles (MP) are well recognised as being involved in the pathogenesis of both 
human and experimental CM17,18,20,21, however the contribution of their protein cargo to the pathological mech-
anisms leading to this syndrome has not been deciphered yet. MP are known to contain proteins derived from 
the cell of origin, and this cargo doesn’t seem to be the consequence of a casual uptake from the parent cell’s cyto-
plasm, but rather the result of specific packaging mechanisms9,24 making these vesicles important players in inter-
cellular communication11. To try to achieve new insights into the pathogenesis of CM and to better understand 
the role of MP in this syndrome, we have established and validated a qualitative and quantitative characterisation 
of the protein content of plasma MP released during ECM. To our knowledge, this is the first time that this strat-
egy is applied to ECM and that the protein cargo of MP obtained from individual mice is successfully investigated 
by TMT quantitative proteomics. Only few other studies have used proteomics to investigate extracellular vesicles 
in malaria models, including P. yoeli-infected mice or in vitro cultured pRBC25,26.
Figure 4. Gene Ontology analysis. Top-10 GO terms represented across all 368 identified murine plasma MP 
proteins. (A) Biological Process GO terms; (B) Molecular Function GO terms; (C) Cellular Component GO terms. 
For each category only significantly represented GO terms have been considered (adjusted p-value < 0.0001) and 
the % of proteins belonging to each term is reported. *Indicates potentially relevant GO terms in the context of MP 
and ECM.
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# AC ID Description
ECM/NI Ratio ECM/d3 pi Ratio
TMT6 #1 TMT6 #2 TMT6 #1 TMT6 #2
1 P05366 SAA1_MOUSE Serum amyloid A-1 protein 4.16 3.52 4.66 4.43
2 P05367 SAA2_MOUSE Amyloid protein A 3.81 — 4.71 —
3 P01942 HBA_MOUSE Hemoglobin subunit alpha 3.56 3.51 4.16 3.14
4 P02089 HBB2_MOUSE Hemoglobin subunit beta-2 3.27 3.56 3.70 3.19
5 P00920 CAH2_MOUSE Carbonic anhydrase 2 (CA-II) 3.39 3.31 4.20 3.20
6 P01872 IGHM_MOUSE Ig mu chain C region 3.25 — 3.56 2.50
7 Q61171 PRDX2_MOUSE Peroxiredoxin-2 (TSA) 3.10 3.25 3.29 3.21
8 P02088 HBB1_MOUSE Hemoglobin subunit beta-1 2.99 3.25 3.32 2.83
9 P08113 ENPL_MOUSE Endoplasmin (GRP-94) (ERp99) 3.02 — — —
10 P04919 B3AT_MOUSE Band 3 anion transport protein, Isoform Kidney 2.37 3.25 2.83 2.73
11 Q9QWK4 CD5L_MOUSE CD5 antigen-like 2.75 — 3.22 —
12 P06800 PTPRC_MOUSE Receptor-type tyrosine-protein phosphatase C, Isoform 3 2.32 3.27 2.85 3.33
13 P09103 PDIA1_MOUSE Protein disulfide-isomerase (PDI) (ER protein 59) 2.75 — — —
14 P01837 IGKC_MOUSE Ig kappa chain C region 2.64 — 3.41 —
15 P13634 CAH1_MOUSE Carbonic anhydrase 1 (CA-I) 2.86 2.40 3.67 2.69
16 P04918 SAA3_MOUSE Serum amyloid A-3 protein 2.52 — 2.67 —
17 P01831 THY1_MOUSE Thy-1 membrane glycoprotein — 2.51 — —
18 P11835 ITB2_MOUSE Integrin beta-2 2.17 2.70 2.46 2.70
19 Q02013 AQP1_MOUSE Aquaporin-1 (AQP-1) (DER2) 2.28 2.37 3.38 2.30
20 P27773 PDIA3_MOUSE Protein disulfide-isomerase A3 (p58) (ERp57) (ERp60) 2.28 — 2.42 —
21 P01897 HA1L_MOUSE H-2 class I histocompatibility antigen, L-D alpha chain — 2.28 — —
22 P24063 ITAL_MOUSE Integrin alpha-L (LFA-1A) (Ly-15) — 2.18 2.36 2.23
23 P05555 ITAM_MOUSE Integrin alpha-M, Isoform 2 — 2.14 — 2.28
24 Q02105 C1QC_MOUSE Complement C1q subcomponent subunit C 2.13 — 2.25 —
25 P12246 SAMP_MOUSE Serum amyloid P-component (SAP) 2.12 — — —
26 P20491 FCERG_MOUSE High affinity Ig epsilon receptor subunit gamma 2.12 — 3.15 —
27 P60766 CDC42_MOUSE Cell division control protein 42 homolog — 2.12 2.19 2.17
28 P08032 SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 — 2.10 — 2.06
29 P03987 IGHG3_MOUSE Ig gamma-3 chain C region, Isoform 2 2.09 — 2.56 —
30 Q61735 CD47_MOUSE Leukocyte surface antigen CD47 (IAP) 2.08 — 2.76 —
31 P54116 STOM_MOUSE Erythrocyte band 7 integral membrane protein 2.08 — 2.30 —
32 P17182 ENOA_MOUSE Alpha-enolase (NNE) — — — 2.51
33 P07356 ANXA2_MOUSE Annexin A2 (PAP-IV) — — 2.37 2.32
34 P62880 GBB2_MOUSE Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 — — 2.28 —
35 Q62469 ITA2_MOUSE Integrin alpha-2 (GPIa) — — — 2.27
36 P01630 KV2A6_MOUSE Ig kappa chain V-II region 7S34.1 — — 2.23 —
37 P26041 MOES_MOUSE Moesin — — 2.30 2.15
38 P18572 BASI_MOUSE Basigin, Isoform 2 — — 2.19 —
39 P06151 LDHA_MOUSE L-lactate dehydrogenase A chain (LDH-A) (LDH-M) — — — 2.19
40 P01631 KV2A7_MOUSE Ig kappa chain V-II region 26-10 — — 2.13 —
41 P15702 LEUK_MOUSE Leukosialin (Ly-48) — — — 2.12
42 P01592 IGJ_MOUSE Immunoglobulin J chain — — 2.07 —
43 Q60963 PAFA_MOUSE Platelet-activating factor acetylhydrolase (PAF acetylhydrolase) Only ID
44 P68254 1433T_MOUSE 14-3-3 protein theta Only ID
45 Q61646 HPT_MOUSE Haptoglobin beta Only ID
46 P21981 TGM2_MOUSE Protein-glutamine gamma-glutamyltransferase 2 Only ID
47 P17156 HSP72_MOUSE Heat shock-related 70 kDa protein 2 Only ID
48 P84244 H33_MOUSE Histone H3.3 Only ID
49 P31725 S10A9_MOUSE Protein S100-A9 (MRP-14) (p14) Only ID
50 P0C0S6 H2AZ_MOUSE Histone H2A.Z (H2A/z) Only ID
51 P27661 H2AX_MOUSE Histone H2AX (H2a/x) Only ID
52 P01670 KV3AI_MOUSE Ig kappa chain V-III region PC 6684 Only ID
Continued
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Through our proteomics investigations we overall identified 368 plasma MP proteins, 290 of which were also 
quantified. These results are comparable with, or higher than, other proteomics studies on human circulating 
MP27,28 and murine plasma exosomes25. The list of identified proteins included some of the most abundant plasma 
proteins, such as albumin, which however were not significantly different between samples. Although a minimal 
contamination from plasma proteins can never be excluded, some of these proteins have already been reported to 
be present within MP even after 10 washes of the vesicle pellet or reported as part of the core proteome of human 
plasma MP27,29. When the immune-depletion of albumin and immunoglobulins was tested on our samples, the 
total number of identified proteins increased by 14% (data not shown); despite the increase in the number of 
identified proteins, such a sample preparation wouldn’t have been compatible with the downstream quantitative 
analysis of MP proteins derived from individual animals due to the limited amount of proteins available. For 
these reasons, we instead reduced the contamination of plasma proteins with two washes of the MP pellet, and we 
increased the number of identified peptides by using a long gradient at the LC-MS/MS level.
To comprehensively evaluate the MP protein cargo, we performed a gene ontology analysis and showed that 
these proteins reflect both MP mechanism of formation - with a significant representation of cytoskeletal and 
structural proteins - and their active biological functions, including binding, enzymatic and regulatory activities. 
This result further sustains that circulating MP released by the host in response to a certain stimulus, transport 
biologically active molecules that are likely to mediate physiological and pathological processes, as already pro-
posed24,30–32. Interestingly, a number of proteins already proposed to be associated with parasite virulence and 
intra-erythrocytic life stage, including basigin, peroxiredoxin 2 and aquaporin 933–35, or associated to the phe-
nomenon of adhesion to the brain microvasculature (integrins) have been identified within ECM MP.
A deeper analysis revealed that these ECM-associated proteins were interconnected in two distinct networks 
reflecting the pathological state of the sample from which they are derived. The first network involved molecules 
and pathways significantly associated with RBC number and morphology, indicating that RBC-MP represent 
an important proportion of circulating vesicles during ECM, as already reported18, and that their protein cargo 
reflects the known alteration of RBC occurring during the infection36. However, whether these proteins are specif-
ically packaged into MP to propagate the infection or are just the result of RBC rupture following the maturation 
of the parasite is still to be determined. These proteomics results were further verified through the validation of 
the increased abundance in ECM MP of carbonic anhydrase I (CA-I), a protein participating in this network. 
CA-I, mainly expressed in RBC and in the gastro-intestinal tract37, belongs to a group of proteins involved in the 
maintenance of the acid-base homeostasis of blood and tissues through the reversible catalysis of carbon dioxide 
and bicarbonate conversion38. In severe malaria, the acid-base balance is often affected, as also indicated by the 
well-reported alteration of the lactate blood levels39 and, more recently, by the association of ECM with brain 
hypoxia and acidosis40. Interestingly, CA-I transcript was found to be up-regulated in the plasma of children 
experiencing severe malaria compared to mild malaria episodes occurring later in the same subjects41, further 
suggesting an interesting role for this protein in CM and raising the possibility that its increased plasma levels 
are due to MP. In our proteomics analyses we identified and quantified both CA-I and CA-II as significantly 
over-expressed in ECM MP compared to both NI and d3 pi MP. The muscle-derived CA isoenzyme, CA-III, had 
been previously identified by affinity proteomics as increased in CM children and as a discriminator between CM 
and both severe malaria anaemia (SMA) and uncomplicated malaria (UM)42.
In our study, CA-I expression was significantly increased in ECM MP compared to NI MP from DBA/1 mice 
when assessed by WB, however its plasma levels were not different between the two conditions. This might sug-
gest that CA-I could be preferentially packaged in MP - probably derived from RBC - to be transported to other 
cells to counteract the cellular and tissue acidosis and hypoxia occurring during ECM. These results were con-
firmed in MP obtained from a different mouse strain (C57BL/6), showing that the increased CA-I expression in 
ECM MP is not genotype dependent. However, in contrast with what was obtained in DBA/1 mice, when assessed 
in plasma samples from C57BL/6 mice, CA-I concentration was higher in ECM compared to NI. More in-depth 
investigations are needed to better understand the contribution of the MP proteome within the plasma proteome.
# AC ID Description
ECM/NI Ratio ECM/d3 pi Ratio
TMT6 #1 TMT6 #2 TMT6 #1 TMT6 #2
53 P14426 HA13_MOUSE H-2 class I histocompatibility antigen, D-K alpha chain (H-2D(K) Only ID
54 P0CW03 LY6C2_MOUSE Lymphocyte antigen 6C2 (Ly-6C2) Only ID
55 Q8BFZ3 ACTBL_MOUSE Beta-actin-like protein 2 Only ID
56 P01749 HVM05_MOUSE Ig heavy chain V region 3 Only ID
57 P01646 KV5AD_MOUSE Ig kappa chain V-V region HP 123E6 Only ID
58 P27005 S10A8_MOUSE Protein S100-A8 (MRP-8) Only ID
59 P62806 H4_MOUSE Histone H4 Only ID
60 P11672 NGAL_MOUSE Neutrophil gelatinase-associated lipocalin (NGAL) Only ID
61 Q8CGP1 H2B1K_MOUSE Histone H2B type 1-K Only ID
62 P50446 K2C6A_MOUSE Keratin, type II cytoskeletal 6 A (CK-6A) Only ID
63 O08677 KNG1_MOUSE Kininogen-1 light chain, Isoform 3 Only ID
Table 1.  ECM-associated proteins. List of proteins significantly over-expressed in ECM either compared to 
d3 pi or to NI (TMT6 experiments #1 and #2) and proteins uniquely identified (Only ID) in the ECM sample 
(TMT0 experiment). —: non differential expression.
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The second network that was significantly represented among ECM-associated MP proteins comprised mol-
ecules implicated in myeloid cell migration, leukocyte activation and inflammatory response in endothelial cells. 
These functions are known to be important in the pathogenesis of both human and murine CM4,43,44 and, in 
recent years, particular attention has been paid to the role of the endothelium in CM pathogenesis45–49. The 
sequestration of different cell types at the brain microvasculature level - with predominant accumulation of pRBC 
in human CM and of leukocytes in ECM - is a typical trait of the syndrome44,47. This adhesion results in the acti-
vation of the endothelium and contributes to the endothelial damage associated with CM46,50. Interestingly, the 
association of markers of endothelial activation and of platelet adhesion with CM was also shown in patients’ 
plasma investigated by affinity proteomics42. The identification of these proteins further substantiates the active 
role of MP in ECM: by carrying important molecules between cells, MP could represent primary mediators in 
cell-to-cell interaction and activation occurring in CM.
Our hypothesis that MP contain proteins actively involved in CM pathogenesis, and in endothelial damage as 
pointed out by the network analysis, was further confirmed by the upstream regulation analysis, through which 
two of the most studied molecules in CM pathogenesis, TNF and TGFβ 1, were predicted to regulate the MP 
proteins experimentally detected as ECM-associated. TNF has been reported to be involved, at different levels, 
in both human and murine CM, including in the interaction between pRBC and leukocytes with the endothe-
lium, sequestration and the release of MP from endothelial cells20,21,51,52. Despite the role of TGFβ still being 
Figure 5. Network and upstream analyses of ECM-associated proteins. (A,B) Most relevant networks 
showing the connectivity between MP proteins experimentally identified as ECM-associated (n = 63). Red: 
proteins identified as significantly over-expressed in ECM; Green: proteins uniquely identified in the ECM 
sample; Orange: multimeric proteins for which one or more chains have been identified as over-expressed 
in ECM. The most important biological functions, associated with each network, in the context of ECM, 
are reported at the bottom of the network. Protein targets selected for verification, CA-I and S100A8, are 
highlighted by a red square. (C) Top-5 molecules that are highly significantly likely to regulate the proteins 
experimentally found to be ECM-associated. For each regulator the list of target proteins in the experimental 
dataset is given. p-value: Fisher’s exact test, indication of the overlap between the proteins in the dataset and the 
genes known to be affected by the regulator.
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controversial, it has been shown that, on the focal brain obstruction, TGFβ released by adherent and activated 
platelets contributes to the cerebral endothelium damage53.
To further verify our proteomics and prediction analysis results, we assessed the abundance of one of the pro-
teins involved in this second network - S100A8 - that was only identified in ECM-derived MP.
S100A8, also known as myeloid-related protein 8 (MRP-8), is a calcium-binding protein constitutively 
expressed mainly by neutrophils and monocytes54. In human cells and body fluids, it often exists as a heterodimer 
or tetramer with S100A9 (or MRP14)55, which we also identified as uniquely expressed in ECM MP. S100A8/A9 
expression can be induced in monocytes, endothelial cells, keratinocytes or epithelial cells by mediators such as 
LPS and TNF56,57 and it is often increased in acute and chronic inflammatory conditions56, including rheumatoid 
arthritis, cancers and neurological disorders58,59 where they seem to play cytokine-like pro-inflammatory effects55.
Our verification data confirmed that S100A8 was detected within ECM MP but almost absent in NI MP, in 
both DBA/1 and C57BL/6 mice. Additionally, its expression was almost not-detectable in plasma samples from 
both mouse strains, suggesting that MP might be a preferential source of plasma S100A8.
In malaria, elevated serum or plasma levels of S100A8/A9 have been reported in two different studies. 
Bordmann et al. showed that in P. falciparum malaria-infected children, S100A8/A9 serum concentration cor-
related with both parasite load and temperature, even though these criteria are no longer sufficient to assess the 
disease severity60. More recently, in PbA-infected BALB/cA mice, an accumulation of S100A8+ and S100A9+ 
macrophages in the spleen was shown, as was an increased plasma concentration of the two proteins61. In our 
study, no difference was observed in S100A8 concentration in the spleen between NI and ECM DBA/1 mice 
(WB, data not shown), however it should be noted that different mouse strains are known to react differently to 
PbA-infection.
Based on their described biological properties, S100A8/A9 might be interesting players in CM. Indeed, 
S100A8/A9 are released by circulating neutrophils and monocytes upon contact with the inflamed endothelium57 
in which they induce the transcription of genes encoding for pro-inflammatory chemokines and adhesion mole-
cules such as ICAM-162. Additionally, S100A8/A9 have been implicated in leukocyte extravasation by increasing 
the binding capacity of leukocytes to endothelial ICAM-162.
The mechanism of secretion of these proteins in the extracellular environment is still not completely charac-
terised. It has been proposed that their secretion could occur through a tubulin and calcium signalling dependent 
mechanism57,63, thus the identification of S100A8 in MP might support these pieces of evidence and represent a 
new mechanism contributing to S100A8/A9 plasma level.
In our study we focused on the characterisation of host proteins and the alteration of their abundance in MP 
during ECM infection; however, as reported in other works on the in vitro study of pRBC-MP26 or on the char-
acterisation of exosomes from P. yoelii-infected mice25, parasite proteins can also be found in extracellular vesi-
cles. Here, we identified only 2 parasite proteins (intra-erythrocytic P. berghei-induced structures protein 1 and 
Figure 6. Western blot results for CA-I and S100A8 detection in murine MP. (A) Detection of CA-I and 
S100A8 in MP samples (2.5 μ g/lane left blot image, 1.8 μ g/lane right blot image) from non-infected (− , NI, 
n = 8) and PbA-infected (+ , ECM, n = 8) DBA/1 mice. A positive control (C+ ) consisting of murine spleen 
extract was included in each experiment. (B) Quantification of CA-I expression in murine plasma MP, showing 
its significantly higher expression in ECM samples (t-test). In each boxplot mean is reported as + . (C) S100A8 
was detectable in only 1 out of 8 NI samples, while it was expressed in all ECM samples. The quantification of 
the detected bands is reported in the graph, where the horizontal line represents the median band volume and 
the error bars the interquartile range.
250
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:37871 | DOI: 10.1038/srep37871
merozoite surface protein-1) in ECM MP analysed using the qualitative approach, potentially as a result of a release 
of MP from pRBC. This number is lower than what was reported by others, however it should be considered that 
in order to avoid pooling of samples from multiple mice, our proteomics experiments were performed on a very 
small amount of protein (approximately 5 μ g per sample). Assuming that, similar to exosomes, circulating MP can 
contain parasite proteins, these would be a minimal proportion of the total protein cargo requiring enrichment 
and fractionation steps for their detection. Such an investigation should be done in the future to decipher the 
in vivo interaction between the host and the parasite and the role of MP in this. Interestingly, one of the two PbA 
proteins that we identified within MP was already reported in P. falciparum-infected red blood cell MP produced 
in vitro26.
Our results indicate that the protein content of host-derived plasma MP is severely altered during ECM, 
compared to the early infection, and that some of the proteins appear to be selectively packaged into these vesi-
cles during the infection. Nonetheless, complementary approaches, such as immune-staining of vesicles released 
under different infection conditions, should be used to confirm this specific packaging. To further evaluate the 
implication of MP-associated proteins, and in particular of CA-I and S100A8, in both human and murine CM, 
additional investigations are needed to establish their exact cellular source and role in disease pathogenesis, using 
in vitro and in vivo models. Despite the fact that the two proteins seem to be associated with ECM, as shown by 
our proteomics results on samples taken at day 3 post-infection, additional investigations should be done using 
non-CM models to prove the specificity of this association with the severe syndrome. Interestingly, when assessed 
in MP from human plasma samples from Ugandan children in a pilot study, the two proteins were increased in 
abundance in MP from children with CM compared to asymptomatic cases and this increase was statistically sig-
nificant for S100A8. Asymptomatic malaria has recently been pointed out as a debilitating infection that should 
be considered seriously and treated64. These observations suggest that the two proteins might not only be associ-
ated to the severe syndrome in mice, but also in humans.
By describing for the first time the protein cargo of murine MP in general and more specifically those released 
during ECM, and by highlighting new potential molecular players, our results indicate that the cargo of plasma 
MP is affected during the severe infection and should be considered in the understanding of CM pathogenesis. 
Additionally, the differences in protein expression between MP and the corresponding PFP indicate that the qual-
itative and quantitative proteomics investigation of extracellular vesicles has great potential as a complementary 
strategy to the more common plasma proteomics in biomarker discovery research, since MP are likely to contain 
molecules specific to the infection or its stage.
The results here presented pave the way to future investigations in multiple directions including the further 
translation to human clinical samples to try and understand the contribution of plasma MP proteome to malaria 
severity and to identify new prognostic markers able to predict the short and long term outcome in CM patients.
Experimental Procedures
Mice and infection. DBA/1 and C57BL/6 CM-susceptible mice were infected with Plasmodium berghei 
ANKA (PbA) strain and developed a neurological pathology 6–8 days after infection17,65. Mice were infected and 
handled as reported elsewhere18. Blood was collected retro-orbitally under isoflurane-induced general anaesthe-
sia either at day 3 post-infection (d3 pi) or at the stage of ECM (end-point) in 3.2% sodium citrate. Blood from NI 
mice was obtained following the same procedure. A total of n = 14 DBA/1 mice were used to perform proteomics 
experiments; while n = 16 DBA/1 and n = 8 C57BL/6 mice were used to perform verification experiments by WB. 
The detailed demographic description is reported in Supplementary Figure S1.
Ethical approval. All procedures performed in the present study have been approved by the Animal Ethics 
Committee of the University of Sydney (Projects n: K00/10-2010/3/5317 and K20/6-2011/3/5569) and adhered 
to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Paediatric clinical samples. Platelet free plasma samples was obtained from children enrolled between 
2008 and 2012 in Uganda in the context of a study whose details, inclusion and exclusion criteria are reported 
elsewhere66. Written informed consent was obtained from parents or guardians of study participants. The 
Institutional Review Boards for human studies at Makerere University School of Medicine (Study # 2008-033) 
and the University of Minnesota granted ethical approval for the study (Study # 0802M27022); all experiments 
were performed in accordance with relevant guidelines and regulations. The demographic description of the 
samples used in the present study is reported in Supplementary Figure S6.
MP preparation, counting by flow cytometry and visualisation by Scanning Electron Microscopy 
(SEM). MP were prepared as previously reported67. Briefly, whole blood was centrifuged at 1,500 g for 15 min 
at room temperature to obtain platelet poor plasma (PPP). PPP was then centrifuged twice at 18,000 g for 3 min to 
remove possible platelet contaminations and/or cell debris and platelet free plasma (PFP) was obtained. MP were 
finally pelleted at 18,000 g for 45 min at 15 °C. To remove possible plasma protein contaminations (not specifically 
bound to MP), MP pellet was washed twice with PBS/3.2% sodium citrate and centrifuged at 18,000 g for 45 min 
after each washing step.
The number of MP in the PFP samples used for proteomics was counted by flow cytometry using Annexin V 
binding on a Beckman Coulter GalliosTM flow cytometer as previously reported13.
To confirm that the isolated population was consistent with plasma MP, vesicles purified from a NI mouse 
were also imaged by scanning electron microscopy. Samples were prepared as reported by Latham et al. and 
imaged with the Zeiss Ultra FESEM68. Imaging was carried out at the Australian Centre for Microscopy & 
Microanalysis (ACMM), The University of Sydney, Australia.
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TMT0 experiment. A pilot experiment using the TMT0 approach was performed on MP proteins from one 
NI and one ECM mouse. For each sample, proteins were extracted from pelleted MP using repeated freeze/thaw 
cycles69, re-suspended in 0.1% Rapigest SF (Waters Corporation) in 0.1 M triethylammonium bicarbonate buffer 
(TEAB) pH 8.0, alkylated with 50 mM TCEP, reduced with 400 mM iodoacetamide and digested with 0.2 μ g/μ L 
trypsin overnight at 37 °C (Promega Corporation). Digested samples were then labelled with the TMT0 reagent 
(Thermo Fisher Scientific) following manufacturer’s instructions, except for the amount of tag used to label the 
samples. Due to the low amount of proteins in MP samples, one TMT vial (0.8 mg) was used to label two samples. 
After TMT labelling, samples were cleaned with C18 ultra-micro spin column (Harvard apparatus) and dried 
under vacuum prior to LC-MS/MS analyses.
TMT6 experiment. MP obtained from 400 μ L of PFP from n = 4 NI, n = 4 d3 pi and n = 4 ECM mice were 
used to perform two parallel TMT6 experiments (TMT6-1 and TMT6-2). Protein extraction, peptide sample 
preparation and labelling were performed as reported for the TMT0. Additionally, each sample was spiked with 
0.05 μ g of bovine beta-lactoglobulin before protein reduction as an internal control.
Samples analysed in the first TMT6 experiment (TMT6-1) were labelled as follows: NI with the tags 126 and 
127; d3 pi with the tags 128 and 129, and ECM with the tags 130 and 131. In the TMT6-2 experiment NI samples 
were labelled with the tags 128 and 129, d3 pi samples with the tags 130 and 131, and ECM samples with the tags 
126 and 127.
After labelling, samples were combined, cleaned with C18 ultra-micro spin column and dried under vacuum 
prior to LC-MS/MS analyses.
Tandem mass spectrometry analyses, protein identification and quantification. Tandem 
mass spectrometry analyses were performed on a QExactive Orbitrap Plus (Thermo Electron) equipped with 
an Ultimate 3000 HPLC and autosampler system (Dionex). Peptide samples were concentrated and desalted 
onto a micro C18 pre-column (300 μ m × 5 mm, Dionex) that was switched, after 4 min wash, into line with a 
fritless nano column (75 μ m × 15 cm) containing C18 media (1.9 μ m, 120 Å, Dr Maisch) manufactured accord-
ing to Gatlin et al.70. For the TMT6 samples, the analytical peptide separation was run for 260 min at a flow rate 
of 200 nL/min; while for the TMT0 samples, a gradient of 140 min was applied. The detailed description of the 
MS/MS settings is reported as Supplementary information. Mass spectrometry analyses were carried out at the 
Bioanalytical Mass Spectrometry Facility, University of New South Wales, Australia.
MS/MS data were analysed using EasyProt platform v2.371. Raw data were converted into.mgf files and peak 
lists generated with MS convert (ProteoWizard 3.0.7529, http://proteowizard.sourceforge.net/tools.shtml). 
Protein identifications were obtained by searching peptide spectral matches against the SwissProt/UniProt data-
base (version October 2014 - 546,790 entries) using the following settings: i) Mus musculus for the taxonomy; 
ii) trypsin as the digestion enzyme with only one missed-cleavage allowed; iii) carbamidomethylation of cysteines 
as fixed modification and oxidation of methionines as variable modification; iv) only peptides with at least 6 resi-
dues were considered for protein identification and v) the precursor ion tolerance was set to 10 ppm. Additionally,
the TMT0 or the TMT6 modifications on lysines and peptide N-termini were added as fixed modifications in the 
respective experiments. Only proteins identified with at least 2 unique peptides and false discovery rate (FDR)
≤ 1%, calculated as reported in71, were considered as true identification matches.
For the quantitative experiment, protein relative quantification was obtained using IsoQuant embedded in the 
EasyProt platform. All peptides corresponding to one unique entry in the job, having FDR ≤ 1% and an intensity 
signal in each of the 6 TMT tags were considered for quantification.
For each TMT6 experiments, protein relative quantification was obtained computing the protein ratios ECM/d3 pi, 
ECM/NI and d3 pi/NI after isotopic purity correction according to the algorithm given by the manufacturer. 
To reduce biases due to potential differences in protein amount among the 6 TMT channels, the reporter ion 
intensities were normalized71 prior to ratio calculation and the distribution of the relative intensities of all pep-
tides considered for protein quantification was checked for normality (Shapiro-Wilk normality test). The ratio 
threshold for considering a protein differentially abundant between the compared conditions was calculated72 
and the significance level was set at 0.01 (Mann-Whitney U test). The technical performance of the two TMT6 
experiments was evaluated through the rate of labelled peptides and the normalised relative intensity distribution 
of bovine beta-lactoglobulin across the 6 tags.
For all TMT0 and TMT6 experiments a second search against the UniProtKB/TrEMBL database (version 
December 2012 - 4,870,157 entries), choosing the Plasmodium berghei taxonomy (ID 5821) was done to search 
for parasite proteins.
Gene ontology, network and upstream regulator analyses. To highlight cellular mechanisms, bio-
logical processes and molecular functions associated with murine plasma MP proteins, the list of all identified 
proteins (TMT0 and TMT6) was submitted to gene ontology (GO) analysis using bioCompendium (http://bio-
compendium.embl.de/). Only GO terms significantly represented after correction for multiple comparisons were 
considered (adjusted p-value < 0.0001).
To evaluate the association of the identified MP proteins with CM pathology, two protein sub-datasets were 
created. A first dataset, called ECM-associated proteins, comprised all proteins found significantly over-abundant 
in ECM MP compared either to d3 pi or to NI MP in at least one of the two TMT6 quantitative experiments, 
and those exclusively identified in the ECM MP sample (TMT0 qualitative experiment). The second dataset, 
NI-associated proteins, included all proteins significantly increased in NI conditions in the TMT6 experiments 
and those only identified in the NI MP in the TMT0 experiment. Both datasets were analysed with Ingenuity® 
Pathway Analysis - IPA (Ingenuity® System, http://www.ingenuity.com). A network analysis was first performed 
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to evaluate the molecular connectivity and interaction between the proteins in the datasets. This analysis is based 
on the assumption that highly connected molecules will have a higher influence on the network and that highly 
interconnected networks will have greater biological significance. Since a network is seen as a set of pathways, the 
different molecular functions determined to be significantly associated with the network can be highlighted73,74.
To evaluate ECM- or NI-associated proteins in a broader molecular and biological context, an upstream reg-
ulator analysis was also performed listing all genes, RNAs and proteins predicted to regulate the molecules in the 
experimental dataset.
Western Blot. Murine samples. The expression of two selected candidates, S100A8 and carbonic anhydrase 
1 (CA-I), was assessed by WB in MP, PFP and MP-free plasma (MFP) samples.
MP protein concentration was determined after protein extraction using the Qubit protein assay (Life 
Technologies). For each MP sample, 1 to 2.5 μ g of proteins were separated on a polyacrylamide gel and transferred 
onto a nitrocellulose membrane. For PFP and MFP 2.5 μ L of sample were used.
CA-I was detected using a rabbit monoclonal anti-mouse CA-I antibody (0.63 μ g/mL, Abcam) and a goat 
anti-rabbit IgG DyLightTM 800 conjugated secondary antibody (0.15 μ g/mL). S100A8 was detected using a goat 
polyclonal anti-mouse S100A8 antibody (0.4 μ g/mL, R&D Systems) and an anti-goat IgG IRDye® 800 conju-
gated, diluted 1/1000. Monoclonal mAb-2A3 against γ -actin, a kind gift from Christine Chaponnier (University 
of Geneva), was used at a 0.2 μ g/mL and detected with an anti-mouse IgG DyLight 680 conjugated secondary 
antibody (0.15 μ g/mL). The fluorescent signal was detected on an Odyssey Infrared Imaging System (LI-COR 
Biosciences) and images analysed with ImageQuant TL software (GE Healthcare Life Sciences). Protein expres-
sion in MP samples was determined as the measured band volume normalised to the amount of loaded protein.
To establish the appropriate number of mice to be used in WB experiments, a sample size calculation was 
done based on the variability of the normalised relative intensities of all the peptides used to quantify CA-I in 
both TMT6 experiments, after data logarithmic transformation to obtain a normal distribution. Considering an 
average standard deviation of 0.3 and 0.7 for ECM and NI samples, respectively, a sample size of n = 8 per group 
was estimated to be sufficient to detect a significant difference at 0.05 level and a fold-change of 2 with a power of 
0.895 (two-sample t test for mean difference with unequal variances).
Human samples. MP were prepared from PFP as previously described13 and proteins extracted and measured 
as reported for the murine samples. For each sample, 2 to 3 μ g of proteins were separated on 15% polyacrylamide 
gels. As these samples were obtained from young children the volume of plasma was minimal (160 μ L), therefore 
due to the low amount of proteins obtained from CC MP, pools of two samples age and sex matched were ana-
lysed. S100A8 was detected using a rabbit polyclonal primary antibody (2.0 μ g/mL, Abcam) and a goat anti-rabbit 
IgG DyLightTM 800 conjugated secondary antibody (0.15 μ g/mL). CA-I was detected with the same antibody used 
for murine samples.
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). Parametric or 
non-parametric statistical tests were applied according to data distribution. Comparisons between two unpaired 
groups were performed with the t-test or the Mann-Whitney U test, while comparisons between three unpaired 
groups were performed with the one-way ANOVA test followed by the Dunnet’s multiple comparison test. Paired 
groups were compared using the Wilcoxon matched-pairs signed rank test. All tests were two-tailed and the 
p-value significance was set at < 0.05.
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